An activating role for neutrophil serine proteases in rapidly progressive glomerulonephritis by Bevins, Anne
  
 
 
 
 
 
An activating role for neutrophil serine 
proteases in rapidly progressive 
glomerulonephritis 
 
 
 
 
Anne Bevins 
A PhD thesis submitted to The University of Birmingham  
2011 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supervisors: 
Professor C O Savage 
Dr G E Rainger 
 
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
 i 
Acknowledgements 
I’d like to thank all of the members of the Renal Immunobiology group for their help and 
support in carrying out this research, in particular Dr Samantha Tull, Dr Neil Holden and Dr 
Matthew Morgan for their invaluable advice. Particular thanks also goes to my supervisor, 
Professor Caroline Savage, for all of her support and guidance. I’d additionally like to thank 
Hannah Morris and Julie Williams for their help with western blots. 
 
I would like to thank my family for supporting me throughout my PhD, particularly to 
Mathias for all the time you have given helping me to finish this thesis. 
 ii 
Work Arising from this Thesis 
 
Data from this thesis has been presented at the following conferences 
 
  “Treatment of Endothelial Cells with Serine Proteases induces Exocytosis of 
Weibel-Palade Bodies” Anne Bevins, Sahithi Panchagnula, Samantha Tull, Matthew 
Morgan, Simon C. Satchell, Lorraine Harper, G. Ed Rainger, Caroline Savage - 
Presented at the Renal Association Conference, Manchester, May 2010 
 
 “Phenotypic Changes of Endothelial Cells Resulting in Increased Neutrophil 
Adhesion in ANCA-Associated Vasculitis” Anne Bevins, Sahithi Panchagnula, 
Simon C. Satchell, Lorraine Harper, G. Ed Rainger, Caroline Savage, Samantha Tull 
- Presented at the ANCA Workshop, Lund Sweden, June 2009 
 
 “Effect of serine proteases, Elastase and Proteinase 3, on glomerular endothelial cell-
neutrophil interactions” Samantha Tull, Sahithi J Panchagnula, Anne Bevins, Simon 
C. Satchell, Lorraine Harper, G. Ed Rainger, Caroline Savage - Presented at the 
Renal Association Conference, Glasgow, May 2008 
 
 iii 
List of Abbreviations 
 
α1-AT   α1-Antitrypsin 
ACD   Acid Citrate Dextrose 
ACE   Angiotensin-Converting Enzyme 
ADAMTS-13 A Disintegrin and Metalloprotease with a Thrombspondin type 1 
Motif, Member 13 
ADP Adenosine-Diphosphate 
ANCA   Anti-Neutrophil Cytoplasm Antibodies 
Ang-1    Angiopoietin-1 
Ang-2   Angiopoietin-2 
Anti-GBM  Anti-Glomerular Basement Membrane 
AP3   Adaptor Protein Complex-3 
ASV   ANCA Systemic Vasculitides 
ATN   Acute Tubular Necrosis 
ATP   Adenosine-5'-Triphosphate 
BSA   Bovine Serum Albumin 
BVAS   Birmingham Vasculitis Activity Score 
C2GNT  Core 2 -1,6-N-acetylglucosaminyltransferase 
CaM   Calmodulin 
cAMP   Cyclic Adenosine Monophosphate 
CDKs   Cyclin-Cyclin Dependant Kinases 
CXCL1  CXC chemokine ligand 1 
CXCL8  CXC chemokine ligand 8 
CXCR1  CXC Chemokine Receptor-1 
CXCR2  CXC Chemokine Receptor-2 
CTLA-4  Cytotoxic T-Lymphocyte Antigen-4 
DMSO   Dimethyl Sulfoxide 
EDTA   Ethylenediaminetetraacetic acid 
EGM-2-MV  Endothelial Growth Medium-2-Microvascular 
ELISA   Enzyme Linked Immunosorbent Assay 
ELR motif  Glu4-Leu5-Arg6 motif  
EnC   Endothelial Cell 
FACS   Fluorescence-Activated Cell Sorting 
FCS   Fetal Calf Serum 
fMLP   Formyl-Methionyl-Leucyl-Phenylalanine 
GAG   Glycoaminoglycans 
GEnC   Glomerular Endothelial Cell 
GP1bα   Glycoprotein-1bα 
H2O2   Hydrogen Peroxide 
HBH   Hanks Buffered Saline Solution plus Hepes 
HCl   Hydrochloric Acid 
HK   High Molecular Weight Kininogen 
HLE   Human Leukocyte Elastase 
HRP   Horseradish Peroxidase 
HUVEC  Human Umbilical Vein Endothelial Cells 
IFNγ   Interferon-γ 
IL-1β   Interleukin-1β 
IL-6   Interleukin-6 
IL-17   Interleukin-17 
IL-18   Interleukin-18 
 iv 
ICAM-1  Intercellular Adhesion Molecule-1 
JNK   Jun N-Terminal Kinase 
KC   Keratinocyte Derived Chemokine 
LF   Lipofectamine 
LFA-1   Lymphocyte Function-associated Antigen-1 (CD11a/CD18) 
LPS   Lipopolysaccharide 
M199   Medium199 
Mac-1   Macrophage Antigen-1 (CD11b/CD18) 
MCP-1  Monocyte Chemoattactant Protein-1 
MMPs   Matrix Metalloproteinases 
MPO   Myeloperoxidase 
MTT   1-(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan 
NAP-1   Neutrophil Activating Protein 
NFκB   Nuclear Factor-κB 
NMR   Nucleotide Monitoring Reagent 
NO   Nitric Oxide 
NOD   Non-obese Diabetic 
NP40   (Octylphenoxy)phenoxypolyethoxylethanol 
NRR   Nucleotide Releasing Reagent 
OPD   o-Phenylenediamine Dihydrochloride 
PAP   Peroxidase Anti-Peroxidase 
PAR   Protease Activated Receptor 
PAR-AP  Protease Activated Receptor Agonist Peptide 
SDS-PAGE  Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
Serpin   Serine Protease Inhibitor 
PBMC   Peripheral Blood Mononuclear Cells 
PBS   Phosphate Buffered Saline 
PFA   Paraformaldehyde 
PI3K   Phosphatidylinositol 3-Kinase 
PKA   Protein Kinase A 
PKC   Protein Kinase C 
PSGL-1  P-Selectin Glycoprotein Ligand-1 
PAF   Platelet Activating Factor 
PMN   Polymorphonuclear Cells 
PR3   Proteinase 3 
ROS   Reactive Oxygen Species 
SDS   Sodium Dodecyl Sulfate 
SCID   Severe Combined Immunodeficiency 
siRNA   Small Interference RNA 
SOD   Superoxide Dismutase 
TBS   Tris Buffered Saline 
TF   Tissue Factor 
Tie-1 Tyrosine Kinase with Immunoglobulin and EGF homology domains-1 
Tie-2 Tyrosine Kinase with Immunoglobulin and EGF homology domains-2 
TLR   Toll-Like Receptor 
TMB   3,3′,5,5′-Tetramethylbenzidine 
TNFα   Tumour Necrosis Factor-α 
Treg   Regulatory T-Lymphocytes 
VCAM-1  Vascular Cell Adhesion Molecule-1 
VEGF   Vascular Endothelial Growth Factor 
VDI   Vasculitis Damage Index 
vWf   von Willebrand Factor 
 v 
WG   Wegener’s Granulomatosis 
WPB   Weibel-Palade Bodies  
 vi 
Abstract 
 
ANCA-systemic vasculitic glomerulonephritides (ASV) are a collection of diseases 
associated with the presence of autoimmune antibodies directed at the components of 
neutrophil cytoplasmic granules, known as ANCA. ANCA is proposed to bind to its antigen 
on the neutrophil surface, from where it can stimulate neutrophil activation and 
consequently, increased adhesion to the vascular endothelium, as well as production of 
reactive oxygen species and release of granular contents. It is believed that the components 
of the alpha neutrophil granules, namely the neutrophil serine proteases, may be involved the 
induction of inflammation and endothelial cell injury observed in ANCA systemic vasculitis. 
This project has focused on the effects of Proteinase 3 (PR3), a neutrophil serine protease, on 
the glomerular endothelium.  
 
To undertake this research we used two endothelial cell types, primary endothelial cells from 
human umbilical cords (HUVEC) and a conditionally immortalised glomerular endothelial 
cell line (GEnC). The data in this thesis proposes that the neutrophil serine proteases, PR3 
and human leukocyte elastase (HLE), have an early activatory role on the vascular 
endothelium, with later long-term injurious effects. Short treatments of endothelial cells with 
PR3 and HLE had no significant effects on mitochondrial activity, endothelial detachment or 
intracellular ADP/ATP levels, whilst 24 hour treatments resulted in endothelial cell 
apoptosis. This was further demonstrated by release of von Willebrand Factor (vWf), which 
was maximal at 24h treatment. Short serine protease treatments resulted in dose-dependant 
release of vWf from endothelial cells, which along with increased release of chemokine 
ligand 8 (CXCL8) and expression of P-Selectin, implicates increased exocytosis of the 
endothelial Weibel-Palade bodies (WPB). 
 
 vii 
Using a static model of neutrophil adhesion, we demonstrated that PR3 and HLE had the 
potential to increase neutrophil adhesion to the endothelium. This adhesion occurs through 
interactions between P-Selectin and its ligand, P-Selectin glycoprotein ligand-1 (PSGL-1), 
on neutrophils, as endothelial treatment with PR3 and HLE resulted in increased membrane 
expression of P-Selectin, whilst blocking antibodies directed at PSGL-1 significantly 
inhibited neutrophil adhesion to protease treated endothelial cells. Further, PR3 and HLE 
have the ability to cleave CXCL8 for support of inflammation, perhaps inducing activation 
of leukocyte integrins to increase adhesion. Moreover, inhibition of CXCL8 receptors, 
CXCR1 and CXCR2, on neutrophils decreased the level of neutrophil adhesion. 
 
The effects of PR3 or HLE on endothelial cell activation do not appear to be occurring 
through the ‘classical’ signalling pathways or through protease activated receptor 
interactions. Interestingly, PR3 treatment does change the pattern of tyrosine and 
serine/threonine phosphorylation, and further investigation into this may identify a unique 
signalling pathway, and thereby, possible therapeutic targets. 
 
 
 viii 
Table of Contents 
 
ACKNOWLEDGEMENTS .......................................................................................................................................I 
WORK ARISING FROM THIS THESIS............................................................................................................. II 
LIST OF ABBREVIATIONS.................................................................................................................................III 
ABSTRACT ..............................................................................................................................................................VI 
1. AN INTRODUCTION TO ANCA-ASSOCIATED VASCULITIS ............................................................... 1 
1.1 VASCULITIC GLOMERULONEPHRITIS ................................................................................................................ 1 
1.2 ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES AND THEIR ANTIGENS ......................................................... 3 
1.3 AETIOPATHOGENESIS OF VASCULITIS............................................................................................................... 5 
1.4 THE NEUTROPHIL............................................................................................................................................. 11 
1.5 THE NEUTROPHIL SERINE PROTEASES............................................................................................................ 13 
1.6 PR3 AND ENDOTHELIAL APOPTOSIS............................................................................................................... 16 
1.7 ALPHA-1 ANTITRYPSIN: A SERINE PROTEASE INHIBITOR............................................................................. 17 
1.8 NEUTROPHILS IN INFLAMMATION: THE PROCESS OF TRANSMIGRATION...................................................... 18 
1.9 CHEMOKINE LIGAND-8 INDUCED NEUTROPHIL ADHESION........................................................................... 22 
1.10 NEUTROPHIL PRIMING BY TUMOUR NECROSIS FACTOR-α.......................................................................... 23 
1.11 OTHER CELL TYPES IMPLICATED IN ASV .................................................................................................... 25 
1.11.1 Macrophages........................................................................................................................................................25 
1.11.2 T-cells...................................................................................................................................................................27 
1.11.3 B-Cells..................................................................................................................................................................28 
1.12 ENDOTHELIAL CELLS IN INFLAMMATION..................................................................................................... 30 
1.13 GLOMERULAR ENDOTHELIUM: A TARGET IN ANCA-ASSOCIATED VASCULITIS ...................................... 33 
1.14 WEIBEL-PALADE BODIES .............................................................................................................................. 35 
1.15 VON WILLEBRAND FACTOR (VWF) AND THE COAGULATION CASCADE .................................................... 37 
1.16 VWF IN ANCA-ASSOCIATED VASCULITIS ................................................................................................... 39 
1.17 OTHER CONSTITUENTS OF WPB................................................................................................................... 39 
1.17.1 Angipoietin-2 .......................................................................................................................................................39 
1.17.2 P-Selectin .............................................................................................................................................................41 
1.17.3 CD63 (Platelet Glycoprotein gp40)....................................................................................................................42 
1.17.4 Chemokine Ligand-8...........................................................................................................................................42 
1.18 EVIDENCE FOR PROTEASE-ACTIVATED RECEPTORS IN VWF RELEASE ...................................................... 44 
1.19 SIGNALLING IN VWF RELEASE FROM WEIBEL-PALADE BODIES ................................................................. 46 
1.20 AIMS AND HYPOTHESIS ................................................................................................................................. 47 
2. MATERIALS AND METHODS ....................................................................................................................... 49 
2.1. CONDITIONALLY IMMORTALISED GLOMERULAR ENDOTHELIAL CELLS ..................................................... 49 
2.2 ISOLATION OF HUVEC FROM UMBILICAL VEINS.......................................................................................... 51 
2.3 MATERIALS ...................................................................................................................................................... 52 
2.4 NEUTROPHIL ISOLATION ................................................................................................................................. 53 
2.5 TREATMENT OF ENDOTHELIAL CELLS WITH TUMOUR NECROSIS FACTOR-α............................................... 54 
2.6 P-SELECTIN, E-SELECTIN, ICAM-1 AND VCAM-1 CELL SURFACE EXPRESSION ELISA .......................... 56 
2.7 QUANTIFICATION OF CXCL8 IN CELL SUPERNATANT .................................................................................. 57 
2.8 PROTEASE DIGESTION OF CXCL8 IN CELL CULTURE SUPERNATANTS ........................................................ 58 
2.9 INHIBITION OF NEUTROPHIL ADHESION BY BLOCKING PSGL-1................................................................... 58 
2.10 INHIBITION OF NEUTROPHIL ADHESION BY BLOCKING CXCR1 AND CXCR2 .......................................... 59 
2.11 VON WILLEBRAND FACTOR ELISA OF SUPERNATANTS............................................................................. 59 
2.12 QUANTIFYING VWF MRNA BY PCR ............................................................................................................ 60 
2.13 CELL SURFACE EXPRESSION OF VWF FOLLOWING PROTEASE TREATMENT............................................... 62 
2.14 VWF EXPRESSION BY FLOW CYTOMETRY.................................................................................................... 63 
2.15 VWF, CD63 AND F-ACTIN STAINING BY CONFOCAL MICROSCOPY........................................................... 63 
2.16 VWF IMMUNOHISTOCHEMISTRY OF KIDNEY BIOPSIES ................................................................................ 64 
2.17 ANGIOPOIETIN-2 ELISA OF SUPERNATANTS............................................................................................... 66 
2.18 RELEASE OF VWF BY PAR AGONISTS .......................................................................................................... 67 
2.19 KNOCKDOWN OF PAR1 AND PAR2 BY SIRNA ........................................................................................... 67 
2.20 RNA ISOLATION AND REAL-TIME PCR OF PAR-1 AND PAR-2................................................................. 68 
2.21 FLOW CYTOMETRY DETERMINATION PAR-1 AND PAR-2 PROTEIN EXPRESSION FOLLOWING SIRNA .... 69 
2.22 INHIBITION OF MAJOR PATHWAYS OF VWF RELEASE ................................................................................. 70 
 ix 
2.23 PKC INHIBITION OF NEUTROPHIL SUPEROXIDE RELEASE........................................................................... 71 
2.24 NEUTROPHIL DEGRANULATION ASSAY........................................................................................................ 72 
2.25 INHIBITION OF VWF RELEASE BY F-ACTIN INHIBITOR, CYTOCHALASIN B................................................. 72 
2.26 STIMULATION OF ENDOTHELIAL VWF RELEASE BY OKADAIC ACID........................................................... 73 
2.27 TYROSINE AND SERINE/THREONINE PHOSPHORYLATION BY WESTERN BLOTTING................................... 73 
2.28 NECROSIS VERSES APOPTOSIS WITH APOGLOW® ....................................................................................... 75 
2.29 CRYSTAL VIOLET STAINING OF ADHERENT CELLS...................................................................................... 76 
2.30 MTT ASSESSMENT OF MITOCHONDRIAL ACTIVITY..................................................................................... 77 
2.31 STATISTICAL ANALYSES ............................................................................................................................... 77 
3. RESULTS .............................................................................................................................................................. 79 
3.1 VISUALISATION OF ENDOTHELIAL CELLS AT DIFFERENT TIME POINTS IN CULTURE .................................. 79 
3.2 CRYSTAL VIOLET STAINING FOR CELL ADHERENCE ..................................................................................... 81 
3.3 MEASURE OF MITOCHONDRIAL ACTIVITY IN SERINE PROTEASE TREATED ENDOTHELIAL CELLS ............. 83 
3.4 MEASURE OF APOPTOSIS BY CONVERSION OF ATP INTO ADP..................................................................... 85 
3.5 VON WILLEBRAND FACTOR RELEASE FROM SERINE PROTEASE TREATED ENDOTHELIAL CELLS.............. 91 
3.6 INCREASED LEVEL OF INTRACELLULAR VWF PROTEIN AND MRNA FOLLOWING TREATMENT .................. 96 
3.7 INHIBITION OF VWF RELEASE BY α1-ANTITRYPSIN .................................................................................... 102 
3.8 CHANGES IN VWF SURFACE EXPRESSION FOLLOWING SERINE PROTEASE TREATMENT........................... 106 
3.9 VWF RELEASE: INTERNAL STORES VERSUS MEMBRANE CLEAVAGE ......................................................... 109 
3.10 CONFOCAL STAINING FOR VWF AND THE PLASMA MEMBRANE............................................................... 111 
3.11 VWF STAINING IN RENAL BIOPSIES ............................................................................................................ 115 
3.11 CHEMOKINE LIGAND-8 RELEASE FOLLOWING SERINE PROTEASE TREATMENT...................................... 118 
3.12 ANGIOPOIETIN-2 RELEASE FROM SERINE PROTEASE TREATED ENDOTHELIAL CELLS............................ 123 
3.13 CD63 EXPRESSION BY SERINE PROTEASE TREATED GENC ..................................................................... 126 
3.14 UPREGULATION OF ENDOTHELIAL MEMBRANE P-SELECTIN EXPRESSION BY PR3 AND HLE ................ 128 
3.15 VWF RELEASE BY PAR AGONIST PEPTIDES .............................................................................................. 131 
3.16 SIRNA KNOCKDOWN OF PAR-1 AND PAR-2 DOES NOT REDUCE VWF RELEASE ................................... 135 
3.17 SIGNALLING PATHWAYS INVOLVED IN VWF RELEASE .............................................................................. 137 
3.18 INHIBITION OF VWF RELEASE BY INHIBITION OF ACTIN POLYMERISATION ............................................. 148 
3.19 INHIBITION OF VWF RELEASE BY INHIBITION OF PHOSPHATASE ACTIVITY ............................................. 150 
3.20 CHANGES IN PHOSPHOPEPTIDES FOLLOWING SERINE PROTEASE TREATMENT ........................................ 154 
3.21 NEUTROPHIL ADHESION TO TNFα TREATED ENDOTHELIAL CELLS ........................................................ 158 
3.22 NEUTROPHIL ADHESION TO PR3 AND HLE TREATED ENDOTHELIAL CELLS........................................... 160 
3.23 MEMBRANE EXPRESSION OF E-SELECTIN FOLLOWING SERINE PROTEASE EXPRESSION ........................ 163 
3.24 EXPRESSION OF SURFACE ICAM-1 FOLLOWING SERINE PROTEASE TREATMENT ................................... 167 
3.25 EXPRESSION OF VCAM-1 ON SERINE PROTEASE TREATED ENDOTHELIAL CELLS .................................. 170 
3.26 BLOCKING PSGL-1 ON NEUTROPHILS INHIBITS ADHESION...................................................................... 173 
3.27 INHIBITION OF CXCR1 AND CXCR2 ON NEUTROPHILS INHIBITS ADHESION ......................................... 175 
4. DISCUSSION...................................................................................................................................................... 177 
4.1 NEUTROPHIL SERINE PROTEASES DO NOT INDUCE ENDOTHELIAL CELL INJURY FOLLOWING SHORT 
INCUBATIONS ....................................................................................................................................................... 177 
4.2 RELEASE OF VWF OCCURS DUE TO ACTIVATION NOT INJURY..................................................................... 179 
4.3 CONFOCAL STAINING OF VWF AND THE ENDOTHELIAL MEMBRANE PRODUCES INCONCLUSIVE RESULTS
.............................................................................................................................................................................. 182 
4.4 PR3 AND HLE CAUSE EXOCYTOSIS OF WEIBEL-PALADE BODY CONSTITUENTS....................................... 183 
4.5 VWF IS CLEAVED AND RELEASED ................................................................................................................ 186 
4.6 VWF PROTEIN AND MRNA IS INCREASED BY SERINE PROTEASES .............................................................. 188 
4.7 VWF EXPRESSION IN RENAL BIOPSIES ......................................................................................................... 190 
4.8 PR3 AND HLE SIGNAL THROUGH A UNIQUE PATHWAY TO INDUCE VWF RELEASE ................................. 191 
4.9 THE SERINE PROTEASES INCREASE NEUTROPHIL ADHESION THROUGH INTERACTIONS BETWEEN P-
SELECTIN AND PSGL-1 ....................................................................................................................................... 197 
4.10 A ROLE FOR CXCL8 IN NEUTROPHIL ADHESION...................................................................................... 201 
4.11 α1-ANTITRYPSIN – A POTENTIAL THERAPY IN ANCA VASCULITIS?...................................................... 204 
4.12 DIFFERENTIAL ROLES FOR PR3 AND HLE? ............................................................................................... 206 
4.13 CAN A GENC LINE ACCURATELY REPRESENT A PRIMARY GLOMERULAR ENDOTHELIAL CELL? .......... 208 
5. CONCLUDING REMARKS............................................................................................................................ 210 
6. FUTURE WORK ............................................................................................................................................... 213 
7. APPENDICES .................................................................................................................................................... 216 
 x 
1. PCR MASTERMIXES ........................................................................................................................................ 216 
2. REAL-TIME PCR MIX...................................................................................................................................... 217 
3. WESTERN BLOT RECIPES................................................................................................................................. 217 
4. APOGLOW® ASSAY GUIDELINE CRITERIA .................................................................................................... 220 
8. REFERENCES ................................................................................................................................................... 221 
 
 
 xi 
Table of Figures 
FIGURE 1 - HYPOTHESISED MECHANISM OF ANCA VASCULITIS .............................................................................. 6 
FIGURE 2 - THE THEORY OF ANTIGEN COMPLEMENTARITY....................................................................................... 8 
FIGURE 3 - ANCA-MEDIATED NEUTROPHIL ACTIVATION......................................................................................... 9 
FIGURE 4 - THE PROCESS OF LEUKOCYTE MIGRATION ............................................................................................ 20 
FIGURE 5 - PROPOSED SIGNALLING PATHWAYS INVOLVED IN VWF RELEASE........................................................ 47 
FIGURE 6 - ACTIVITY TEST FOR ENZYMES AND INHIBITORS .................................................................................... 53 
FIGURE 7 - VISUALISATION OF ENDOTHELIAL CELLS AT DIFFERENT TIME-POINT ................................................. 80 
FIGURE 8 – TIMECOURSE OF CRYSTAL VIOLET STAINING FOR ENDOTHELIAL DETACHMENT ............................... 82 
FIGURE 9 - CRYSTAL VIOLET STAINING FOR ENDOTHELIAL DETACHMENT FOLLOWING TREATMENT WITH 
INCREASING CONCENTRATIONS OF SERINE PROTEASE.................................................................................... 82 
FIGURE 10 - MITOCHONDRIAL ACTIVITY FOLLOWING A TIMECOURSE OF PROTEASE TREATMENT....................... 84 
FIGURE 11 - MITOCHONDRIAL ACTIVITY FOLLOWING TREATMENT WITH INCREASING CONCENTRATIONS OF 
SERINE PROTEASE............................................................................................................................................. 84 
FIGURE 12 - CHANGES IN INTRACELLULAR ATP LEVELS AT 2 HOURS .................................................................... 88 
FIGURE 13 - CHANGES IN THE ADP:ATP RATIO AT 2 HOURS.................................................................................. 88 
FIGURE 14 - CHANGES IN INTRACELLULAR ATP LEVELS AT 24 HOURS.................................................................. 89 
FIGURE 15 - CHANGES IN THE ADP:ATP RATIO AT 24 HOURS................................................................................ 89 
FIGURE 16 - VISUALISATION OF GENC AFTER SERINE PROTEASE TREATMENT ..................................................... 90 
FIGURE 17 - VWF RELEASE FROM PR3 AND HLE TREATED ENDOTHELIAL CELLS AT 2 HOURS ........................... 93 
FIGURE 18 - VWF RELEASE FROM PR3 AND HLE TREATED ENDOTHELIAL CELLS AT 24 HOURS ......................... 93 
FIGURE 19 - TIMECOURSE OF VWF RELEASE FROM PR3 TREATED ENDOTHELIAL CELLS ..................................... 94 
FIGURE 20 - TIMECOURSE OF VWF RELEASE FROM HLE TREATED ENDOTHELIAL CELLS..................................... 94 
FIGURE 21 - VWF RELEASE FROM HUVEC AS A PERCENTAGE OF TOTAL VWF..................................................... 95 
FIGURE 22 - VWF RELEASE FROM GENC AS A PERCENTAGE OF TOTAL VWF......................................................... 95 
FIGURE 23 - LEVEL OF INTRACELLULAR VWF REMAINING IN HUVEC AFTER SERINE PROTEASE TREATMENT .. 98 
FIGURE 24 - LEVEL OF INTRACELLULAR VWF REMAINING IN GENC AFTER SERINE PROTEASE TREATMENT...... 98 
FIGURE 25 - TOTAL VWF AFTER TREATMENT OF HUVEC WITH SERINE PROTEASES ............................................ 99 
FIGURE 26 - TOTAL VWF AFTER TREATMENT OF GENC WITH SERINE PROTEASES ............................................... 99 
FIGURE 27 - CLEAVAGE OF VWF BY PR3 AND HLE............................................................................................... 100 
FIGURE 28 - VWF MRNA LEVELS FOLLOWING SERINE PROTEASE TREATMENT................................................... 101 
FIGURE 29 - INHIBITION OF VWF RELEASE BY α1AT AT 2 HOURS ........................................................................ 103 
FIGURE 30 - INHIBITION OF VWF RELEASE BY α1AT AT 24 HOURS ...................................................................... 103 
FIGURE 31 - α1AT INHIBITION OF VWF RELEASE FROM HUVEC AT HIGHER CONCENTRATIONS OF SERINE 
PROTEASE........................................................................................................................................................ 104 
FIGURE 32 - α1AT INHIBITION OF VWF RELEASE FROM GENC AT HIGHER CONCENTRATIONS OF SERINE 
PROTEASE........................................................................................................................................................ 104 
FIGURE 33 - HUVEC DETACHMENT FOLLOWING TREATMENT WITH HIGHER DOSES OF PR3 AND HLE........... 105 
FIGURE 34 - GENC DETACHMENT FOLLOWING TREATMENT WITH HIGHER DOSES OF PR3 AND HLE .............. 105 
FIGURE 35 - SURFACE EXPRESSION OF VWF ON HUVEC FOLLOWING SERINE PROTEASE TREATMENT............. 107 
FIGURE 36 - SURFACE EXPRESSION OF VWF ON GENC FOLLOWING SERINE PROTEASE TREATMENT ................ 107 
FIGURE 37 - SURFACE EXPRESSION OF VWF ON HUVEC CAN BE RESTORED BY α1AT ...................................... 108 
FIGURE 38 - SURFACE EXPRESSION OF VWF ON GENC CAN BE RESTORED BY α1AT .......................................... 108 
FIGURE 39 - FACS ANALYSIS OF VWF RELEASE FROM SURFACE AND INTERNAL STORES ................................. 110 
FIGURE 40 - LOCALISATION OF VWF WITH THE PLASMA MEMBRANE................................................................... 113 
FIGURE 41 - Z-STACK IMAGING OF VWF STAINING................................................................................................ 114 
FIGURE 42 - VWF STAINING IN RENAL BIOPSIES .................................................................................................... 117 
FIGURE 43 - CHEMOKINE LIGAND-8 RELEASE FROM SERINE PROTEASE TREATED HUVEC............................... 120 
FIGURE 44 – CHEMOKINE LIGAND-8 RELEASE FROM SERINE PROTEASE TREATED GENC.................................. 120 
FIGURE 45 - CLEAVAGE OF CHEMOKINE LIGAND-8 BY PR3 AND HLE................................................................. 121 
FIGURE 46 – CHEMOKINE LIGAND-8 CLEAVAGE BY HLE CAN BE INHIBITED BY α1AT...................................... 121 
FIGURE 47 – CHEMOKINE LIGAND-8 RELEASE FOLLOWING REMOVAL OF SERINE PROTEASES 1 HOUR 
INCUBATION .................................................................................................................................................... 122 
FIGURE 48 – CHEMOKINE LIGAND-8 RELEASE FOLLOWING REMOVAL OF SERINE PROTEASES 1 AND 2 HOUR 
INCUBATIONS .................................................................................................................................................. 122 
FIGURE 49 - ANGIOPOIETIN-2 RELEASE FROM HUVEC FOLLOWING SERINE PROTEASE TREATMENT ............... 124 
FIGURE 50 - ANGIOPOIETIN-2 RELEASE FROM GENC FOLLOWING SERINE PROTEASE TREATMENT................... 124 
FIGURE 51 - PR3 AND HLE CLEAVE ANGIOPOIETIN-2 .......................................................................................... 125 
FIGURE 52 - ANGIOPOIETIN-2 RELEASE AFTER REMOVAL OF PR3 AND HLE....................................................... 125 
FIGURE 53 - CD63 STAINING FOLLOWING PROTEASE TREATMENT....................................................................... 127 
FIGURE 54 - P-SELECTIN SURFACE EXPRESSION FOLLOWING PR3 AND HLE TREATMENT................................. 130 
 xii 
FIGURE 55 - INHIBITION OF P-SELECTIN EXPRESSION BY α1AT............................................................................ 130 
FIGURE 56 - OPTIMISATION OF PAR AGONIST PEPTIDE INDUCED VWF RELEASE ................................................ 132 
FIGURE 57 - EFFECT OF PAR AGONISTS ON VWF RELEASE................................................................................... 133 
FIGURE 58 - EFFECT OF PAR AGONISTS ON ENDOTHELIAL CELL DETACHMENT ................................................. 133 
FIGURE 59 - CONFIRMATION OF KNOCKDOWN OF PAR-1 AND PAR-2 BY MRNA LEVELS ................................. 134 
FIGURE 60 - CONFIRMATION OF PAR-1 KNOCKDOWN BY FLOW CYTOMETRY .................................................... 134 
FIGURE 61 - KNOCKDOWN OF PAR-1 AND PAR-2 DOES NOT REDUCE VWF RELEASE......................................... 136 
FIGURE 62 – PR3 MEDIATED VWF RELEASE FOLLOWING INHIBITION OF PKC.................................................... 139 
FIGURE 63 - HLE MEDIATED VWF RELEASE FOLLOWING INHIBITION OF PKC.................................................... 139 
FIGURE 64 - EFFECT OF PKC INHIBITOR ON MITOCHONDRIAL ACTIVITY............................................................. 140 
FIGURE 65 - CONFIRMATION OF THE PKC INHIBITOR BY MEASURING SUPEROXIDE PRODUCTION ..................... 140 
FIGURE 66 - PR3 MEDIATED VWF RELEASE FOLLOWING INHIBITION OF PKA .................................................... 141 
FIGURE 67- HLE MEDIATED VWF RELEASE FOLLOWING INHIBITION OF PKA..................................................... 141 
FIGURE 68 - EFFECT OF PKA INHIBITOR ON MITOCHONDRIAL ACTIVITY............................................................. 142 
FIGURE 69 - PR3 MEDIATED VWF RELEASE FOLLOWING INHIBITION OF CALMODULIN...................................... 143 
FIGURE 70 - HLE MEDIATED VWF RELEASE FOLLOWING INHIBITION OF CALMODULIN..................................... 143 
FIGURE 71 - EFFECT OF CALMODULIN INHIBITOR ON MITOCHONDRIAL ACTIVITY .............................................. 144 
FIGURE 72 - PR3 MEDIATED VWF RELEASE FOLLOWING INHIBITION OF PI3K..................................................... 145 
FIGURE 73 - HLE MEDIATED VWF RELEASE FOLLOWING INHIBITION OF PI3K.................................................... 145 
FIGURE 74 - EFFECT OF PI3K INHIBITOR ON MITOCHONDRIAL ACTIVITY............................................................. 146 
FIGURE 75 - CONFIRMATION OF THE PI3K INHIBITOR BY MEASURING NEUTROPHIL DEGRANULATION .............. 146 
FIGURE 76 - INHIBITION OF ACTIN POLYMERISATION BY CYTOCHALASIN B........................................................ 147 
FIGURE 77 - CONFOCAL STAINING FOR VWF AND F-ACTIN ................................................................................... 149 
FIGURE 78 - VWF RELEASE BY OKADAIC ACID ...................................................................................................... 152 
FIGURE 79 - CRYSTAL VIOLET OF OKADAIC ACID DOSE CURVE........................................................................... 152 
FIGURE 80 - EFFECTS OF OKADAIC ACID ON PR3 AND HLE MEDIATED VWF RELEASE ..................................... 153 
FIGURE 81 - MITOCHONDRIAL ACTIVITY AFTER OKADAIC ACID TREATMENT..................................................... 153 
FIGURE 82 - WESTERN BLOT FOR TYROSINE PHOSPHORYLATION......................................................................... 156 
FIGURE 83 - WESTERN BLOT FOR SERINE/THREONINE PHOSPHORYLATION ......................................................... 157 
FIGURE 84 - NEUTROPHIL ADHESION TO TNFα TREATED ENDOTHELIAL CELLS................................................. 159 
FIGURE 85 - NEUTROPHIL ADHESION TO PR3/HLE TREATED HUVEC................................................................ 161 
FIGURE 86 - NEUTROPHIL ADHESION TO PR3/HLE TREATED GENC ................................................................... 161 
FIGURE 87 - INHIBITION OF NEUTROPHIL ADHESION TO HUVEC BY α1AT ........................................................ 162 
FIGURE 88 - INHIBITION OF NEUTROPHIL ADHESION OF GENC BY α1AT ............................................................ 162 
FIGURE 89 - OPTIMISATION OF E-SELECTIN ELISA ............................................................................................... 165 
FIGURE 90 - E-SELECTIN EXPRESSION ON HUVEC FOLLOWING SERINE PROTEASE TREATMENT ...................... 166 
FIGURE 91 - E-SELECTIN EXPRESSION ON GENC FOLLOWING SERINE PROTEASE TREATMENT.......................... 166 
FIGURE 92 - OPTIMISATION OF ICAM-1 ELISA..................................................................................................... 168 
FIGURE 93 - ICAM-1 EXPRESSION ON HUVEC FOLLOWING SERINE PROTEASE TREATMENT............................ 169 
FIGURE 94 - ICAM-1 EXPRESSION ON GENC FOLLOWING SERINE PROTEASE TREATMENT ............................... 169 
FIGURE 95 - OPTIMISATION OF VCAM-1 ELISA ................................................................................................... 171 
FIGURE 96 - VCAM-1 EXPRESSION ON HUVEC FOLLOWING SERINE PROTEASE TREATMENT .......................... 172 
FIGURE 97 - VCAM-1 EXPRESSION ON GENC FOLLOWING SERINE PROTEASE TREATMENT.............................. 172 
FIGURE 98 - BLOCKING PSGL-1 ON NEUTROPHILS INHIBITS ADHESION TO HUVEC.......................................... 174 
FIGURE 99 - BLOCKING PSGL-1 ON NEUTROPHILS INHIBITS ADHESION TO GENC ............................................. 174 
FIGURE 100 - BLOCKING CXCR1 AND CXCR2 ON NEUTROPHILS INHIBITS ADHESION TO HUVEC ................. 176 
FIGURE 101 - BLOCKING CXCR1 AND CXCR2 ON NEUTROPHILS INHIBITS ADHESION TO GENC..................... 176 
FIGURE 102 - SERINE PROTEASES CAUSE DISEASE PROPAGATION BY SUPPORTING INFLAMMATORY PROCESSES
......................................................................................................................................................................... 203 
 
 xiii 
Table of Tables 
TABLE 1 - SUMMARY OF ANCA-ASSOCIATED SMALL VESSEL VASCULITIDES........................................................ 2 
TABLE 2 - OVERVIEW OF NEUTROPHIL GRANULAR CONTENTS ............................................................................... 12 
TABLE 3 - SUMMARY OF FUNCTIONS OF PR3 AND HLE .......................................................................................... 16 
TABLE 4 - DIFFERENT SUBSETS OF MACROPHAGES.................................................................................................. 26 
TABLE 5 - CONSTITUENTS OF ENDOTHELIAL GROWTH MEDIUM-2-MICROVASCULAR (EGM-2-MV) .................. 50 
TABLE 6 - CONSTITUENTS OF COMPLETE MEDIUM199 ............................................................................................ 50 
TABLE 7 - TNF-α DILUTIONS ..................................................................................................................................... 55 
TABLE 8 - PRIMARY ANTIBODIES FOR ELISA .......................................................................................................... 56 
TABLE 9 - CONSTITUENTS OF CARBONATE BUFFER ................................................................................................. 60 
TABLE 10 - PCR PROGRAMME FOR REVERSE TRANSCRIPTION ............................................................................... 61 
TABLE 11 - PCR PROGRAMME FOR VWF AMPLIFICATION....................................................................................... 62 
TABLE 12 - PRIMARY ANTIBODIES FOR IMMUNOCYTOCHEMISTRY ......................................................................... 64 
TABLE 13 - CONSTITUENTS OF TBS PH 7.6 .............................................................................................................. 66 
TABLE 14 - ANTIBODIES FOR PAR FLOW CYTOMETRY............................................................................................ 70 
TABLE 15 - INHIBITORS USED FOR VWF RELEASE ..................................................................................................... 71 
TABLE 16 - CONSTITUENTS OF NP40 LYSIS BUFFER................................................................................................ 74 
TABLE 17 - ANTIBODIES USED FOR WESTERN BLOTTING......................................................................................... 75 
TABLE 18 - NUMERICAL DATA FOR APOGLOW® ASSAY AT 2 HOURS .................................................................... 87 
TABLE 19 - NUMERICAL DATA FOR APOGLOW® ASSAY AT 24 HOURS .................................................................. 87 
TABLE 20 – TAQMAN® REVERSE TRANSCRIPTION MASTERMIX .......................................................................... 216 
TABLE 21 - PCR MASTERMIX.................................................................................................................................. 216 
TABLE 22 - REAL-TIME PCR MASTERMIX.............................................................................................................. 217 
TABLE 23 - GEL RECIPES.......................................................................................................................................... 217 
TABLE 24 - CONSTITUENTS OF WESTERN BLOT RUNNING BUFFER....................................................................... 218 
TABLE 25 - CONSTITUENTS OF WESTERN BLOT TBS-T ......................................................................................... 218 
TABLE 26 - CONSTITUENTS OF WESTERN BLOT TRANSFER BUFFER ..................................................................... 218 
TABLE 27 - CONSTITUENTS OF SDS-PAGE LOADING BUFFER.............................................................................. 219 
TABLE 28 - CONSTITUENTS OF COOMASSIE STAIN/DESTAIN ................................................................................. 219 
 
 
 
 
 1 
1. An Introduction to ANCA-Associated Vasculitis 
 
1.1 Vasculitic Glomerulonephritis 
 
Vasculitis is defined as the inflammation and consequent necrosis of blood vessel walls. It 
consists of a group of diseases that can be localised or systemic, although currently there is 
no robust way of classification. In one system, vasculitides are classified by the size of the 
vessel predominantly affected [1, 2], however this system disregards the overlap that may 
occur between the groups (reviewed in [3]).  
 
The small vessel vasculitides are of particular interest, and include Wegener’s 
granulomatosis, microscopic polyangiitis and Churg-Strauss syndrome. These disorders are 
commonly associated with the presence of anti-neutrophil cytoplasm antibodies (ANCA) 
directed at antigens within the cytoplasmic granules of neutrophils and monocytes. ANCA-
associated systemic vasculitides (ASV) usually affect small vessels of the vasculature, 
including the arterioles, venules and capillaries; however, they can sometimes affect larger 
arteries. Although multiple organs can be affected, the pulmonary and renal circulations are 
preferentially targeted. ASV share common pathological features, including the development 
of focal necrotizing lesions within the glomerulus of the kidney, which may progress to 
cause acute renal failure (reviewed in [4]). In Wegener’s granulomatosis (WG) 
approximately 80% of patients present renal involvement at some point during their illness, 
with over 90% of patients also displaying some form of upper respiratory tract disease, 
which can progress to pulmonary haemorrhage. Although, other systems may also be 
involved [5] (see table 1 for more detail). Taken together, ASV have a combined incidence 
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of 20 per million individuals per year in the UK, with a mean age of 59 (interquartile range 
47 - 70 years) [6-9]. The presence of autoantibodies in ASV allows us to describe the 
associated conditions as autoimmune diseases which is more rigorously backed up by 
observation that ANCA are directly pathogenic to the neonate after transfer across the 
placenta [10] and by the observation that vasculitis can be induced in naïve animals 
following transfer of ANCA IgG [11, 12].  
 
Table 1 - Summary of ANCA-Associated Small Vessel Vasculitides 
 Wegener’s Granulomatosis Microscopic Polyangiitis Churg-Strauss Syndrome 
ANCA Present in 80-90% cases 
90% PR3-ANCA 
10% MPO-ANCA 
 
Present in 50-70% cases 
10% PR3-ANCA 
80% MPO-ANCA 
Present in 35-45% cases 
10% PR3-ANCA 
75% MPO-ANCA 
Vessels 
Affected 
 
Small-medium vessels Small-medium vessels Small vessels 
Histology Necrotising vasculitis 
Granulomatous Inflammation 
Necrotising vasculitis 
No Granulomas 
Necrotising vasculitis 
Eosinophilic Infiltrate 
Extravascular Granulomas 
 
Primary Organ 
Involvement 
Otolaryngeal (ENT) 80-90% 
Pulmonary 50-80% 
Renal 50-80% 
Articular 50-80% 
Renal 90-100% 
Articular 30-70% 
Skin 40-70% 
Pulmonary 96-100% 
Otolaryngeal 50-80% 
Skin 50-80% 
Axonal Peripheral 
Neuropathy 70% 
 
Average Age 47 years 
 
49 years 47 years 
Sex 54% Male 
 
59% Male 51% Male 
Adapted from Puechal 2007 [13] 
 
Clinically, disease activity is assessed by two main systems, the Birmingham vasculitis 
activity score (BVAS) and the vasculitis damage index (VDI). ANCA-associated vasculitis 
is currently being treated by a cocktail of drugs, including steroids and immunosuppressive 
agents, which, although having successfully increased the survival rate from 20% survival at 
2 years to 80% survival at 5 years, have transformed ASV into a relapsing remitting disease. 
Additionally, this treatment has been associated with high morbidity and mortality rates due 
to infection, neoplasm and other complications, with 25% of patients displaying treatment-
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associated adverse effects [14]. It is therefore important that research into the underlying 
issues of ASV and the development of new effective treatments with improved safety 
profiles be undertaken. 
 
 
 
1.2 Anti-Neutrophil Cytoplasmic Antibodies and their Antigens 
 
ANCA were first described in eight patients diagnosed with glomerulonephritis by Davies et 
al., 1982, who identified IgG antibodies in serum that stained the cytoplasm of neutrophils 
[15]. This discovery has prompted much interest into the involvement of ANCA in small 
vessel vasculitides. ANCA are autoantibodies directed predominantly at the components of 
the primary granules in neutrophils, and lysosomes in monocytes (reviewed in [3]). They are 
present in 90% of patients with pauci-immune vasculitis where there is little deposition of 
immune proteins within lesions. It has been suggested that ANCA play an important role in 
the pathogenesis of ASV by inducing the activation of ANCA-antigen expressing cytokine-
primed neutrophils and monocytes [16, 17], although it remains unclear why ANCA 
production is initially induced. It has previously been demonstrated that ANCA levels can 
correlate with vasculitic disease activity and severity, and that changes in ANCA titres may 
reflect changes in disease activity [18, 19]. The two classes of ANCA, cytoplasmic and 
perinuclear, were first recognised by the differences in their immunofluorescence staining 
pattern. Falk et al., 1988 demonstrated that c-ANCA produced a granular cytoplasmic 
staining pattern on ethanol fixed granulocytes, whilst p-ANCA produced a perinuclear 
staining pattern [20]. It has been demonstrated that both p- and c-ANCA will activate 
neutrophils in vitro, resulting in degranulation and the production of reactive oxygen species 
(ROS) [16].  
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There are two clinically relevant ANCA-antigens; these are Proteinase 3 (PR3) and 
Myeloperoxidase (MPO) (reviewed in [13]). More recently, lysosomal membrane protein-2 
(LAMP-2) has been speculated as another target of ANCA, although this is awaiting 
independent clinical validation. LAMP-2 was first identified as a target for ANCA in 1995 
by Kain et al., who immunoblotted neutrophil proteins with patient ANCA [21]. These 
autoantibodies are suggested to co-exist with PR3- and MPO-ANCA in almost all patients 
(>90%) with ANCA mediated glomerulonephritis, and have been shown to activate 
neutrophils in vitro and induce endothelial cell injury [22]. The upregulation of LAMP-2 to 
the neutrophil surface is suggested to mediate adhesion to endothelial E-Selectin [23, 24]. 
Interestingly, in neutrophils LAMP-2 is expressed in the membrane of the PR3 and MPO 
containing alpha granules [22]. 
 
PR3 is the major target of c-ANCA. The development of autoantibodies directed at PR3 is 
usually associated with Wegener’s granulomatosis [25, 26], whereas p-ANCA antibodies 
directed against MPO are more commonly associated with microscopic polyangiitis and 
Churg-Strauss syndrome [20, 27-29]. A possible explanation for the development of ANCA 
is that in “normal” circumstances, PR3 and MPO are quickly scavenged upon release from 
the cell, however, following neutrophil priming with inflammatory cytokine Tumour 
Necrosis Factor-α (TNFα) their expression is increased on the cell surface [30, 31], thereby 
allowing them to be targeted by the non-tolerized immune system and potentially resulting in 
the production of autoimmune antibodies. However, this may be an over simplistic view. 
Certainly, ANCA binding to the surface of neutrophils induces excessive respiratory burst 
and the subsequent release of granule enzymes and cytokines from the cell [16], resulting in 
an inflammatory response and endothelial cell damage. 
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1.3 Aetiopathogenesis of Vasculitis 
 
Although the exact underlying mechanism of vasculitis remains unknown, it is hypothesised 
that infection and an enhanced inflammatory environment leads to an upregulation of 
ANCA-antigen, PR3, on the surface of the neutrophil [16] (see figure 1). This phenomenon 
has previously been demonstrated in vitro, in which, neutrophil priming with TNFα resulted 
in the increased expression of surface bound PR3 [30, 31]. This membrane expressed PR3 
has been demonstrated to co-localise with the expression of β2 integrin CD11b/CD18 [32], 
and the ligation of CD11b/CD18 is essential for activation of the neutrophil by ANCA [33]. 
ANCA can bind to the membrane expressed PR3/β2 integrin on the surface of neutrophils 
[34] by its Fab2 domain, whilst the ANCA Fc portion cross-links the Fcγ receptor on the 
surface of neutrophils [35-37] inducing reactive oxygen species production and 
degranulation [16]. Together these result in the induction an inflammatory response and 
endothelial cell damage [38-40]. The activation of the neutrophil by ANCA requires binding 
of both its Fab2 and Fc domains [41-43]. 
 
It is hypothesised that ASV patients may display an increased expression of membrane PR3, 
which may allow for recognition by ANCA [44, 45]. A second explanation may be due to a 
loss of epigenetic silencing of MPO/PR3 genes and consequent abnormal gene transcription 
and expression [46]. The mRNA level of MPO/PR3 correlates with disease activity in 
patients displaying unregulated expression during active disease [47]. 
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Figure 1 - Hypothesised Mechanism of ANCA Vasculitis 
 
 
 
 
 
 
 
 
 
 
 
Increased neutrophil priming and activation of the endothelial monolayer are required for the development of 
ANCA associated vasculitis. Neutrophil priming and the consequent surface expression of PR3/MPO allow for 
activation by ANCA. This unnecessary neutrophil activation results in the direct injury to the vascular 
endothelium associated with vasculitis. 
 
 
It is proposed that activation of the alternative complement pathway may be involved in 
disease propagation. Xiao et al., 2007 demonstrated that the binding of ANCA to neutrophils 
resulted in the release of mediators that resulted in activation of the complement pathway 
and hence amplification of the inflammatory response. Incubation of normal human serum 
with ANCA-IgG alone did not result in complement activation. They further identified a 
requirement for complement in the induction of MPO-ANCA induced glomerulonephritis 
(GN) by the absence of GN development in complement deficient mice [48]. Mellbye et al., 
also demonstrated an ability of c-ANCA treated neutrophils to induce complement 
activation, and identified complement C5b-C9 complex, termed the membrane attack 
complex (MAC), depositions in 50% of the sera [49]. Activation of the alternative 
complement pathway causes the activation and cleavage of C3. Whilst C3a is involved in 
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chemotaxis and mast cell degranulation, C3b acts to further enhance the immune response by 
cleavage of C5 into C5a, a potent neutrophil chemoattractant. The effects of the complement 
pathway in ASV can be inhibited by blocking antibodies directed towards C5 receptors [50]. 
Interestingly, mice deficient for C5 are resistant to the development of non-crescentic 
glomerulonephritis by MPO-ANCA [48]. Furthermore, deposition of the C5b-C9 complex 
has been identified in fibrous glomerular crescents, whilst tubular interstitial C5b-C9 
expression was correlated with plasma creatinine levels and was predictive of renal outcome 
[51]. 
 
Another important field of research has been the investigation into the development of 
ANCA. Currently there is still much debate over the differing theories. The auto-antigen 
complementarity theory proposes that complementary proteins may initiate an immune 
response, from which the anti-idiotypic counter response cross-reacts with PR3/MPO to 
produce ANCA [52] (see figure 2). The source of this complementary protein is much 
debated, with some suggesting complementary or mimicking peptides produced and 
expressed by invading pathogens, whilst the aberrant anti-sense (non-coding) transcription of 
human PR3/MPO is another possibility. 
 
A second theory suggests that neutrophil extracellular traps (NETs) act as a platform for PR3 
to initiate an autoimmune reaction. NETs are made up of fibrous chromatin, DNA and 
protein deposits, which can trap and bind bacteria. Furthermore, NETs have been shown to 
degrade virulent peptides and actively kill bacteria [53]. ANCA has been demonstrated to 
induce the release of NETs containing PR3 and MPO, which can be deposited in the kidney 
[54]. The release of NETs is dependant upon the neutrophil generation of reactive oxygen 
species, as the catalytic conversion of hydrogen peroxide into water and dioxygen 
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completely inhibits the release of NETs [55]. The release of NETs containing the ANCA-
antigens is well suited for identification by autoreactive B-Cells [56]. 
 
 
Figure 2 - The Theory of Antigen Complementarity 
 
 
 
 
 
 
 
 
 
 
 
The theory of antigen complementarity requires an initial immune reaction directed against the complementary 
peptide, in which anti-idiotypic antibodies are produced. Antibodies directed at these anti-idiotypic antibodies 
can also recognise and interact with the peptide, for example PR3, and induce an immune reaction. 
 
 
There have been a host of environmental triggers linked to the development of ANCA. 
Firstly, it was noted that there was an increased incidence of nasal carriage of 
Staphylococcus Aureus in patients with Wegeners’ granulomatosis compared to healthy 
controls [57, 58]. Moreover, antibiotic treatment with a combination of trimethoprim and 
sulfamethoxazole proved beneficial in reducing the rate of relapse in WG patients [59]. 
Secondly, a link between anti-thyroid treatment and the development of ANCA-vasculitis 
has been identified. The presence of ANCA in patients receiving long-term propylthuouracil 
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(PTU) treatment was first demonstrated by Stankus and Johnson in 1992, who described a 
72-year old woman with respiratory failure and haemoptysis [60]. 
 
Figure 3 - ANCA-Mediated Neutrophil Activation 
 
 
 
 Of the patients receiving anti-thyroid treatment, for illnesses such as Graves disease, 88% of 
those who developed ANCA associated vasculitis were taking PTU as a long-term therapy 
(>18 months), although ANCA was also present with treatment with other medication, 
including Carbimazole [61]. Interestingly, 7 of the 8 patients included in the Gunton et al., 
study, developed ANCA directed at neutrophil MPO. This appears to be a common feature 
with multiple independent researchers reporting the presence of p-ANCA [62-64]. The 
development of ANCA against MPO following PTU treatment may be the result of its ability 
 
 
 
Activation of neutrophils by ANCA binding results in aberrant neutrophil degranulation as 
well as increased adhesion to the vascular endothelium and generation of reactive oxygen 
species. ANCA-mediated neutrophil degranulation results in the release of primary (or 
azurophilic) granular contents that are normally involved in digestion of phagocytosed 
pathogens.   
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to enter neutrophils and alter the configuration of MPO [65]. More recently a link between 
silica dust exposure and the development of ANCA vasculitis has been identified (odds ratio 
4.43), whilst pesticide exposure also had an increased odds ratio (2.32) [66]. This association 
with silica dust was first identified by Gregorini et al., in 1993 using a cohort of 16 ANCA-
positive patients and 32 controls [67], with this observation being repeatedly reported from 
different groups [66, 68, 69]. 
 
A genetic risk factor for the development of Wegeners’ granulomatosis has been identified in 
first-degree relatives, although occurrence is low (relative risk 1.56). The relative risk of WG 
in the children of WG patients is 2.56 [70]. Moreover, the PRTN3 gene, which encodes 
neutrophil PR3, may be involved in the increased expression of membrane bound PR3 
observed in ASV patients [71]. It has been demonstrated that there are populations of 
neutrophils expressing either low or high membrane PR3. The presence of this high 
membrane PR3 expressing neutrophil population is significantly increased in patients with 
ASV (85%) compared to healthy controls (55%) [72]. Witko-Sarsat et al., also demonstrated 
a genetic disposition to the inheritance of either low or high membrane PR3 over three 
generations of 2 families. This observation of increased membrane PR3 has been reported by 
other groups [45, 73], who also further confirmed a genetic factor by demonstrating that high 
membrane PR3 was strongly correlated in monozygotic twins (r=0.99) but not in dizygotic 
twins (r=0.06) [45]. Furthermore, the increased membrane expression of PR3 on neutrophils 
significantly correlates with an increase rate of relapse [73].  
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1.4 The Neutrophil 
 
The polymorphonuclear leukocyte (PMN) was first described by Paul Ehrlich in 1900. 
Neutrophils are the predominant cell of the innate immune system, accounting for 
approximately 60% of the total leukocyte pool in humans, with on average 3 to 6 million 
cells per millilitre of blood in healthy individuals. They are short-lived cells, circulating in 
the blood for around 12 hours prior to migration into tissues, following stimulation, where 
they can survive for up to a further 5 days. Neutrophils play an important role in the rapid 
development of defence mechanisms against invading microbial pathogens, particularly 
during a bacterial infection. These antimicrobial actions of neutrophils involve the 
phagocytosis of the invading pathogen, and/or the degranulation and release of microbicidal 
molecules from intracellular granules. The granules present within the neutrophil were 
originally classified on the presence of MPO (reviewed in [74]), thus producing two groups 
that became known as the primary granules, described as spherical, and the secretory specific 
granules, which appear more irregular in shape [75]. It has been suggested that the specific 
granules are involved in the mediation of an inflammatory response [76], whereas the 
primary granules are more associated with the antimicrobial actions following phagocytosis 
[77, 78]. The neutrophil primary granules are formed from the golgi apparatus during the 
maturation of the cell from a myeloblast into a promyeloblast, whilst the specific granules 
are formed later in development during the myelocyte stage [75, 79]. As research has 
progressed it has been established that the granules can be sub-classified on the presence of 
intragranule proteins (reviewed in [74]). The primary granules, which are positive for MPO, 
can be either positive or negative for defensin, whilst the specific granules have been further 
classified as secondary, lactoferrin positive, or tertiary, gelatinase positive, granules; with 
another group known as the secretory vesicles added to the classifications [80-82].   
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Exocytosis of the granular content following elevation of intracellular Ca2+ [83, 84], involves 
the fusion of the vesicle membrane with, and incorporation into, the plasma membrane. 
Therefore, proteins present on the inner membrane of the vesicle will become expressed on 
the surface of the cell [85-87]. It has been shown that the mobilisation of the neutrophil 
secretory vesicles is mediated by signalling through selectin molecules [88, 89] or in 
response to inflammatory mediators such as Histamine or Loxosceles venom [90, 91]. 
 
 
Table 2 - Overview of Neutrophil Granular Contents 
 Secretory 
Granules 
Teritiary Graules Secondary Granules Primary Granules 
Other 
Names 
Secretory vesicles 
 
Gelatinase graules Specific granules Alpha granules 
Azurophilic granules 
 
Main 
Constituents 
CR1 
Mac-1 
(CD11b/CD18) 
FPR 
CD14 
CD16 
Proteinase 3 
Cytochrome b588 
Plasma proteins 
 
 
Gelatinase (MMP9) 
Lysozyme 
Leukolysin 
NRAMP1 
Cytochrome b588 
 
Lactoferrin 
Cathelicidin 
Lysozyme 
Collagenase 
Leukolysin 
Cytochrome b588 
NGAL 
Myeloperoxidase 
Elastase 
Cathepsin G 
Proteinase 3 
Azurocidin 
Bacterial Permeability-
increasing protein 
Defensins 
Primary 
Function 
Neutrophil 
adhesion 
 
 
Breaks down 
collagen & 
basement 
membrane 
Breaks down 
collagen & basement 
membrane 
Digests engulfed 
pathogens/debris 
Bacteriocidal 
 
 
The antimicrobial actions of the neutrophil involves two separate mechanisms. Firstly there 
is the generation and release of reactive oxygen species (ROS), which results in direct injury 
to pathogens, and secondly the neutrophil can release enzymatic or antimicrobial proteins 
from the intracellular granules. Both the peroxidase positive and negative granules have been 
shown to be required for the release of reactive oxygen species from neutrophils. The 
primary granules contain MPO, which converts hydrogen peroxide (H2O2), a product of 
NADPH oxidase, into hypochlorous acid [92], whilst the peroxidase negative granules 
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contain flavocytochrome b558, a component of the NADPH oxidase molecule [93]. ROS have 
also been implicated, along with human leukocyte elastase (HLE), to be involved in the 
conversion of gelatinase and collagenases from their pro-form into active proteases, which 
can inflict damage onto the invading pathogen [94-96]. 
 
 
 
1.5 The Neutrophil Serine Proteases 
 
There are four families of proteinases; serine, cysteine, aspartic and metallo, defined by the 
most prominent functional group in the enzymes active site. The serine proteases cleave 
peptides by the formation of a covalent tetrahedral state to form two smaller peptides [97]. 
HLE and PR3 are chymotrypsin-like serine proteases found in the neutrophil primary 
granules, which are released following neutrophil degranulation. These proteases have the 
ability to degrade components that make up the extracellular matrix. PR3, a 29kDa 
glycoprotein, was first described in 1978 by Baggiolini et al. [98], and has since been 
identified as a key target in ASV [26, 99]. It has been demonstrated to degrade elastin in 
vitro, resulting in tissue damage to the lungs when administered to hamsters via inhalation 
[100], and is suggested to have serine protease, antibiotic and myeloblastic activity [25, 101, 
102]. PR3 exhibits high sequence homology with HLE, demonstrated by Rao et al., 1991 
[103] by analysis of the first 40 residues having approximately 60% homology, whilst the 
first four N-terminal residues are identical to HLE. They also reinforced the idea that PR3 
was the antigenic target for c-ANCA by confirming that the first 20 residues of PR3 were 
identical to that of the proposed target antigen. The high sequence homology between PR3 
and HLE posed the question as to whether HLE also plays a role in ASV. Tervaert et al., 
1993 tested for the presence of HLE autoantibodies in patient serum samples by enzyme 
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linked immunosorbent assay (ELISA), and identified patients that were positive for HLE 
with a p-ANCA staining pattern. PR3, however, did not test positive in these patients and 
there were no positive HLE serum with a c-ANCA pattern [104]. This proposes that PR3 and 
HLE are not targeted by the same antibodies. More recently HLE was again identified as a 
target for p-ANCA by the presence of HLE-ANCA following the injection of rats with 
syngenic apoptotic neutrophils [105]. Although they may be targeted by separate antibodies, 
both PR3 and HLE are released from neutrophil primary granules simultaneously, and have 
been shown to induce apoptosis of endothelial cells via chromatin condensation and DNA 
fragmentation [106], hence, PR3, in particular, may be both a target for autoantibodies and 
an important mediator of endothelial injury. A key area of interest is the effect of the 
neutrophil granule contents, including the serine proteases, on the vascular endothelium 
following neutrophil degranulation. It is believed that ANCA activated neutrophils become 
trapped and inappropriately activated in the small vessels, thereby releasing granular 
contents directly onto the microvasculature.  
 
PR3 is shown to promote endothelial apoptosis, as well as inducing chemokine ligand-8 
(CXCL8) production, a chemotactic factor for neutrophils [107], and promoting monocyte 
chemoattractant protein-1 (MCP-1) expression by endothelial cells, thereby resulting in 
increased monocyte recruitment [108]. It is suggested that treatment with PR3 can result in 
the increased expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell 
adhesion molecule-1 (VCAM-1) on endothelial cells, resulting in increased static adherence 
of neutrophils to the vascular walls via an ICAM-1/β2 integrin interaction [108, 109], whilst 
PR3-ANCA is also suggested to increase VCAM-1 expression [110]. 
 
Although stored in the primary granules, PR3 is also stored in the secretory granules and so 
can be easily mobilised to the neutrophil surface following gentle stimulation [111]. These 
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granules are released from the neutrophil during adhesion to the endothelial membrane. PR3 
has been demonstrated to degrade matrix proteins [112], which may aid neutrophil 
trafficking. Other physiological roles of PR3 include cytokine/chemokine cleavage, for 
example cleavage of CXCL8 to a more active form to enhance neutrophil recruitment [113]. 
As well the amplification of CXCL8 activity, PR3 and HLE has a host of effects on 
chemokine activity during inflammation. Both serine proteases have been implicated in the 
fragmentation and inactivation of IL-6 at sites of inflammation [114, 115], thereby 
promoting a negative feedback loop against further inflammation and prevention of the acute 
phase response [116]. Interestingly, however, IL-6 possesses both pro- and anti-
inflammatory properties and is also involved in the induction of immuno-supressive agents. 
HLE is also reported to cleave and inactivate IL-2. This cleavage of IL-2 results in the 
formation of three products, one of which naturally antagonises the proinflammatory 
adhesive properties of IL-2 [117]. Unlike PR3, HLE can induce the inactivation of TNFα 
and CXCL8 [118-121], whilst PR3 acts to convert the inactive precursors of TNFα and IL-
1β into functional cytokines [122, 123]. 
 
One of the key functions of the neutrophil serine proteases is their ability of intralysosomal 
degradation of engulfed cell debris and mircoorganisms. HLE mediates its bactericidal 
effects by degrading the bacterial cell wall, thereby facilitating the entry of other 
antimicrobial agents [124]. HLE also potentiates the antibiotic effects of cathepsin G and 
MPO, as well as the lytic activity of lysozyme [124-126]. PR3 had been demonstrated to 
have microbicidal effects against both gram-negative and gram-positive bacteria [127]. 
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Table 3 - Summary of Functions of PR3 and HLE 
 Proteinase 3 Human Leukocyte Elastase 
Abbreviation PR3 HLE 
 
Protein Size 222 amino acids 
29kDa  [103] 
218 amino acids 
30kDa  [128] 
 
Concentration 3.24pg/cell (±0.24 SD)  [129] 1-3pg/cell  [113, 130-132] 
 
Location in 
Neutrophil 
 
Primary (azurophilic/alpha) granules 
Secretory vesicles  [111] 
 
Primary (azurophilic/alpha) granules 
[111] 
Functions Intralysosomal proteolysis 
Degradation of matrix proteins  [100] 
Microbicidal  [127] 
Induction of apoptosis  [106] 
Increased adhesion molecule 
expression  [108] 
 
Intralysosomal proteolysis 
Degradation of matrix proteins  [100, 
133] 
Anti-Microbial  [124, 125, 134] 
Induction of apoptosis  [106] 
 
Roles in Apoptosis 
 
Detachment and cytolysis  [135] 
Internalisation  [136, 137] 
DNA fragmentation  [106] 
Nuclear fragmentation  [136] 
Chromatin condensation  [106] 
Stops cell cycle at G0/G1 phase  [136] 
Cleavage of p21Waf1  [138] 
Proapoptotic signalling through JNK 
and p38 MAPK  [137] 
 
Detachment and cytolysis  [135] 
Internalisation  [137] 
DNA fragmentation  [106] 
Chromatin condensation  [106] 
Proapoptotic signalling through p38 
MAPK [137]  
Cytokine 
Interactions 
Inactivation of IL-6 and IL-2 [115, 
139] 
Activation of IL-1β, TNFα and IL-18 
[122, 123, 140] 
Amplification of CXCL8 [113] 
 
Inactivation of TNFα, IL-6, CXCL8 
and IL-2  [114, 115, 117-121] 
Receptor shedding of IL-2Rα, TNF-
RII and IL-6R  [139, 141] 
Processing of TGF-α  [142] 
 
 
 
 
1.6 PR3 and Endothelial Apoptosis 
 
Neutrophil serine proteases, PR3 and HLE, were initially suggested to induce endothelial 
cell detachment and cytolysis [135], however, further research into this has unveiled a role 
for these proteases in apoptosis. Endothelial treatment with PR3 and HLE was demonstrated 
to increase DNA fragmentation at concentrations of 1µg/ml, whilst visualisation of these 
cells confirmed an apoptotic role for PR3 and HLE [106]. PR3 can traverse the endothelial 
cell membrane and consequently induce cell apoptosis [136]. Both the catalytically active 
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and inactive forms of PR3 have been shown to induce endothelial cell apoptosis. Inactive 
PR3 causes apoptosis within 24 hours [136] possibly due to interactions at the C-terminal 
region of the peptide [138], whilst active PR3 results in cleavage and consequent inactivation 
of nuclear factor-κB (NFκB) and sustained activation of Jun N-terminal kinase (JNK) [137]. 
 
More recently PR3 has been demonstrated to enter endothelial cells and cleave p21Waf1 
[138]. p21Waf1 is a major determinant of cell fate, primarily involved in the regulation of the 
cell cycle [143]. p21Waf1 is potent inhibitor of G1 cyclin-cyclin dependant kinase (CDK) 
activity. The CDKs are required for the transition from the G1 phase, growth and 
biosynthetic activity of the cell, to the S phase, DNA synthesis in preparation for mitosis, of 
the cell cycle. In particular p21Waf1 inhibits the actions of CDK2 and CDK4. The cleavage of 
p21Waf1 by caspase 3 is required for endothelial cell apoptosis. Cleavage of endothelial 
p21Waf1 by PR3 results in the loss of p21Waf1 from the cytoplasm and from CDKs [138]. This 
cleavage does not occur following HLE treatment in in vitro cellular models [144]. 
 
 
 
1.7 Alpha-1 Antitrypsin: A Serine Protease Inhibitor 
 
Alpha-1 antitrypsin (α1AT) is a natural inhibitor for the neutrophil serine proteases [145]. 
α1AT is a small globular glycoprotein that can readily diffuse throughout interstitial fluids. 
It is primarily produced by liver hepatocytes [146], although there is evidence that α1AT can 
also be produced by macrophages, monocytes, and lung alveolar epithelial cells [147-150]. 
The production of α1AT by monocytes and macrophages is only about 0.15% of that 
produced in the liver [151]. α1AT is one of the most abundant serine protease inhibitors 
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(serpin), with an average plasma concentration of 1.3mg/ml in healthy individuals. α1AT is 
an acute phase protein, and plasma concentrations can increase 2-4 fold upon 
inflammation[152, 153]. One of the most potent stimuli for α1AT production in hepatocytes 
is interleukin-6 (IL-6), via signalling through nuclear factor interleukin-6 (NF-IL6) or 
JAK/STAT pathways [149, 154]. As well as stimulation of α1AT production by IL-6, 
release from monocytes, macrophages and lung epithelial cells can also be induced by 
lipopolysaccharide (LPS), IL-1β and TNFα [150, 155, 156]. 
 
Although α1AT is a general serine protease inhibitor, its prime targets are the neutrophil 
proteases, in particular HLE. Importantly, α1AT is involved in the protection of the lower 
respiratory tract from HLE [157, 158], for instance in the prevention of emphysema. α1AT 
prevents the enzymatic actions of HLE by the rapid formation of an irreversible 1:1 complex, 
which renders the serine protease inactive until it can be removed from the circulation. 
Further investigation has proposed that this α1AT:HLE complex may also have a role in 
neutrophil chemotaxis, itself acting as a chemoattactant molecule [159]. Recently, a 
defective α1AT allele (piZ), which results in the loss of functional protein, has been 
identified at an increased frequency in patients with ANCA-associated vasculitis [160-163]. 
 
 
 
1.8 Neutrophils in Inflammation: The Process of Transmigration 
 
Serine proteases play important roles in a host of physiological processes, of which, we are 
particularly interested in their roles during leukocyte recruitment from the circulation 
previously discussed by Henson et al., 1987 [164]. Recently there has been much interest 
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into the development of an animal model for vasculitis. Two key publications have both 
reported an increase in leukocyte transmigration in vivo in an MPO-model of vasculitis. 
Nolan et al., 2008 treated mice with anti-MPO IgG directed at murine MPO on chemokine 
ligand-1 (CXCL1) (also known as keratinocyte derived chemokine (KC) and Groα) 
stimulated leukocytes, thereby demonstrating an increased conversion of rolling leukocytes 
into firmly adherent and transmigrated leukocytes across the vascular endothelium [165]. 
The other important study reported that intramuscular injection of MPO IgG, thereby 
inducing production of anti-MPO antibodies directed at rat leukocytes, resulted in increased 
adhesion and transmigration in response to stimulation with CXCL1 [166]. Both of these 
animal models support a role for MPO-ANCA in the induction of neutrophil recruitment in 
the presence of CXCL8. Furthermore, patient ANCA-IgG have been demonstrated to 
increase neutrophil adhesion and transmigration in in vitro flow models of adhesion [167, 
168]. 
 
Leukocyte trafficking is a well-regulated multi-step process; involving capture from flow, 
firm adhesion and migration into surrounding tissues (see figure 4). Leukocytes circulate 
close to the vascular endothelium rather than in the centre of the vessel. This is known as 
margination, and facilitates the capture of circulating leukocytes by adhesion molecules 
expressed on the vascular endothelium. A group of adhesion molecules known as the 
selectins play a crucial role in the capture and rolling of leukocytes along the endothelium 
[169-172]. The selectins are a family of carbohydrate-recognising transmembrane proteins. 
There are three known types of selectin, L-Selectin is constitutively expressed on leukocytes, 
whilst P- and E-Selectin are expressed on the vascular endothelium [173]. The selectins form 
weak bonds between sialyl-lewisx surface glycans on the leukocyte and endothelium [174], 
which are repeatedly broken and reformed giving the appearance of the leukocyte rolling 
across the endothelial surface. 
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One of the best-characterised selectin ligands involved in leukocyte rolling is P-Selectin 
glycoprotein ligand-1 (PSGL-1). Although PSGL-1 is the major ligand for P-Selectin, it has 
been suggested to weakly interact with E-Selectin and L-Selectin. PSGL-1 is constitutively 
expressed on the membrane of leukocytes, and contains a sialyl lewisx domain that is 
recognised by endothelial Selectins [175]. Expression of sialyl lewisx and core 2-1,6-N-
acetylglucosaminyltransferase (C2GnT) domains are both required for binding of PSGL-1 by 
P-Selectin, as PSGL-1 on CHO cells, which do not express sialyl lewisx, was unable to bind 
to P-Selectin [176]. 
 
Figure 4 - The Process of Leukocyte Migration 
 
 
 
 
 
The process of leukocyte recruitment. First, flowing leukocytes are captured by weak transient bonds 
between endothelial selectins and their ligands (rolling). The leukocyte is activated by chemokine 
signals causing integrin molecules to undergo a conformational change. Interactions between these 
activated integrins and their endothelial ligands results in the firm adhesion of the leukocyte to the 
endothelial surface. From here the leukocyte can traverse the endothelial membrane and migrate to sites 
of tissue inflammation. 
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The rolling leukocytes that are in contact with the endothelium are guided by 
chemoattractant gradients produced by activated endothelial cells, for example the 
production of CXCL8 and platelet activating factor (PAF).  The second stage of leukocyte 
migration involves the integrin-mediated firm adhesion to the vascular endothelium, thereby 
enabling migration through endothelial tight junctions. Integrins are a family of αβ 
heterodimers, constitutively expressed on leukocytes, that can be increased following 
stimulation, e.g. with TNFα. All leukocytes express β2 integrins, whilst eosinophils, 
monocytes and lymphocytes also express β1, β7 and α4 integrins. Stimulation by chemokines 
results in a conformational change brought about by inside-out signalling within the 
leukocyte, which include the activation of surface integrin molecules to the extended 
conformation structure required for high affinity adhesion [177], as well as the 
polymerisation of G-Actin into F-Actin (reviewed in [173]). An increase in this conversion 
to F-Actin has been noted in neutrophils following treatment with ANCA IgG [178], and it is 
likely that the consequent increase in cell rigidity may be involved in the increased 
neutrophil sequestration in capillary beds of vasculitic patients. Integrin interactions are 
dependent upon this conformational change in order to achieve the firm adhesion of the 
leukocyte. For neutrophils, firm adhesion is dependent upon the interactions of the integrins, 
lymphocyte function-associated antigen-1 (LFA-1, CD11a/CD18) and macrophage antigen-1 
(Mac-1, CD11b/CD18), with the vascular surface. It has been demonstrated that patients 
deficient in these β2 integrins have an inability to recruit neutrophils from the vasculature 
(reviewed in [179]). Integrins interact with members of the immunoglobulin superfamily on 
the surface of endothelial cells; in particular, LFA-1 and Mac-1 bind to ICAM-1 [180, 181], 
whilst LFA-1 also interacts with ICAM-2 [182]. The immunoglobulin superfamily 
encompasses a wide range of molecules with multiple Ig-like domains. ICAM-1 is 
constitutively expressed on many cell types, however its expression on endothelial cells can 
be further regulated and increased upon stimulation. ICAM-2 is also expressed on 
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endothelial cells, however it is not increased following activation [183]. It has previously 
been demonstrated that patients suffering with Wegener’s Granulomatosis display increased 
expression of ICAM-1 and VCAM-1 in tissues [184, 185], which may play a role in the 
increased level of neutrophil adhesion to the vascular endothelium observed in vasculitic 
patients. 
 
 
 
1.9 Chemokine Ligand-8 Induced Neutrophil Adhesion 
 
Chemokine ligand-8 (CXCL8, also known as interleukin-8 and neutrophil activating protein 
NAP-1) is a pro-inflammatory cytokine, primarily concerned with neutrophil recruitment to 
sites of inflammation, although, it has previously been suggested to also have a role in the 
increased adhesion and transmigration of leukocytes across endothelial membranes. 
Neutrophils stimulated with CXCL8 have been shown to become activated and migrate 
across the endothelium [186]. This increased neutrophil adhesion occurs both in the presence 
or absence of the inflammatory stimuli TNFα, with the presence of TNFα having an additive 
effect on the levels of neutrophil adhesion [187]. Other functions of CXCL8 include 
neutrophil granule exocytosis and respiratory burst [188]. 
 
Early reports suggest that CXCL8 can act to increase expression of adhesion molecules, 
probably by surface remodelling following granule exocytosis, thereby increasing leukocyte 
transmigration (reviewed in [188], [189]). CXCL8 has been identified on the luminal surface 
of endothelial cells, from where it can stimulate the conversion of neutrophils from rolling to 
firmly adhered through interactions between ICAM-1 and the neutrophil β2 integrins [190]. 
CXCL8 induces rapid rates of adhesion via LFA-1 dependant and Mac-1 dependant adhesion 
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to ICAM-1, which can be inhibited by the addition of blocking antibodies directed at the 
endothelial CXCL8 receptors CXCR1 and CXCR2 [191]. CXCR1 is an CXCL8 specific 
membrane receptor, however, CXCR2 is known to also interact with other circulating 
chemokines of the ELR family that are directed towards neutrophils [192, 193]. A key 
adhesion molecule of interest is the β2 integrin Mac-1. CXCL8 has been shown to stimulate 
the binding activity of Mac-1 [189], with transmigration through the vascular endothelium 
reliant upon CXCL8 induced Mac-1 activation [194]. Arndt et al., 1996, demonstrated that 
by blocking CXCL8 or CD11b they could reduce the level of leukocyte adhesion to the 
vascular endothelium in rat venules. They suggested that CXCL8 was acting to promote 
adhesion by increasing the surface expression or activation of Mac-1 [195]. CXCL8 can also 
induce the redistribution of the P-Selectin ligand, PSGL-1, in neutrophils to promote rolling 
[196]. Furthermore, CXCL8 has been shown to increase actin polymerisation in neutrophils 
[197], thereby inducing cellular shape changes that facilitate adhesion and transmigration. 
 
 
 
1.10 Neutrophil Priming by Tumour Necrosis Factor-α  
 
It has previously been demonstrated that TNFα mRNA expression and cytokine release is 
upregulated during active ASV, particularly in Wegener’s granulomatosis and microscopic 
polyangiitis [198-200]. This may result in the priming of neutrophils for an ANCA-induced 
respiratory burst [16, 201, 202]. Neutrophil priming by TNFα enhances the ability of the 
neutrophil to undergo respiratory burst following ANCA stimulation [203]. It has been 
reported that this priming of neutrophils may also be crucial in the induction of surface 
expression of ANCA-antigens [16, 204]. TNFα priming of neutrophils can increase the 
membrane expression of PR3 2-fold, however, the addition of PR3-ANCA amplifies this 
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system, increasing membrane PR3 expression 24-fold [205]. It has also been shown that 
TNFα can induce accelerated apoptosis of neutrophils in a caspase-dependant manner, 
thereby suggesting a dual role for TNFα in both neutrophil activation and death [206]. It has 
been suggested that the activation of neutrophils by ANCA induces unregulated neutrophil 
apoptosis, driven by the production of reactive oxygen species. This may result in the 
formation of an enhanced inflammatory environment, especially as ANCA-activated 
neutrophils have been shown to have a delay in the expression of surface phosphatidylserines 
that are necessary for the recognition and clearance of apoptotic cells by macrophages [207]. 
It is possible that this could drive the progression of cells from apoptosis towards secondary 
necrosis and the consequent release of pro-inflammatory cell contents, potentially resulting 
in endothelial cell damage. 
 
In vivo, TNFα is released into the circulation during an inflammatory response and therefore, 
may play a key role in the priming of neutrophils and consequently the increased ANCA-
induced neutrophil activation observed in vasculitis patients [16]. TNFα stimulation of 
neutrophils has been demonstrated to increase the level of adhesion to the vascular 
endothelium [208], allowing for the direct release of neutrophil granular contents onto the 
endothelial surface. The stimulation of endothelial cells with TNFα also results in an 
increased level of neutrophil adhesion [208]. This is likely to be due to the increased 
expression of classical endothelial adhesion molecules, P-Selectin, E-Selectin, ICAM-1 and 
VCAM-1 [209, 210]. Further investigation has identified a role for tyrosine kinase signalling 
in the upregulation of ICAM-1 by TNFα on endothelial cells [211]. 
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1.11 Other Cell Types Implicated in ASV 
1.11.1 Macrophages 
 
The migration of monocytes into tissues allows for their terminal differentiation into 
macrophages. Macrophages are central to the innate immune response. Activation of these 
cells in inflamed tissues results in phagocytosis and the production of a host of inflammatory 
cytokines. Macrophages can be characterised into two distinct subsets depending on their 
method of activation [212]. M1 macrophages are classically activated by stimuli including 
IFNγ, lipopolysaccharide (LPS), TNFα and GM-CSF. These classically activated 
macrophages produce IL-12 and IL-23 to support a Th1/Th17 immune response. The 
alternatively activated macrophages, known as M2, can be further subdivided by their 
activatory stimuli (see table below) [213]. The alternative pathway of activation is thought to 
have immunosuppressive functions [214] and have more of an effect on the resolution of 
inflammation by endocytic clearance and decreased production of proinflammatory 
cytokines [215]. 
 
These different subsets of macrophage have very distinct functions in renal inflammation. 
Most glomerular diseases are characterised by an infiltration of macrophages. Here 
macrophages have dual roles in the modulation of the immune response and repair processes 
as well as the clearage of debris and apoptotic cells. However, the continuous production of 
growth factors by macrophages can result in renal fibrosis and ultimately chronic kidney 
disease [213]. This progression to renal scarring occurs as a result of interplay between T-
cells, dendritic cells and macrophage responses [216-218], although ultimately macrophages 
are the dominant cell type involved in fibrosis. Interestingly, the injection of anti-
inflammatory IL-4 expressing M2 macrophages into the renal artery in a rat model of 
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nephrotoxic nephritis caused reduced proteinuria and albuminuria, and further decreased 
glomerular macrophage infiltration [219]. 
 
 
Table 4 - Different Subsets of Macrophages 
 Activating Stimuli Functions Cytokine Profile 
M1 IFNγ 
LPS 
TNFα 
GM-CSF 
 
Proinflammatory 
Th1/Th17 Response 
IL-12Hi 
IL-23Hi 
MHC class IIHi 
CD80/86 
M2a IL-4 
IL-13 
 
Immunoregulation 
Tissue Remodelling 
Mannose Receptor 
Scavenger Receptor 
MHC class IIHi 
Decoy IL-1R11 
 
M2b Immune Complexes 
IL-1β 
LPS 
 
Immunoregulation 
Th2 Activation 
CD86 
MHC class IIHi 
IL-12Lo 
IL-10Hi 
 
M2c IL-10 
TGF-β 
Glucocorticoids 
 
Immunosuppression 
Tissue Remodelling 
SLAM (CD150) 
Mannose Receptor 
MHC class IILo 
 
Adapted from Ricardo 2008 [213] 
 
In ANCA-associated vasculitis it is believed that inappropriate activation of macrophages 
results in tissue damage, which is maintained by further recruitment of monocytes [220]. 
Macrophages were first identified in isolated glomeruli from patients with crescentic 
glomerulonephritis in 1976 [221]. More recently macrophages were identified in the 
glomeruli in renal biopsies from ANCA-associated vasculitis patients [184]. Histological 
analysis of ANCA positive renal biopsies demonstrated that, along with glomerular 
infiltration of macrophages and monocytes, T cell and neutrophil infiltrates are present 
within the renal interstitium [222]. 
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The mechanism of recruitment of macrophages to glomerular inflammatory infiltrates 
remains elusive, however, it is generally believed to be due to a combination of increased 
adhesion molecule expression, increased circulating chemotactic factors, and changes in 
haemodynamic conditions [220, 223]. Adhesion molecules ICAM-1 and VCAM-1 have a 
well-established role in the trafficking of leukocytes and other inflammatory cells into 
tissues. In ASV, expression of ICAM-1 by glomerular endothelial cells is increased. More 
interestingly, VCAM-1, which is normally only expressed by epithelial cells of the 
Bowman’s Capsule, has been demonstrated to be expressed in the glomerular crescents with 
extracapillary damage [223]. 
 
 
 
1.11.2 T-cells 
 
Patients with Wegener’s granulomatosis have been demonstrated to display a shift in their 
peripheral T-cell populations from CD4+ to CD8+ T-cells. This is suggested to be due to both 
a decreased number of circulating naive CD4+ T-cells, apparent in both patients with active 
disease and those in remission who are not receiving immunosuppressive therapy, and 
increased percentages and absolute numbers of CD8+ T-cells [224-227]. Patients with active 
WG also display an increased number of activated CD4+ and CD8+ T-cells compared to 
control [227]. Other features in these patients include the decreased expression of co-
stimulatory molecule CD28 and increased CD80/CD86 [225, 226, 228, 229]. Activation of 
T-cells with CD28 costimulation primarily promotes differentiation into T-helper-2 cells, 
which supports plasma cell antibody production. The combined effects of the decreased 
CD28 expression along with increased expression of CD80/CD86 expression promote 
differentiation of CD4+ T-cells into T-helper-1 cells, which go on to activate macrophages. 
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These T-cells also display increased expression of cytotoxic T-lymphocyte antigen-4 
(CTLA-4) [230], which is suggested to induce resistance to apoptosis [231]. It has been 
reported that polymorphisms in CTLA-4 may be responsible for the on-going activation of 
T-cells in ASV [232].  
 
More recently an IL-17 producing subset of CD4+ T-cells, known as Th17 cells, have been 
implicated in the pathogenesis of vasculitis. An expansion in Th17 T-cell population has 
been identified in the blood of patients with WG [233]. The IL-17 produced from these cells 
induces release of pro-inflammatory cytokines, including IL-1β and TNFα [234], which 
themselves may contribute to the neutrophil priming required for ANCA activation. 
Furthermore, WG patients have been shown to have an expanded population of functionally 
defective regulatory T-lymphocytes (Treg) [235]. This has been previously identified in 
other autoimmune diseases, and indicates that a breakdown in Treg self-tolerance may be 
contributing to pathogenesis of ASV.  
 
 
 
1.11.3 B-Cells 
 
It is well known that, in normal physiology, B-cells can act to support an immune response 
by interactions with antigen presenting cells, as well as acting as antigen presenting cells 
themselves, supporting T-cell mediated responses and the production of antibodies [236]. 
Activated CD4+ helper T-cells can deliver activating signals to B-cells in a process known as 
linked recognition, which occurs through common recognition of a pathogen and requires B-
cell surface expression of the antigen on its MHC class II. The release of IL-4, along with 
CD40 stimulation, from Th2 cells induces B-cell proliferation, which can then differentiate 
 29 
into memory B-cells or antibody producing plasma cells [237]. The isotype of the antibody 
produced is influenced by the cytokine stimulation received by the plasma cell, in particular 
IL-5 is required to induce recombination, whilst IL-4 (IgG1, IgE), TGFβ (IgA) and IFNγ 
(IgG2a IgG3) may also be involved [238, 239]. 
 
Recently B-cells have been suggested to be involved in the loss of T-cell tolerance and the 
development of autoreactivity. T-cell function is reliant upon correct B-cell function, and 
together these cells create a positive feedback process that results in expansion of the 
immune response [240]. Aberrant T-cell function is a known feature of ANCA vasculitis, 
and may be a downstream effect of abnormal interactions between B-cells and T-cells. This 
has previously been described in rheumatoid arthritis, in which B-cell depleted mice could 
not support T-cell activation, whilst treatment with anti-CD20 mAb, a B-cell targeting 
therapy, inhibited inflammatory cytokine production [241]. Furthermore, an accumulation of 
B-cells has been identified in a host of tissues affected by autoimmune diseases, as well as in 
inflamed renal biopsies from patients with membranous glomerulonephritis [242]. Whilst in 
vasculitis, abnormal B-cell clusters have been identified in ANCA positive nasal biopsies 
[243]. 
 
Currently a major part of the treatment regime for ANCA-vasculitis involves targeting the 
immune response through a combination of chemotherapy agents and broad-spectrum 
immunosuppressive steroids. Due to the side effects associated with this treatment, more 
recent studies have been directed at anti-B-cell therapies. Two trials in particular have 
compared treatment with this current regime to an anti-B-cell therapy called Rituximab. 
Rituximab is an anti-CD20 monoclonal antibody that can bind to CD20 expressed on B-
cells, from where it can induce apoptosis. CD20 is expressed on all B-cells excluding the 
antibody producing plasma cells. Two impartial clinical trials both demonstrate that the 
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treatment of ANCA-vasculitis by Rituximab results in the same level of induction into 
remission as treatment with the standard treatment regime [244, 245]. Although, 
improvements in the long-term side effects of this treatment is awaited from patient follow-
up. 
 
 
 
1.12 Endothelial Cells in Inflammation 
 
The endothelium is the thin layer of cells that line the blood vessels of the body. The 
phenotype of the vascular endothelium is dependant on the microenvironment in which it 
exists, thereby aiding its organ specific functions. The endothelial cells play an important 
role in the regulation of vessel structure and function, as well as the transit of immune cells 
from the vasculature into tissues during inflammation. A key characteristic of endothelial 
cells is their ability to undergo rapid cell division and migration, which is of particular 
importance following injury to the vessel wall.  
 
The vascular endothelium has a constant need to remodel to accommodate the needs and 
requirements of the surrounding tissues. The activation of the endothelial cells in response to 
inflammation results in changes to the ability of the endothelium to recruit inflammatory 
cells, as well as the initiation of angiogenesis [246]. The increased requirement for 
trafficking of immune cells is associated with an increased vascular endothelial leakiness. 
This is achieved by the increased production of vascular endothelial growth factor (VEGF), 
nitric oxide (NO), and angiopoietin-2 (Ang-2) [247, 248]. The endothelial barrier consists of 
two types of junctions, namely the tight junctions; consisting of claudins, occludins and 
junctional adhesion molecules, and the adheren junctions, consisting of catenins and 
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cadherins [246]. VEGF acts to increase endothelial permeability through adherens junctions, 
mainly through VE-cadherin [249, 250], whilst Ang-2 acts as a natural inhibitor to 
angiopoietin-1 (Ang-1), thereby increasing vascular permeability [248, 251, 252]. During 
inflammation there is also a need for the development of new vessels as the requirement for 
immune cells increases. This is achieved by endothelial sprouting, which involves the 
colonisation of non-vascularised areas by migrating/proliferating endothelial cells. 
 
The anti-thrombotic state influenced by the vascular endothelium is important to maintain, as 
the induction of thrombosis can contribute to the pathophysiology of vasculitis. Glomerular 
thrombus formation is often present in glomerulonephritic kidneys, and may be involved in 
the progression to acute renal failure. Using a mouse model of thrombotic 
glomerulonephritis, the β2 integrin Mac-1 was highlighted as a key molecular link in the 
induction of neutrophil recruitment, endothelial injury, and thrombotic glomerular lesions 
[253]. Furthermore, engagement of Mac-1 on neutrophils can induce release of HLE [254], 
which can further potentiate glomerular injury. Mac-1 can also interact with platelet GP1bα 
to promote thrombosis, thereby supplying a link between the induction of inflammation and 
thrombus formation [253]. 
 
The vascular endothelium has the ability to upregulate the expression of adhesion molecules 
to increase leukocyte migration for immune surveillance and aid the inflammatory response. 
The expression of endothelial adhesion molecules varies upon site, with high constituent 
expression at sites of continuous immune cell recruitment [255], such as the lymph nodes, 
whilst inflamed sites require endothelial activation for the upregulation of adhesion 
molecules upon requirement. ICAM-1 is an example of an endothelial adhesion molecule 
that is constituently expressed on many types of endothelial cell, although expression is 
further increased upon activation. ICAM-1 binding by its ligands has reported to induce the 
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production of endothelial chemokines, CXCL8 and RANTES [256]. Activation of ICAM-1 
by leukocyte binding is suggested to regulate the endothelial actin cytoskeleton thereby 
aiding leukocyte migration [257]. VCAM-1 is also reported to induce endothelial shape 
change by regulation of actin following lymphocyte binding or anti-VCAM-1 antibodies 
[258, 259]. Binding of lymphocytes to VCAM-1 results in the production of ROS via the 
activation of NADPH oxidase, as demonstrated in murine endothelial cells [259]. One of 
these reported reactive oxygen species produced is hydrogen peroxide (H2O2). Low 
concentrations of H2O2 are produced by endothelial cells following VCAM-1 activation, 
which is suggested to induce the delayed activation of matrix metalloproteinases (MMPs) (2-
5 hours after lymphocyte binding to VCAM-1) [260]. The MMPs are required for 
degradation of the endothelial cell matrix and junctional adhesion molecules, for example 
VE-Cadherin [261], to facilitate migration.  
 
The endothelium also plays a fundamental role in vascular repair following injury and the 
initiation of the coagulation cascade. The endothelium forms a barrier between tissue factor 
(TF) expressing fibroblasts and smooth muscle cells, and their ligand, circulating Factor 
VII/VIIa. A breakage in this endothelial barrier results in the exposure of TF and the rapid 
activation of the coagulation cascade [262]. Another way by which the endothelium is 
involved in clotting is by the release and expression of von Willebrand factor (vWf). vWf is 
constitutively expressed in endothelial cells and released in response to activation or stress 
signals. vWf induces platelet adhesion to the endothelium at sites of vascular injury by 
binding to activated factor VIII, platelet glycoproteins, or constituents of connective tissue, 
thereby activating the coagulation cascade.  
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1.13 Glomerular Endothelium: A Target in ANCA-Associated Vasculitis 
 
The glomerular endothelium is a prime target in ASV, with glomerulonephritis observed in 
50-80% of patients presenting with Wegener’s granulomatosis and 90-100% of patients with 
microscopic polyangiitis [13] (see table 1 for more detail). The glomerulus consists of a 
specialised collection of capillaries in the kidney, which function as a site for filtration and 
removal of waste products from the blood. The endothelial monolayer here provides the first 
stage of a three-layer filter crucial to the charge-dependant and size-dependant filtration. The 
endothelial monolayer consists of flattened cells with thin cytoplasmic areas, large nuclei 
and very few mitochondria. Another characteristic of the glomerular endothelium is the 
presence of many fenestrations without diaphragms [263, 264], also key to the filtration 
process. The endothelial cell monolayer sits on top of a structure known as the glomerular 
basement membrane, which itself sits on top of visceral epithelial cells, known as podocytes. 
The basement membrane is considered to be the principle barrier in the filtration of large 
molecules, with abnormalities in the structural components of the basement membrane 
linked to proteinurea. The endothelial glycocalyx forms part of the endothelial surface layer, 
along with a loosely attached glomerular cell coat. The negatively charged properties of the 
glycocalyx are suggested to contribute to the charge selective filtration of the glomerular 
filter, first described by a preference for filtration of neutral dextran over negatively charged 
dextran sulfate [265]. The glycocalyx is comprised of a host of glycoproteins and lipids, of 
which the glycoaminoglycans (GAG) are of particular importance in the maintaining the 
charge-selective filtration. Enzymatic degradation of these GAGs alters this charge-selective 
filtration and consequently decreases the transendothelial resistance [266], thereby altering 
the glycocalyx charge density [267], and increasing the flux of albumin across the 
glomerular filter [266, 268]. This observation has also been reported following the injection 
of rats with hypertonic sodium chloride solution, which increased albumin flux whilst having 
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no effect on the filtration of neutral ficoll [267]. The ability of angiopoeitin-1 to increase the 
depth of the glycocalyx to decrease water permeability and albumin flux [269], provides a 
mechanism by which the kidneys can control and alter the charge-selective properties of the 
glomerular filter. 
 
The glycocalyx forms a mesh-like structure across the surface of all vascular endothelial 
cells. This barrier, in part, regulates inflammation by masking the adhesion molecules 
essential for leukocyte transmigration [270]. Furthermore, the perfusion or hydrocortisone or 
antithrombin has been shown to maintain the glycocalyx structure by decreasing shedding, 
which consequently reduces aberrant leukocyte adhesion in a model of ischemia-reperfusion 
injury [271]. Henry et al. demonstrated that, upon the induction of inflammation, TNFα can 
modify the glycocalyx to support inflammatory cell recruitment by reducing the thickness of 
the glycocalyx, which allowed increased permeation of the glycocalyx by larger 
macromolecules including dextran, albumin and IgG, as well as increasing leukocyte 
adherence, presumably by exposing endothelial adhesion molecules [272]. The acute phase 
protein, C-reactive protein, has also been shown to reduce the thickness of the glycocalyx, 
resulting in increased ICAM-1 release and monocyte adhesion to arterial endothelial cells 
[273]. 
 
Human glomerular endothelial cells were first isolated in culture by Striker et al., 1984, who 
used von Willebrand factor (vWf) and angiotensin-converting enzyme (ACE) as markers for 
characterisation [274]. The disadvantage of primary endothelial cell cultures is their limited 
life span and their loss of characteristics following passage, thereby indicating a requirement 
for a conditionally immortalised human glomerular endothelial cell line. The development of 
this cell line by Satchell et al., in 2006 has allowed for greater progress into the 
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understanding of the physiological functions of the glomerulus and its relationship with ASV 
[275]. 
 
 
 
1.14 Weibel-Palade Bodies 
 
The endothelial monolayer provides an important barrier between the bloodstream and 
surrounding tissues and therefore must be repaired quickly upon injury, a phenomenon 
known as coagulation. vWf plays a key role in the initiation of this coagulation cascade and 
mediation of platelet aggregation following vascular injury, and therefore has been referred 
to as a marker of endothelial dysfunction [276]. It is exclusively produced by 
megakaryocytes and endothelial cells and stored in rod-shaped storage vesicles known as 
Weibel-Palade bodies (WPBs) [277, 278]. Although vWf is the major component of WPBs, 
these structures have also been suggested as a storage site for other proteins, including P-
Selectin, Ang-2, CD63 and CXCL8. The formation of these ‘bodies’ begins with the 
monomeric form of vWf, derived from the trans-golgi network. Monomeric PrePro-vWf 
dimerises by the formation of a disulfide bond between its cystine knots as it is translocated 
to the endoplasmic reticulum. This Pro-vWf is transported to the golgi network where it 
undergoes cleavage and formation of a second disulfide bond. The acidic environment of the 
golgi prevents disulfide rearrangement, allowing linkage of subunit inter-chain disulfide 
bonds, thereby resulting in the formation of vWf multimers [279]. Small amounts of 
monomeric vWf are constitutively released, although the majority dissociates from the golgi 
as clathrin coated secretory granules [280], which mature into WPBs [281]. This idea is 
supported by evidence that dogs with severe von Willebrand disease lack the WBP 
biogenesis, which can be restored upon expression of vWf [282]. Recent studies have 
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suggested that, apart from vWf, the components of WPBs can differ, indicating a range of 
WPB subsets. It is proposed that CXCL8 is only stored in the WPBs of human umbilical 
vein endothelial cells (HUVEC) after its synthesis has been stimulated by other 
inflammatory cytokines. The stimulation of HUVEC with IL-1β does not induce expression 
of CXCL8 in all WPBs of an endothelial cell, suggesting WPBs not expressing CXCL8 were 
formed prior to the inflammatory stimulation [283-285]. Alternatively, there is evidence 
demonstrating CXCL8 co-localisation with vWf with no prior stimulation in other 
endothelial cell types including the human microvascular endothelial cells [283]. Although 
both identified in WPBs, angiopoietin-2 expression appears to be completely separate from 
P-Selectin, and previous studies have demonstrated no co-localisation between the two 
[286]. Furthermore, it has been demonstrated that components of WPBs can occur 
independently of one another. Cleator et al., showed that HUVEC stimulated with cyclic 
adenosine monophosphate (cAMP) or protease activated receptor-2 agonist peptides (PAR2-
APs) resulted in release of vWf from WPBs with minimal release of P-Selectin, thereby 
proposing different mechanisms for release of the different components of the WPBs [287]. 
Mature WPB are susceptible to stimulation by secretagogues, including thrombin and 
histamine, which induce WPB exocytosis by raising intracellular calcium levels or 
stimulating the production of cAMP, a process that can occur very rapidly [288, 289]. 
Although the mechanism of exocytosis is yet to be clarified, a selection of GTPases have 
been implicated in WPB release. Overexpression of activated Rab3D inhibits the release of 
WPB contents, indicating a negative regulatory role [290], whilst overexpression of RalA 
initiates exocytosis [291, 292].  The incubation of endothelial cells with thrombin results in 
WPB exocytosis via a calcium dependant pathway, which has been suggested to result in the 
activation of GTPase RhoA, whist cAMP mediated release of WPB results in the activation 
of a different GTPase, Rap1 [293]. 
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1.15 Von Willebrand Factor (vWf) and the Coagulation Cascade 
 
vWf is a multimeric glycoprotein, which, when released from endothelial cells in response to 
activation and/or stress, acts to support platelet adhesion to the vascular endothelium at sites 
of injury. Its functions in coagulation are highlighted in patients with von Willebrand 
Disease, who display mild bleeding symptoms due to a hereditary loss in the expression of a 
functional vWf protein. 
 
vWf mediates its actions by binding to components of the coagulation cascade, particularly 
activated factor VIII, as well as platelet glycoproteins and constituents of exposed connective 
tissue. Following vascular injury, vWf is secreted from endothelial cells as a high molecular 
weight molecule known as ultra-large vWf (ULVWF). ULVWF is composed of between 50-
100 monomers which join to form a large multimer that can reach molecular weights of up to 
20MDa [294]. This ULVWF is released from endothelial cells as large strings that can 
capture multiple platelets along its length. To prevent inappropriate platelet capture, 
multimeric ULVWF is cleaved into smaller monomers by metalloproteinase ADAMTS-13 (a 
disintegrin and metalloproteinase with a thrombspondin type 1 motif, member 13) [295]. 
Failure to cleave the larger multimers of vWf can result in thrombus formation [294]. 
 
vWf can bind to a range of collagens that form part of the endothelial connective tissue 
[296]. In particular collagen type VI has demonstrated a key role in vWf mediated 
coagulation [297], although other components of the endothelial connective tissue may also 
be involved, thereby allowing recruitment of platelets from flow and thrombus formation. 
Although vWf is one of the many molecules involved in platelet capture at low flow rates, it 
is the main protein involved in capture at high shear flow rates [295]. The interaction 
between platelets and adhered vWf is reliant upon the glycoprotein Ib-IX-V complex on non-
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activated platelets [296], in particular the glycoprotein-1bα (GP1bα) chain of the complex 
[298]. GP1bα acts to form weak bonds between the endothelial tissue and the platelets. 
These bonds are easily broken under the high flow rates, however, are key in slowing 
platelets in flow so that stronger interactions can be formed [299, 300]. Another mechanism 
by which vWf can induce platelet aggregation is via interactions with integrin α2bβ3. α2bβ3 
has also been shown to bind fibrinogen and fibronectin [301, 302], further components of the 
coagulation cascade. vWf interactions with α2bβ3 result in the firm adhesion of platelets to 
the site of vascular injury, and the consequent formation of a thrombus [295]. This 
interaction is mainly responsible for the non-reversible binding of platelets to the 
subendothelium at high shear flow [303]. The kidneys receive approximately one fifth of the 
cardiac output, so glomerular capillaries are exposed to high flow rates.  
 
Although vWf is involved in repairing the vasculature following injury, is not a specific 
marker of endothelial cell damage. It is also released in the absence of vascular injury as an 
acute plasma reactant, as well as following endothelial cell stimulation. There have been 
very few in vivo models of vWf as a marker of dysfunction, with most experiments having 
been carried out in vitro on endothelial cell lines [304], so whilst it has been shown to be 
released from the endothelium following vascular injury, it can only be used as a marker for 
damage if this is verified by use of a second marker. vWf expression has been previously 
identified on the surface of endothelial cells as WPBs fuse with the cell membrane. This vWf 
expression occurs in small patches and has a life-time of up to 20 minutes [305]. vWf can 
also adhere to the endothelial surface by forming a complex with Factor VIII [306]. vWf acts 
to stabilise Factor VIII, increasing its half-life by up to 20-fold [294]. 
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1.16 vWf in ANCA-Associated Vasculitis 
 
There has been little research into the expression and actions of vWf during active vasculitis, 
or else the actions of PR3 on vWf release and expression by the endothelium. Previous 
studies into ASV have demonstrated an increased level of circulating vWf in patients with 
active Wegener’s granulomatosis or microscopic polyangiitis [307, 308].  Also, Lu et al., 
2006 identified increased levels of vWf release from endothelial cells following culture with 
ANCA-activated neutrophils, which could be abolished with the addition of serine protease 
inhibitors [309]. They also demonstrated an increase in vWf release following the addition of 
PR3 directly to endothelial cells. This discovery was fundamental in establishing a role for 
serine proteases in mediating the endothelial cell injury known to be associated with 
vasculitis. However, the detailed consequences of the direct effects of proteinase 3 on vWf 
release from endothelial cells has yet to be determined, as is a mechanism by which serine 
proteases are inducing release of vWf.  
 
 
 
1.17 Other Constituents of WPB 
1.17.1 Angipoietin-2  
 
Angiopoietin-2 (Ang-2) belongs to a family of growth factors involved in the formation and 
regulation of the vasculature. Currently four members of the angiopoietin family have been 
identified, of which only Ang-2 is present in endothelial WPBs [286]. Whilst Ang-2 is 
almost exclusively present in endothelial cells, it is most abundantly expressed at sites of 
vessel remodelling [310]. Ang-2 has been identified as a natural antagonist for its sister 
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ligand, Angiopoeitin-1. Ang-1 mediates its anti-inflammatory actions by “sealing” vessels, 
preventing plasma leakage and inflammatory cell migration, whilst its anti-apoptotic effects 
maintain endothelial cell integrity and survival [311-313]. Ang-1 is also instrumental in the 
maturation of blood vessels. The exact roles of Ang-2 in inflammation remain elusive. To 
date it has been demonstrated to increase vessel leakage by destabilisation of the endothelial 
cell-cell junctions and consequently promoting inflammation and endothelial cell detachment 
[286, 314, 315]. Ang-2 is also associated with the expression of vascular endothelial growth 
factor (VEGF). Together they act to induce new vessel formation, whilst the addition of 
Ang-1 can inhibit this VEGF-Ang-2 mediated angiogenesis [316]. The actions of VEGF on 
increasing vascular permeability are primarily mediated through signalling through VEGF 
receptor-2 (VEGFR2) [317, 318]. Furthermore, VEGF has been implicated in increasing 
paracellular permeability by promoting contraction of the actin cytoskeleton and opening of 
the cell-cell junctions [319-321]. 
 
Tie-2 has been identified as the principle receptor for the angiopoietins, although they can 
also interact with the Tie-1 receptor. Both of these receptors have been shown to be 
expressed by vascular endothelial cells. The Tie receptors are members of the tyrosine-
kinase group of receptors, with an extracellular domain consisting of three Ig–like domains 
divided by three epidermal growth factor-like cysteine repeats and followed by three 
fibronectin typeIII domains [251]. Ang-1 and Ang-2 bind to this extracellular binding 
domain of Tie-2 in an autocrine fashion as homodimers or multimers [322, 323]. 
 
Currently there has been little research into a role for Angiopoietin-2 in vasculitis. However, 
it has recently been demonstrated that patients with active glomerulonephritis have increased 
serum concentrations of Ang-2 compared to patients in remission, and that these 
concentrations decreased steadily during treatment [324]. 
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1.17.2 P-Selectin 
 
Whilst being storage vesicles for vWf, the Weibel-Palade bodies also contain P-Selectin 
(also known as GMP-140 and CD62p) [278, 325], an important adhesion molecule in 
leukocyte capture from flow and ultimately migration from the vasculature. The selectin 
family of adhesion molecules are associated with the initial capture stage of leukocyte 
transmigration. The selectins have the ability to form weak bonds with leukocytes at high 
shear rates, which cause the leukocyte to slow along the endothelial surface. The repeated 
formation and breakage of these selectin bonds give the impression that the cell is rolling 
across the endothelium, and allow for the formation of stronger integrin bonds between the 
leukocyte and the endothelium, which ultimately results in transmigration. The perfusion of 
neutrophils over P-Selectin in a flow model of adhesion resulted in neutrophil rolling in 
more than 97% of these cells. Further, perfusion of ANCA IgG over rolling these neutrophils 
caused the slow conversion of rolling to firmly adherent cells [309, 326, 327]. 
 
Along with CD63, P-Selectin comprises the major membrane protein of WPBs [328]. Fusion 
of WPBs with the endothelial membrane results in the rapid expression of P-Selectin on the 
endothelial surface [278, 329]. Following this brief exposure, of approximately 20 minutes, 
the P-Selectin is recycled back into the endothelial cell, where it can return to the trans golgi 
network and reform WPBs along with vWf [328, 330]. Although vWf and P-Selectin have 
demonstrated to be co-expressed in WPBs, their release can occur independently of one 
another [287]. 
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1.17.3 CD63 (Platelet Glycoprotein gp40) 
 
The tetraspanin glycoprotein, CD63, is universally expressed in a host of cell types, whilst 
more recently identified as another constituent of the WPB membrane. As with P-Selectin, 
membrane expressed CD63 can be recycled back into the endothelial cell and into 
developing WPBs [331]. However, unlike P-Selectin this incorporation into WPBs does not 
occur at the early trans-golgi network stage of development, but rather CD63 is recruited to 
later more developed WPB. Furthermore, P-Selectin trafficking occurs via an adaptor protein 
complex-3 (AP-3) independent mechanism, whilst CD63 is reliant upon AP-3 signalling 
[332]. CD63 has been implicated in the adhesion and activation of platelets, and has been 
demonstrated to interact with integrins α4β1, α3β1, α6β1, and members the β2 family, 
including LFA-1 [333]. 
 
A role for CD63 in vasculitis has been demonstrated in neutrophils and other inflammatory 
cells, however, a role for endothelial CD63 has yet to be determined. Patients with active 
disease display increased CD63 on neutrophils than healthy controls. Whilst expression of 
CD63 correlated with BVAS (Birmingham Vasculitis Activity Score) but not with ANCA 
titres [17]. 
 
 
 
1.17.4 Chemokine Ligand-8 
 
CXCL8 is a pro-inflammatory chemokine released from the activated vascular endothelium 
[334]. CXCL8 has two known receptors, CXCR1 and CXCR2, widely expressed on various 
cells, which have a high affinity for binding CXCL8 [335]. Whilst CXCR1 is specific for 
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recognising CXCL8, CXCR2 has also been shown to interact with other chemokines [192, 
193]. Both CXCL8 and its receptors have been shown to be expressed by endothelial cells 
[336-338] and have been suggested to play a role in endothelial cell proliferation [339]. 
Other cells types have been shown to produce CXCL8, including monocytes, lymphocytes, 
fibroblasts and epithelial cells [340-343]. Synthesis of IL8 by endothelial cells can be 
increased by treatment with TNFα, lipopolysaccharide (LPS) and IL-1β [341, 344-346], 
whilst TNFα stimulated increase from HUVEC can be inhibited by the presence of 
interferon-γ (IFNγ) [347]. In vivo, CXCL8 is suggested to have many physiological roles in 
inflammation, including increased leukocyte chemotaxis and transmigration, and endothelial 
cell angiogenesis [339, 348]. The primary actions of CXCL8 are in the activation of 
neutrophils [349], including directional migration, increased expression and activation of 
adhesion molecules, and induction of neutrophil degranulation and reactive oxygen species 
production (reviewed in [188], [189, 350]). This effect of CXCL8 on increased neutrophil 
adhesion to the endothelial monolayer remains controversial, with many researchers 
reporting conflicting statements. Some suggest that CXCL8, once secreted by activated 
endothelial cells, inhibits the adhesion of neutrophils to the endothelium [351], however, the 
majority report a pro-inflammatory role for CXCL8 in increasing adhesion and migration of 
immune cells.  CXCL8 produced by endothelial cells has been shown stimulate the binding 
activity of integrin Mac-1 (CD11b/CD18) on the surface of neutrophils [189].  
 
The presence of increased CXCL8 levels in an inflamed environment has led to speculation 
of a possible involvement in the progression of ASV. Harper et al., 2001 demonstrated 
increased production of CXCL8 and IL-1 from macrophages following phagocytosis of 
ANCA-opsonised apoptotic neutrophils when compared to non-ANCA-opsonised 
neutrophils [352]. It has also been shown that direct treatment of HUVEC with PR3 and 
HLE for 24 hours can result in increased secretion of CXCL8, which can be inhibited with 
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the presence of α1-antitrypsin [107]. Although the intracellular location for CXCL8 storage 
is widely speculated, it has been suggested that a proportion of the chemokine may be stored 
in Weibel-Palade bodies along with vWf and P-Selectin [284]. This colocalisation of CXCL8 
and vWf poses a role for protease-activated receptors (PARs) in the release of CXCL8 from 
endothelial cells upon stimulation. It has previously been reported that co-stimulation of 
PAR-1 and PAR-2 on epithelial cells results in increased release of CXCL8 [353]. Further 
evidence supporting a possible role for PARs was produced by Compton et al., 2000, who 
demonstrated that endothelial cells secrete CXCL8 following 24h stimulation with mast cell 
tryptase [354], a known stimulant of PAR-2 [355]. CXCL8 is of key importance in ASV, 
particularly as PR3 has been demonstrated to cleave and process CXCL8 into its more active 
form [113], potentially aiding neutophil chemotaxis and transmigration to sites of vascular 
inflammation. Serine proteases have also been demonstrated to alter the activity of other 
cytokines including TNFα, IL-6 and IL-18 [139] (see table 3 for more detail). 
 
 
 
1.18 Evidence for Protease-Activated Receptors in vWf Release 
 
The protease-activated receptors are a family G-protein coupled receptors, of which four 
have currently been identified as PAR-1 to PAR-4 [356]. All four PARs have been shown to 
be expressed on the endothelial surface, although expression of PAR-2 and PAR-4 are 
increased in inflammatory environments [357]. PAR signalling requires the proteolytic 
cleavage of the amino terminus, thereby exposing a new ligand and initiating signal 
transduction [358, 359]. PAR-1, -3 and -4 have been identified as substrates for thrombin, 
whilst PAR-2 can be activated by tryptase and trypsin [355, 360]. Previous studies have 
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demonstrated a role for PAR activation in the release of vWf from endothelial cells. 
Stimulation of PAR-1 on the endothelial surface induces reorganisation of the cytoskeleton 
and the exocytosis of Weibel-Palade bodies [361], and therefore, the release of vWf, CXCL8 
and mobilisation of P-Selectin [284, 325].  PAR-2 has also been shown to be involved in the 
regulated release of vWf from these storage vesicles [361, 362]. This can be induced by 
trypsin treatment of endothelial cells [363]. The expression of PAR-2 has been observed in 
several tissues [364], with high expression on endothelial and epithelial cells [365]. It is 
suggested to play a role in the inflammatory process, as mice deficient for PAR-2 
demonstrate impaired immune responses [366]. Cleator et al., 2006 demonstrated that PAR-
2 agonist peptides selectively stimulate the release of vWf, whilst only causing minimal 
release of P-Selectin [287]. PR3 has been shown to interact with PAR-2 on the surface of 
oral epithelial cells resulting in cell activation and secretion of cytokines CXCL8 and MCP-1 
[367, 368]. An interaction between PR3 and PAR-2 on immature dendritic cells has also 
been demonstrated, inducing dendritic cell differentiation into mature antigen presenting 
cells [369], although there remains no direct evidence for an interaction on endothelial cells. 
 
Another receptor of interest is the Toll-Like Receptor (TLR). TLR2 and TLR4 have been 
implicated in release of vWf from endothelial cells, as mice deficient for these receptors 
cannot release vWf in response to uric acid [281]. TLR2 has been shown to signal via 
elevations in the intracellular calcium concentration. More recently it has been demonstrated 
that the incubation of PR3 with high molecular weight kininogen (HK) results in the 
formation of bradykinin with 2 additional amino terminals, termed PR3-Kinin, and this has 
been shown to bind to B2 receptors on endothelial cells [370]. Bradykinin has been 
demonstrated to mediate proinflammatory leukocyte recruitment. 
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1.19 Signalling in vWf release from Weibel-Palade Bodies 
 
The signalling mechanisms involved in the release of vWf from WPBs are yet to be fully 
defined, with a host of mediators suggested to be involved (see figure 5 below). It is known 
that vWf release from WPB’s can occur through both calcium and cAMP signalling 
pathways. Thrombin and PAR-1 agonist peptides are known to induce the calcium dependant 
release of vWf, whilst PAR-2 agonists stimulate release via cAMP. One of the best studied 
signalling pathways of vWf release is that of VEGF stimulation. Currently two contrasting 
mechanisms exist. Initially VEGF mediated vWf release from HUVEC was shown be 
inhibited by the addition of a selection of protein kinase C (PKC) inhibitors, whilst these 
inhibitors had no effect on histamine mediated release. Small interference RNA (siRNA) 
allowed further evaluation for a role of PKCδ in this release [371]. More recently, VEGF 
induced release was shown to be reliant upon signalling through VEGFR2, which signalled 
through phospholipase Cγ1 (PLCγ1) and protein kinase A (PKA) to induce full vWf release 
[372]. Moreover, PKA has been implicated in the mobilisation and clustering of WPBs, as 
seen during cAMP mediated vWf release [293, 373]. 
 
A second well-studied signalling pathway is that of thrombin mediated release. Thrombin 
mediated vWf release can be inhibited by the addition of calcium chelator MAPTA (bis-(2-
amino-5-methylphenoxy)-ethane-N,N,N',N'-tetraacetic acid) in the presence of 
Ethylenediaminetetraacetic acid (EDTA), whilst the addition of inhibitors directed at PKC 
had no effect [374]. 
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Figure 5 - Proposed Signalling Pathways Involved in vWf Release 
Taken from Goligorsky 2009 [281]. The schematic shown here demonstrates the known signalling pathways 
through which Weibel-Palade body exocytosis can be initiated. vWf release by VEGF is suggested to involve 
signalling through both the PKC and PKA pathways, whilst thrombin signalling is proposed to involve 
increased intracellular calcium but does not appear to progress through PKC signalling. 
 
 
 
1.20 Aims and Hypothesis 
 
It is well documented that the neutrophil serine proteases, in particular PR3, have the ability 
to induce endothelial cell injury, detachment and apoptosis, however, previous data suggests 
that they may also have an immune response in the removal of invading pathogens as well as 
leukocyte transmigration. It is also noted that these serine proteases are directly released onto 
the vascular endothelium following ANCA-mediated neutrophil activation. In this project we 
aim to investigate a role for the neutrophil serine proteases in the vascular activation and 
injury during ANCA-associated vasculitis. We hypothesised that the neutrophil serine 
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proteases may be having an early activatory role on the glomerular endothelium for support 
of inflammatory processes, as well as inducing endothelial cell injury at later time points. 
Here we aim to investigate the effects that the direct interactions between PR3 and the 
glomerular endothelium may be having in the development of inflammation. We aim to 
further evaluate whether, at short time points, PR3 is inducing endothelial cell injury or if 
these responses are the result of an activatory process. It is also important in investigate any 
signalling pathways that are involved in PR3 mediated endothelial responses, as this may 
result in the identification of possible therapeutic targets. 
 
 
Specifically, this project sought to 
1. Investigate the level of endothelial cell detachment, injury and apoptosis at short and 
longer incubation periods with physiological concentrations of the neutrophil serine 
proteases, PR3 and HLE. 
2. Confirm that PR3 can induce the release of vWf from HUVEC, and repeat this 
observation on glomerular endothelial cells, comparing the level of PR3 induced vWf 
release to that following HLE treatment. Cleavage of vWf from the endothelial 
membrane was also assessed following serine protease treatment. 
3. Explore the signalling molecules and receptors that are involved in the PR3 and HLE 
stimulated release of vWf from endothelial cells. 
4. Determine whether PR3 and HLE also induce release or expression of other Weibel-
Palade body constituents. 
5. Investigate a role for PR3 and HLE in increased leukocyte transmigration, and any 
mechanisms by which this may be occurring.  
6. Determine whether inhibition of PR3 and HLE by serine protease inhibitor, α1-
antitrypsin, can prevent any PR3 or HLE mediated effects. 
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2. Materials and Methods 
 
2.1. Conditionally Immortalised Glomerular Endothelial Cells 
 
A conditionally immortalised glomerular endothelial cell line (GEnC) was used in all 
experiments (gift from Dr S. Satchell, Bristol UK) [275]. The GEnC were allowed to 
proliferate at 33°C (due to growth arrest at 37°C) until confluent. At which point the cells 
were either divided into three new T75cm2 culture flasks for maintenance or into 96- or 24-
well culture plates for experimental use. It is believed that the conditionally immortalised 
cells should retain the morphological features of primary cells until at earliest passage 41. 
GEnC are grown in Endothelial Growth Medium-2-Microvascular (EGM-2-MV, Lonza, 
Wokingham UK, see table 5) with 5% fetal calf serum and supplements as supplied. 
 
GEnC were passaged when confluence was reached at 33°C  (typically every 4-5 days). 
Cells were passaged by washing initially in 2.5ml of 0.02% EDTA 
(Ehtylenediaminetetraacetic Acid Disodium Salt, Sigma-Aldrich, Poole UK), followed by 
the addition of 2.5ml of 1x Trypsin/EDTA (T4174 Sigma-Aldrich) for 1-2minutes. Firmly 
tapping the confluent flask dislodges the cells from the surface. The trypsin was neutralised 
in 5ml of complete EGM-2-MV and the cells were centrifuged at 1500rpm for 5minutes. 
After discarding the supernatant the pellet was resuspended in 2ml fresh medium and the 
cells counted on a haemocytometer. Cells were reseeded in T75cm2 culture flasks at a 
dilution of 1:3, or into plates at 2x104 or 4x104 cells per well. The cells were incubated at 
33°C until confluence was achieved, at which point the cells were transferred to 37°C. Cells 
were kept at 37°C 24 hours before used in experiments. 
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Table 5 - Constituents of Endothelial Growth Medium-2-Microvascular (EGM-2-MV)  
 
Medium and Additives Volume Final 
Concentration 
Source 
Endothelial Basal Medium-
2 (EBM-2) 
500ml - Lonza 
Foetal Bovine Serum (FBS) 25ml 5% Lonza 
Human Fibroblast Growth 
Factor-B 
2ml - Lonza 
GA-1000 (Gentamicin 
Sulfate, Amphotericin-B) 
500µl - Lonza 
Recombinant-longR-Insulin 
like Growth Factor-1 
500µl - Lonza 
Vascular Endothelial 
Growth Factor (VEGF) 
500µl - Lonza 
Hydrocortisone 200µl - Lonza 
Human Epidermal Growth 
Factor 
500µl - Lonza 
NB Lonza were unwilling to disclose concentrations of reagents provided in the Bullet Kit 
 
 
Table 6 - Constituents of Complete Medium199 
Medium and Additives Volume Final 
Concentration 
Source 
Medium 199 with Phenol 
Red 
80ml - Gibco 
Foetal Calf Serum 20ml 20% Sigma-Aldrich 
Penicillin and Streptomycin 1ml 1mM Sigma-Aldrich 
L-Glutamine 1ml 20mM Sigma-Aldrich 
Epidermal Growth Factor 10µl 1ng/ml Sigma-Aldrich 
Hydrocortisone 10µl 1µg/ml Sigma-Aldrich 
Amphotericin B 1ml 2.5µg/ml Sigma-Aldrich 
 
 
 51 
2.2 Isolation of HUVEC from Umbilical Veins 
 
Human umbilical cords were collected from consenting donors at Birmingham Women’s 
Hospital UK with ethical approval (Ethics Code 5779). Cords were checked for clamp or 
needle marks, cleaned with ethanol and placed into an ethanol soaked tray for isolation of 
endothelial cells. The vein is located at one end of the cord. The cannula was inserted into 
the vein and held in place using an electrician’s tie. Using a 20ml syringe, the cannula and 
vein were flushed with Dulbecco’s phosphate buffered saline (PBS, Sigma Aldrich) until it 
ran clear, followed by flushing through with air to remove any residual PBS from inside the 
vein. The other end of the vein was then cannulated and tied in place. Collagenase (Sigma-
Aldrich) was diluted to 1mg/ml with PBS, and 10ml injected into the vein and cannulae. The 
cannulae clips were closed and the cord placed into an ethanol filled plastic bag and 
incubated for 15 minutes at 37°C in 5% CO2. Each 10-15cm of umbilical cord was isolated 
into a 25cm2 culture flask. Gelatin (Sigma-Aldrich) was diluted to 1% in PBS and 2.5ml 
added to each 25cm2 flask, which was left for 30minutes. Following the 15minute 
incubation, the cord was removed from the incubator, the ties tightened, and massaged for 
1minute to aid release of the endothelial cells. The cord was washed through with PBS and 
air, and the contents collected and spun at 1400rpm for 5minutes. The supernatant was 
aspirated off and a small amount (approx 500µl) of complete M199 (see table 6) added to 
break up any clumps. The pellet was resuspended in 4ml of complete M199, and was added 
to the culture flasks following aspiration of the gelatin. The culture flasks were incubated at 
37°C in 5% CO2 until use. The medium was changed following 1 day incubation, then again 
at 3-4 days incubation. HUVEC were not passaged, but instead put into plates for use in 
experiments. The cells were harvested from the culture flasks by addition of trypsin, in the 
same way as GEnC. The cells were counted and applied to plates at 2x104 or 4x104 cells per 
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well. Plates were kept at 37°C in 5% CO2 until required for use. Isolated HUVEC were 
confirmed to be endothelial cells by vWf staining performed by Samantha Tull. 
 
 
 
2.3 Materials 
 
Endothelial cells cultured in 96-well plates were treated with PR3 (Athens Research and 
Technology, Georgia USA, Stock 100µg reconstituted in 100µl sterile H2O) and HLE 
(Calbiochem, UK, stock 100µg reconstituted in 100µl PBS) at concentrations between 
0.5µg/ml and 5µg/ml (1µg/ml = 34nM). The concentrations of serine protease used in our 
experiments were based on the assumption that, should all of the enzyme come out of 
solution, there would be approximately 25pg of protease per endothelial cell (for a 1µg/ml 
treatment), given that a confluent 96-well culture plate would contain around 40,000 cells. 
Dilutions of PR3 and HLE were performed in Medium199 + 0.05% bovine serum albumin 
(BSA, Sigma Aldrich). Following addition of the protease to the EnC monolayer, the cells 
were incubated at 37°C in 5% CO2. Endothelial cells were treated for durations of up to 24h 
with PR3 and HLE prior to use in other procedures. 
 
Serine protease inhibitor, α1-AntiTrypsin, was added to endothelial cell cultures at the same 
time as protease treatment. α1-AntiTrypsin (α1-AT, a gift from Talecris Biotherapeutics, 
USA) (stock 1000mg reconstituted in 40ml sterile H2O) was diluted in M199 + 0.1% BSA to 
give a working concentration of 140nM. Endothelial cells were treated with α1-AT for 
durations of up to 24h. 
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Enzymatic activity of PR3 and HLE was checked for each batch upon first reconstitution of 
the enzyme. This was achieved by the incubation of 5µg/ml PR3 or HLE with N-methoxy-
succinyl-ala-ala-pro-val-p-nitroanalide (2mM, Sigma-Aldrich) alone, or in the presence of 
α1-AT 36µg/ml or FCS (6%) (Sigma-Aldrich), in a 96-well plate. The plates were incubated 
at room temperature protected from light and read at 5minutes and 4 hours at 405nm. The 
enzyme activities were assessed in triplicate. Figure 6 demonstrates the mean and standard 
error from a typical result from an activity test. 
 
Figure 6 - Activity Test for Enzymes and Inhibitors 
 
 
 
2.4 Neutrophil Isolation 
 
Peripheral blood was taken from healthy volunteers, added to 10% acid citrate dextrose 
(ACD, Sigma Aldrich) and inverted gently to mix. The blood was diluted 1:2 with 2% 
 
Figure 6 demonstrates a typical enzyme activity test. Enzyme activity tests were routinely 
performed to check the activity of both the enzymes and inhibitors. 5µg/ml PR3 and HLE were 
incubated for 4 hours with a serine protease substrate (Sigma-Aldrich) in the presence of α1-
Antitrypsin (36µg/ml) or fetal calf serum (6%). 
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dextran (GE Healthcare, UK) and inverted to mix, before spinning at 20g for 20minutes. The 
supernatants were collected and spun for a further 7minutes at 150g to form a pellet. Percoll 
gradients (GE Healthcare, Bucks, UK), made up in a 1.5M saline solution (NaCl from Sigma 
Aldrich), were used to separate the blood into cells types to allow the isolation of 
neutrophils. The 100% percoll gradient was prepared into 81%, 70% and 55% concentrations 
by dilution with calcium and magnesium free PBS (Sigma-Aldrich). The gradients were 
layered, according to density, in a polystyrene conical tube, with 4.5ml of 81% followed by 
3ml of 70% and finally 2.5ml of 55% containing the resuspended pellet. The gradients were 
spun for 30-40minutes at 1500g. Using a sterile pasteur pipette, the top layer from the 
gradient was removed and discarded. The 55-70% interface contains peripheral blood 
mononuclear cells (PBMCs) and was also removed and discarded. The neutrophil layer is 
located at the 70-81% interface and was removed, diluted in PBS and inverted several times 
to remove the percoll gradient. Following spinning at 400g for 5minutes, the supernatant was 
removed, and the pellet resuspended and washed in PBS as before. The pellet was finally 
resuspended in 2ml Hanks buffered saline solution plus hepes (HBH) (Invitrogen) and 
neutrophils counted on a haemocytometer. The isolated neutrophils had an expected purity of 
around 95%, whilst Trypan blue (Sigma-Aldrich) staining was used to confirm neutrophil 
viability (discarded if below 90% viable). Furthermore, neutrophils were size-excluded using 
a cell counter. Neutrophils were diluted to 5x106 cells/ml and used immediately. 
2.5 Treatment of Endothelial Cells with Tumour Necrosis Factor-α  
 
Endothelial cells, both GEnC and HUVEC, cultured in a 96-well plate (see sections 2.1 and 
2.2 respectively) were grown to confluence at 33°C for three days before transferring to 
37°C for 24 hours. The medium was aspirated from the cells and the cells washed twice with 
PBS (Sigma-Aldrich). TNF-α (NIBSC, stock concentration of 40,000 units/ml) was diluted 
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accordingly (see table 7) in Medium199 with 0.1% BSA (Sigma-Aldrich) made up to a 
volume of 1ml.  
 
Table 7 - TNF-α dilutions 
TNF-α  Units/ml TNF-α  Volume TNF-α  1:100 
Volume 
Medium199 
Volume 
0 0 0 1ml 
1 0.025µl 2.5µl 997.5µl 
5 0.125µl 12.5µl 987.5µl 
10 0.25µl 25µl 975µl 
25 0.625µl 62.5µl 937.5µl 
50 1.25µl 125µl 875µl 
100 2.5µl 250µl 750µl 
 
 
Following removal of PBS from the EnC, 100µl of TNF-α was added to the relevant wells 
and the cells incubated at 37°C for 4 hours. The cells were then washed three times in PBS 
and 50µl of M199 + 0.1% BSA was added to the wells. The neutrophils were added to all 
wells, excluding the negative control, at a concentration of 2.5x105 cells per well and further 
incubated at 37°C for an hour. At the same time, the standard curve was prepared. 
Neutrophils were applied via serial dilution down from a starting concentration of 2.5x105 
cells per well. Following the incubation the neutrophils were discarded, and the EnC washed 
three times with PBS leaving them in 50µl PBS. 20µl of 1% Triton x100 (Sigma-Aldrich) 
was added to each well and the cells shaken to lyse. Addition of 100µl of o-
Phenylenediamine dihydrochloride (OPD) substrate (Sigma-Aldrich) with a 30 minute 
incubation whilst protected from the light allows for the quantification of neutrophil 
adherence to the endothelial monolayer when compared to the standard curve. Absorbance 
was read at 450nm on a Thermo© Multiskan Ascent plate reader.  
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2.6 P-Selectin, E-Selectin, ICAM-1 and VCAM-1 Cell Surface Expression 
ELISA 
 
Endothelial cells were grown to confluence in 96-well culture plates and treated with PR3 
and HLE at concentrations of 0.5, 1 and 2µg/ml for 2 hours at 37°C with 5% CO2, with a 4 
hour (E-Selectin ELISA) or 8 hour (ICAM-1, VCAM-1 ELISA) treatment with 100units of 
TNFα, or 15-30min Thrombin (Sigma-Aldrich) (P-Selectin) as a positive control. Following 
treatment the cells were washed three times in PBS, before being fixed in 2% 
paraformaldehyde (PFA, Sigma-Aldrich) with 4% sucrose (Sigma-Aldrich) for 20 minutes at 
4°C. Following another series of washes the cells were blocked for 30 minutes with 
StabilCoat® (Diarect Ag, Frieburg Germany). The primary antibodies (see table 8) were 
added in PBS with 4% goat serum (Sigma-Aldrich) and incubated at room temperature on a 
rotating plate for 1 hour. 
 
Table 8 - Primary Antibodies for ELISA 
Antibody Raised in Working Dilution Source 
Anti-Human E-
Selectin IgG1 
Mouse 1:1000 R&D Systems 
Anti-Human P-
Selectin IgG1 
Mouse 1:1000 AbCam 
Anti-Human 
ICAM-1 IgG2a 
Mouse 1:1000 AbCam 
Anti-Human 
VCAM-1 IgG1 
Mouse 1:1000 R&D Systems 
IgG1 Isotype 
Control 
Mouse 1:1000 Sigma 
IgG2a Isotype 
Control 
Mouse 1:2500 R&D Systems 
 
The cells were washed and the secondary antibody, goat anti-mouse IgG HRP-linked 
(Dako), was applied at a 1:2000 dilution in PBS with 4% goat serum. Following a 45 minute 
incubation on the rotating plate the cells were washed for a final time and the plate dried by 
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inverting gently on paper towels. 3,3′,5,5′-Tetramethylbenzidine (TMB) solution 
(Calbiochem) was added to the cells at 50µl per well, and incubated at room temperature 
protected from light for 15 minutes. The reaction was stopped by the addition of 50µl of 2M 
hydrochloric acid (HCl, BDH UK) and the plate read at 450nm. 
 
 
 
2.7 Quantification of CXCL8 in Cell Supernatant  
 
Endothelial cells were grown to confluence in 96-well culture plates, then treated with graded 
concentrations of PR3 and HLE in the presence or absence of 〈1-AT for a duration of 2 hours 
at 37°C. CXCL8 was quantified in cell culture supernatants using a capture ELISA kit from 
BD. A 96-well ELISA plate (NUNC, Thermo Scientific) was coated CXCL8 capture 
antibody (1:250) overnight at 4ºC. The following day the plate was washed in PBS + 0.05% 
Tween-20 and blocked for 1 hour at room temperature with PBS+10% fetal calf serum (FCS, 
Sigma-Aldrich). Following a second wash step, the standards and samples were added to the 
plate in duplicate and incubated at room temperature for 2 hours. Standards were made by 
serial dilution down from a starting concentration of 400pg/ml. The plate was washed in PBS 
+ 0.05% Tween-20 (Sigma-Aldrich) and the detection antibody plus HRP reagent (1:250) 
added to the plate for 1 hour. The plate was finally washed and developed with TMB 
solution (Calbiochem), which was stopped with 2M HCl. 
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2.8 Protease Digestion of CXCL8 in Cell Culture Supernatants  
 
Endothelial cells were treated for 4 hours with 100 units of TNFα, following which cell 
culture supernatants were transferred into a second 96 well culture plate. PR3, HLE and α1-
antitrypsin were added to some of the supernatants and incubated for a further 2 hours at 
37°C. CXCL8 measurement in the treated supernatants was then performed using the 
capture ELISA method described in section 2.7. 
 
 
 
2.9 Inhibition of Neutrophil Adhesion by Blocking PSGL-1 
 
Neutrophils were isolated, as described in section 2.4, from healthy donors and incubated in 
the presence of 10µg/ml anti-CD162/PSGL-1 (clone PL1) (antibodies-online GmbH, 
Germany) or the corresponding isotype control for 30minutes. Neutrophils were incubated 
with protease treated endothelial cells for an hour at 37°C, during which a standard curve 
was prepared by serial dilution from a starting concentration of 2.5x105 cells per well. 
Following the incubation, non-adherent neutrophils were removed by washing. The 
remaining endothelial cell-neutrophil co-culture was left in 50µl PBS, then lysed in 1% 
Triton x100 (Sigma-Aldrich). The neutrophil adherence was quantified by colorimetric assay 
in which Sigma-Fast OPD substrate (Sigma-Aldrich) is converted to a coloured product by 
neutrophil MPO. Absorbance was read at 450nm on a BioTek EL808 plate reader using 
Gen5 software. 
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2.10 Inhibition of Neutrophil Adhesion by Blocking CXCR1 and CXCR2 
 
Isolated neutrophils were incubated at 37°C on a rocking platform for 30minutes in the 
presence or absence of blocking antibodies directed at CXCR1 and CXCR2 (R&D systems, 
final concentration 4µg/ml). Neutrophils were added to endothelial cells treated for 2hours 
with 1µg/ml PR3 or HLE at 2.5x105 neutrophils per well and incubated for 1hour at 37°C. A 
standard curve was prepared by serial dilution. Following incubation, the supernatants and 
non-adherent neutrophils were removed. The endothelial cells were washed and left in 50µl 
PBS. The endothelial cell-neutrophil co-culture was lysed in 1% Triton x100 (Sigma-
Aldrich) and 100µl of OPD substrate (Sigma-Aldrich) added, followed by a 30minute 
incubation whilst protected from the light. Absorbance was read at 450nm on a BioTek 
EL808 plate reader. 
 
 
 
2.11 Von Willebrand Factor ELISA of Supernatants 
 
Polyclonal rabbit anti-human von Willebrand factor (Dako, UK) diluted 1:500 in carbonate 
buffer (filter sterilised, see table 9) was added at a volume of 100µl per well into an 
Immunol2 Dynatech plate (Fisher Scientific) and incubated overnight at 4°C. Excess 
antibody was removed by washing three times in PBS + 0.05% Tween 20 (Sigma-Aldrich).  
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Table 9 - Constituents of Carbonate Buffer 
Medium and 
Additives 
Volume Final 
Concentration 
Source 
Na2CO3 0.40g 19mM BDH Chemicals 
LTD, Poole UK 
NaHCO3 0.74g 28mM Fisons,  
Ipswich UK 
Distilled Water 
 
250ml - - 
 
 
A vWf NIBSC international reference standard (stock 100IU/DL reconstituted in 1ml sterile 
H2O) was used to allow quantification of the data. Standards were added to columns 1 and 2 
of the 96-well ELISA plate by serial dilution from a starting concentration of 0.625IU/DL. A 
negative control was also included. All dilutions were performed using PBS + 0.05% Tween 
20. Cell culture supernatants were used undiluted and repeated in 100µl triplicates. 
Following a 1 hour incubation in a wet box, the plate was washed and polyclonal rabbit anti-
human vWf-HRP conjugated secondary antibody (Dako) was diluted 1:500 in PBS + 0.05% 
Tween 20, and added to the wells (100µl per well) for a further hour. Addition of 100µl OPD 
substrate (Sigma-Aldrich) with 30minutes incubation in the dark allowed for quantification 
of the vWf present in the supernatants. The plate was read at 450nm. 
 
 
 
2.12 Quantifying vWf mRNA by PCR 
 
Endothelial cells treated with PR3 and HLE were removed from culture flasks with trypsin 
and spun at 1500RPM for 5 minutes to produce a pellet. RNA was isolated using the RNeasy 
kit (Qiagen) with QIAshredder (Qiagen). Eluted RNA was quantified using the RNA-40 
programme on a Nano-Drop. 1.5µg of RNA from each sample was converted to cDNA using 
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a TaqMan® reverse transcription kit (Applied Biosystems). For TaqMan® reverse 
transcription mastermix see appendix. 
 
 
Table 10 - PCR Programme for Reverse Transcription 
Temperature Time Number of Cycles 
25°C 10 min 1 
37°C 60 min 1 
48°C 30 min 1 
95°C 5 min 1 
Hold 10°C - - 
 
Produced cDNA was quantified using the DNA-50 programme on a Nano-Drop, and purity 
assessed using the ratio of absorbance at 260 and 280nm (pure cDNA has a ratio 
approximately 1.8). 1µg of DNA was using added to the PCR mastermix for amplification 
using vWf primers produced by Alta Bioscience, University of Birmingham (forward primer 
GCCACCCCACCCCAAAACAAGTG, reverse primer TCCCTTTACCGCCCCAGGA- 
GAG, stock 100pm/µl). Primers were used neat, and diluted 1:10 or 1:100 for optimisation. 
See appendix for constituents of PCR mastermix. TATA-box binding protein (TBP) was 
used as a house-keeping gene to demonstrate equal loading. TBP primers were produced at 
Alta Bioscience (forward primer ATGGATCAGAACAACAGCCTG, reverse primer 
CCCTGTGTTGCCTGCTGGGA, stock 100pm/µl) and used at a 1:32 dilution, the PCR 
protocol below was used but with a 61°C annealing temperature. 
 
PCR products were diluted in 6x loading buffer (Fermentas) and analysed on a 1% agarose 
gel (Sigma-Aldrich) in TBE (Gibco) with ethidium bromide (Sigma-Adrich). The gel was 
visualised and photographed using GeneSnap software.  
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Table 11 - PCR Programme for vWf Amplification 
 Temperature Time Number of Cycles 
Initial Denaturation 95°C 3min 1 
Denaturation 95°C 40sec 40 
Annealing 60°C 40sec 40 
Extension 72°C 1min 40 
Final Extension 72°C 10min 1 
Hold 10°C - - 
 
 
 
2.13 Cell Surface Expression of vWf following Protease Treatment 
 
Endothelial cells were treated with graded concentrations of serine protease (HLE and PR3) 
in the presence or absence of α1-AT for 2 hours at 37°C. Following treatment the cells were 
fixed with 4% sucrose (Sigma-Aldrich) in 2% PFA (Sigma-Aldrich) for 15 minutes, washed 
with PBS and the endogenous peroxide inhibited with 0.1% hydrogen peroxide (H2O2) 
(Sigma-Aldrich) in methanol for 15 minutes. The endothelial cells were then blocked with 
10% marvel in PBS for 1 hour prior to the addition of polyclonal rabbit anti-human vWf-
HRP (1:2000) (Dako, Ely UK) for a further hour at room temperature. TMB solution was 
used to develop the ELISA, and stopped after 10 minutes with 2M HCl (BDH). The plate 
was read at 450nm. 
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2.14 vWf Expression by Flow Cytometry 
 
Endothelial cells were grown to confluence in T25 culture flasks and treated for 2h with 
1µg/ml PR3 or HLE, or 1Unit Thrombin (Sigma-Aldrich). Cells were washed in blank 
medium 199 (Gibco) and removed from flasks using cell dissociation buffer (Sigma-Aldrich) 
and gentle scraping. Cells were washed and split into fluorescence-activated cell sorting 
(FACS) tubes. Half the cells were fixed in 2% PFA, the other half permeabilised using a 
Fix&Perm solution (Invitrogen) and stained for vWf using 1:200 sheep anti-human 
polyclonal vWf (Serotec, Kidlington UK) or the corresponding isotype control (Binding 
Site). Cells were incubated in the dark at room temperature for 30minutes, resuspended in 
2% PFA and analysed immediately on BD FACSCalibur. For each treatment 10000 events 
were collected and analysed using winMDI.  
 
 
 
2.15 vWf, CD63 and F-Actin Staining by Confocal Microscopy 
 
Endothelial cells were grown to confluence on 8-well chamber slides, and treated with 
1µg/ml PR3 or HLE. The cells were fixed with ice-cold methanol (Fisher Scientific), for 
vWf/CD63/Phalloidin staining. Alternatively, a membrane stain, wheat germ agglutinin 
Alexa fluor®594 (Image-IT™ LIVE, Invitrogen), was incubated with the treated cells for the 
final 15minutes of treatment, before washing and fixing the cells with 2% PFA. Fixed 
endothelial cells were prepared using a PAP (Peroxidase Anti-Peroxidase) pen (Dako, UK) 
and washed in PBS with gentle agitation. Antibodies were prepared in diluent PBS 
containing 1% BSA and 2% FSC, see table below. 
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Table 12 - Primary Antibodies for Immunocytochemistry 
Antibody Raised in Clone Working 
Dilution 
Source 
Polyclonal Anti-
Human vWf 
FITC 
Sheep - 1:100 Serotec 
Anti-Human 
CD63 FITC 
Mouse MEM-259 1:10 Serotec 
Phalloidin Toxin 
RPE 
- - 1:20 Sigma 
Image It Live 
Alexa Fluor 594 
- - 1:200 Invitrogen 
Polyclonal Ig 
FITC 
Sheep - 1:100 Binding Site 
IgG1 Isotype 
Control FITC 
Mouse F8-11-13 1:10 Serotec 
 
Primary antibody was incubated in the dark for 1 hour at room temperature in a humid 
chamber. Slides were washed in PBS with gentle agitation and counterstained with a 
Hoechst (Invitrogen) nuclei stain for 1hour in the dark. Slides were washed in PBS and 
mounted using slowfade mounting medium (Invitrogen). Slides were viewed immediately by 
confocal microscope using Zeiss image browser.   
 
 
 
2.16 vWf Immunohistochemistry of Kidney Biopsies 
 
Renal biopsy sections were provided by clinical pathology at the Queen Elizabeth Hospital 
Birmingham under the ethics code 07/Q2602/42. Ethical approval was granted by the North 
Staffordshire Research and Ethics Committee. Sections were chosen for the number of 
glomeruli present. Patients included in this research consisted of (i) two female Caucasians, 
aged 59 and 44 at the time of biopsy, with severe acute-tubular necrosis (both patients have 
been dialysis dependent at some stage during treatment) (ii) two female Caucasians, aged 59 
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and 55 at time of biopsy, with severe anti-glomerular basement membrane disease 
(Goodpastures) and (iii) four patients with ANCA-positive vasculitis. The ASV patients 
were predominantly female (3 out of 4) with a mean age of 49 (range 33-67). 3 patients were 
positive for PR3 ANCA and one for MPO (all titres >100EU/ml) with moderate to severe 
renal failure (mean creatinine 470.5µmol/L, range 240-717). 
 
Removal of paraffin and rehydration of sections was achieved by incubation of slides in 
Xylene for 10minutes, followed by 100%, 80%, 75% ethanol and running water each for 
5minutes respectively. Antigen retrieval was performed by incubation of the sections citrate 
buffer (S-2369, Dako, UK) for 20 minutes at 95°C in a water bath. Slides were left to cool in 
the citrate buffer for a further 20 minutes, following which the sections were washed for 10 
minutes in cold running water. The slides were blocked for 30 minutes with 0.3% H2O2 
(Sigma-Aldrich) in methanol. Sections were washed repeatedly with agitation in tris-
buffered saline (TBS) (see recipe below) for 5 minutes, before blocking in 20% goat serum 
(Sigma-Aldrich) for 20 minutes. The primary antibody, rabbit polyclonal vWf (stock 
3.1mg/ml, Dako UK) and rabbit IgG isotype control (stock 1mg/ml, R&D systems UK), was 
diluted 1:400 and 3:400 respectively in TBS and left in a humid chamber overnight at 4°C. 
 
The slides were repeatedly washed in TBS with agitation and developed using a Dako 
Envision Kit (K5007) following manufacturers guidelines. Sections were counterstained in 
Harris haematoxylin (Sigma-Aldrich) for 5 min (Tonsil sections) or 10 minutes (Kidney 
sections). The slides were mounted on ImmunoMount (Thermo Scientific) and visualised 
using a Nikon Eclipse E400 microscope. 
 
 66 
Table 13 - Constituents of TBS pH 7.6 
Medium and Additives Volume Source 
TBS Stock Solution 
(48.44g in 400ml dH2O) 
100ml Sigma-Aldrich 
Distilled Water 1900ml – 
Sodium Chloride 17.6g Sigma-Aldrich 
 
 
 
2.17 Angiopoietin-2 ELISA of Supernatants 
 
Angiopoietin-2 was measured in supernatants from endothelial cells treated with serine 
proteases for 2 hours using a pre-optimised kit from R&D (DY623). Following 
manufacturers guidelines, the primary capture antibody was diluted 1:360 (working 
concentration 1µg/ml) and incubated in NUNC ELISA plates overnight at room temperature. 
The plate was washed in PBS + 0.05% Tween 20 (Simga-Aldrich) and blotted dry before 
blocking with 1% BSA in PBS for 1 hour at room temperature. After further washing, 
standards were added from a starting concentration of 3500pg/ml (stock 150ng/ml) by serial 
dilution in 1% BSA in PBS, whilst samples were used neat. The plate was covered and left 
for 2 hours at room temperature. After washing in PBS + 0.05% Tween 20, the detection 
antibody was diluted 1in360 (working concentration 2µg/ml) in 1% BSA in PBS and 100µl 
added to each well. The plate was incubated at room temperature for 2 hours, washed, and 
incubated for a further 20 minutes in streptavidin-HRP (1:200) avoiding direct light. After a 
final set of washes the plate developed using TMB solution for 20 minutes in the dark. The 
reaction was stopped by the addition of 50µl 2M HCl and the plate read at 450nm 
(subtracting 540nm as background). 
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2.18 Release of vWf by PAR Agonists 
 
Endothelial cells were grown to confluence in 96-well culture plates at 37°C prior to 
treatment with graded doses of PR3 and HLE, as well as 100µM of PAR-1 agonist peptide 
(PAR1-AP) (H-Thr-Phe-Leu-Leu-Arg-NH2, Peptides International), PAR-2 agonist peptide 
(PAR2-AP) (H-Ser-Leu-Ile-Gly-Lys-Val-NH2, Peptides International) and PAR-2 negative 
control  (H-Leu-Ser-Ile-Gly-Lys-Val-NH2, Peptides International) for 2 hours, (doses and 
times were determined in preliminary experiments, see figure 56). Following treatment cell 
culture supernatants were analysed for vWf using the capture ELISA, whilst crystal violet 
staining was used to determine cell detachment following treatment. 
 
 
 
2.19 Knockdown of PAR1 and PAR2 by siRNA 
 
HUVEC were grown to confluence in 24-well culture plates, and incubated for 4 hours with 
either 
i. Optimem medium alone 
ii. Optimem medium containing 0.2% lipofectamine (LF) RNAiMax  
iii. Optimem medium containing LF RNAiMax, 20nM of Sheath™ RNAi for silencing 
PAR-1 RNA (FR2 code: HSS103468 – GCUGAUCAUUUCCACGGUCUGUUAU, 
Applied Biosystems UK) 
iv. Optimem medium containing LF RNAiMax, 20nM of Sheath™ RNAi for silencing 
PAR-2 RNA (F2RL1 code: HSS103471 – UCAACCACUGUUAAGACCUCC 
UAUU, Applied Biosystems UK) 
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v. Optimem medium containing LF RNAiMax, 20nM of non-silencing Sheath™ RNAi 
negative control 
(all siRNA reagents were supplied by Invitrogen, UK) 
After 4hour treatment, HUVEC were incubated with 500µl of complete M199 without 
antibiotics (penicillin, streptomycin and amphotericin B) for 48-72hours before use in 
experiments. 
 
 
 
2.20 RNA Isolation and Real-Time PCR of PAR-1 and PAR-2 
 
RNA was extracted from siRNA treated HUVEC using the Qiagen RNeasy Mini Kit 50 
(Qiagen, UK) following manufacturers guidelines. HUVEC were washed in PBS and lysed 
with 350µl RTL lysis buffer. 350µl of 70% ethanol was added to the cell lysates and mixed 
before transferring to columns. Columns were centrifuged for 1 minute at 8000g, the buffer 
was eluted and 350µl of RW1 added to each column before a further centrifugation at 8000g 
for 1 minute. 500µl of RPE buffer was added to the columns and centrifuged for 1 minute at 
8000g, this was repeated and centrifuged at 8000g for 2 minutes. The columns were placed 
into new collection tubes and 30µl of RNAse free water added. Eluted RNA was quantified 
for purity and concentration on an Eppendorf Biophotometer. 
 
Real-time PCR was performed using a QuantiTect™ probe RT-PCR kit (Qiagen) following 
manufacturers guidelines. 10ng of RNA was added to a 96well optimal reaction plate 
(Applied Biosystems) containing 23µl of mastermix containing QuantiTect™ probe 
mastermix, RNA water, QuantiTect™ reverse transcriptase mastermix, VIC-labelled β-Actin 
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primers (Applied Biosystems) and either FAM-labelled PAR-1 primers (Hs00169258_ml, 
Applied Bioscience) or PAR-2 primers (Hs00608346_ml, Applied Biosystems) see appendix 
2. Samples were amplified for 35 cycles and analysed using the 7500 Real-Time PCR 
machine (Applied Biosystems). The relative expression was determined by comparing the 
target genes to β-Actin. Changes in mRNA expression were expressed compared to their 
relative controls (negative siRNA and LF control). 
 
 
 
2.21 Flow Cytometry determination PAR-1 and PAR-2 Protein Expression 
following siRNA 
 
HUVEC treated with siRNA were assessed for changes in protein expression by flow 
cytometry. Treated HUVEC were grown to confluence in T75 culture flasks. HUVEC were 
either unstimulated or further treated with 2ng/ml TNFα for 24 hours. HUVEC were washed 
with 7.5% EDTA (Sigma-Aldrich) before addition of 6.5ml of cell dissociation buffer 
(Invitrogen). Cells were incubated in dissociation buffer for up to 3 minutes and scraped to 
remove them from the flask. HUVEC were centrifuged for 5 minutes at 1500rpm, and 
resuspended in a new tube at a minimum concentration of 5x105/100µl. Primary antibodies 
(table 14) were added to FACS tubes at 20µl per tube, followed by 100µl of the cell 
suspension.  
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Table 14 - Antibodies for PAR Flow Cytometry 
 Isotype Clone Source 
PAR-1-PE IgG1 MOPC-21 BD 
Isotype control-PE IgG1 WEDE15 Fisher Scientific 
PAR-1-FITC IgG1 ATAP2 Santa-Cruz 
Isotype control-FITC IgG1 SC2855 Santa-Cruz 
PAR-2-FITC IgG2a SAM11 Santa-Cruz 
Isotype control-FITC IgG2a SC2856 Santa-Cruz 
 
FACS tubes were vortexed and incubated at room temperature for 20 minutes whilst 
protected from light. Cells were washed by diluting in 1ml FACS buffer (BD) and 
centrifuged for 5 minutes at 1500rpm. The supernatant was removed, the cells resuspended 
in FACS buffer and analysed immediately on the BD FACSCalibur flow cytometer. 
 
 
 
2.22 Inhibition of Major Pathways of vWf Release 
 
Inhibitors directed at the common signalling pathways associated with vWf release were 
purchased from Calbiochem. In particular, four signalling molecules were targeted, PKC, 
PKA, Phosphatidylinositol 3-kinase (PI3K), and Calmodulin (CaM) (see table below). Cells 
were pre-treated with the inhibitors for 15minutes before the addition HLE or PR3 (2µg/ml) 
into the system. The supernatants were removed and analysed for vWf by ELISA. The cells 
were analysed by MTT for cell viability. 
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Table 15 - Inhibitors used for vWf release 
Target Inhibitor Stock Source Working 
Concentrations 
PKC Gö6983 1000µM Calbiochem 0.01-1µM 
PKA Myristoylated PKI 
(14-22) amide 
500µM Calbiochem 0.01-10µM 
Calmodulin Calmadizolium 14.5mM Calbiochem 0.001-1µM 
PI3K Wortmannin 58.35mM Calbiochem 5-20nM 
 
 
 
2.23 PKC inhibition of Neutrophil Superoxide Release 
 
Neutrophils were isolated following the method described in section 2.4. HBH and 
Cytochrome C (final concentration 0.93mg/ml, Sigma-Aldrich) were added to each well. 
Superoxide Dismutase (SOD, Sigma-Aldrich) was added as a control for inhibited 
superoxide release (final concentration 1,200U/ml). Neutrophils were primed with 2ng/ml 
TNFα (NIBSC) and 10µM cytochalasin B (Sigma-Aldrich) at 37°C for 15 minutes, and 
added to each well (100,000/well) in the presence/absence of a stimulus, either ANCA IgG 
(final concentration 200µg/ml) or fMLP (Formyl-Methionyl-Leucyl-Phenylalanine, Sigma-
Aldrich) (final concentration 1µM), and in the presence/absence of PKC inhibitor (Gö6983) 
(final concentration 1µM). The plate was read at 550nm on a BioTek EL808 plate reader at 5 
minute intervals for 120 minutes whilst incubating at 37°C. 
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2.24 Neutrophil Degranulation Assay 
 
Neutrophils were isolated, as previously described, and diluted to 2.5x106cells/ml in Hanks 
buffered salt solution with 10mM HEPES (final pH 7.4). Neutrophils were primed for 15 
minutes with TNFα (2ng/ml, NIBSC) in the presence of cytochalasin B (10µM, Sigma-
Aldrich) at 37 oC. Primed neutrophils were added to round bottom 96- well culture plates and 
stimulated with either 200µg/ml of ANCA IgG, normal IgG or fMLP (1µM, Sigma-Aldrich) 
as a positive control, for 15 minutes at 37oC. Following stimulation, neutrophils were 
centrifuged at 400g for 5 minutes and the supernatants collected. The MPO activity within 
the supernatants was investigated using SigmaFast OPD substrate following manufacture’s 
guidelines. The reaction was stopped with 100% acetic acid (Fisher Scientific) and read at 
450nm (Multiskan Thermo-Fisher, MA, USA). This method was provided by Dr Neil 
Holden.  
 
 
 
2.25 Inhibition of vWf release by F-Actin inhibitor, Cytochalasin B 
 
Cytochalasin B is a fungal metabolite that inhibits the polymerisation of the actin 
cytoskeleton, hence can be used to investigate cellular mobilisation. HUVEC were pre-
treated for 5 minutes with a range of dilutions of cytochalasin B (Sigma-Aldrich) in 
M199+0.5% BSA, before the addition of 2µg/ml HLE. The cells were incubated for 2 hours 
at 37°C, following which, supernatants were removed and analysed for vWf by capture 
ELISA as described previously. The endothelial cells were then either quantified for changes 
in mitochondrial activity by MTT or visualised by phase microscopy. 
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2.26 Stimulation of Endothelial vWf release by Okadaic Acid 
 
Endothelial cells were initially treated with a range of dilutions of Okadaic Acid (sodium salt 
459620, Calbiochem, UK) from 500nM to 1nM for 2 hours at 37°C. Cells were also treated 
with PR3 and HLE for comparative purposes. Following treatment, the supernatants were 
removed and analysed for vWf release by capture ELISA, the remaining endothelial cells 
were stained will crystal violet to assess cell detachment (for method see section 2.29). For 
later experiments Okadaic acid was used at a concentration of 100nM for 2 hours in the 
presence or absence of serine proteases, this was followed by MTT to assess endothelial cell 
viability (see section 2.30). 
 
 
 
2.27 Tyrosine and Serine/Threonine Phosphorylation by Western Blotting 
 
Endothelial cells were treated with 1µg/ml PR3 and HLE in the presence or absence of 
α1AT, or 100nM Okadaic Acid. Following removal of supernatants the cells were scraped 
into NP40 ((Octylphenoxy)phenoxypolyethoxylethanol) lysis buffer containing protease 
inhibitor cocktail III and a phosphatase inhibitor cocktail (Calbiochem, 1:100 dilution), see 
recipe below.  
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Table 16 - Constituents of NP40 Lysis Buffer 
 Stock Concentration Volume Source 
NP40  500µl Sigma-Aldrich 
Water N/A 27.8ml - 
EDTA 50mM 2ml Sigma-Aldrich 
Glycerol 99.9% 5ml Sigma-Aldrich 
Tris-HCl 1M 1ml Calbiochem 
Sodium Chloride 
Solution 
0.5M 13.7ml Calbiochem 
 
 
Samples were spun at 7000g for 10min at 4°C and the supernatant removed for 
quantification of protein by Nano-Drop Spectrophotometer ND-1000. 250µg of protein was 
diluted in 6x SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) 
loading buffer (see appendix for recipes) and boiled for a further 5min before loading into a 
10% SDS-PAGE gel. The gel was run for 1 hour at 120V, and transferred onto a 
nitrocellulose membrane using a semi dry unit at 34mA for 1 hour. The membrane was 
blocked for 1 hour in 5% BSA in TBS-0.01% Tween (TBS-T) (powdered BSA, Triza-Base 
and Tween-20 all from Sigma-Aldrich). Primary antibody was diluted in 5% BSA in TBS-T 
and incubated overnight at 4°C with agitation. The membrane was washed in TBS-T and 
incubated with secondary antibody at room temperature for 1 hour with agitation. The blot 
was incubated with ECL+ (Amersham, GE Healthcare) for 5min, drained and wrapped in 
saran wrap. The blot was exposed to X-Ray film (Amersham, GE Healthcare) for up to 
10min and developed on a Xograph imaging system (compact X4).  
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Table 17 - Antibodies used for Western Blotting 
Antibody Raised in Clone Working 
Dilution 
Source 
Anti-Human 
Phosphotyrosine 
Mouse p-tyr-100 1:1000 New England 
Biolabs 
Polyclonal Anti-
Human Phospho- 
serine/threonine 
Rabbit - 1:750 AbCam 
Anti-Mouse HRP - - 1:2000 New England 
Biolabs 
Anti-Rabbit HRP 
 
- - 1:10000 Amersham 
 
 
 
2.28 Necrosis verses Apoptosis with ApoGlow® 
 
Apoptosis, necrosis and proliferation was determined by Adenosine-5'-triphosphate (ATP) 
levels and the Adenosine-diphosphate (ADP):ATP   ratio  in   cultured   cells   using   the   
ApoGlow®   Assay  (Lonza, UK). ApoGlow® uses the conversion of ATP into ADP as a 
marker for apoptosis and necrosis. ATP is measured in endothelial cells as a marker of 
mitochondrial activity, and is present in all metabolically active cells. As cells undergo 
apoptosis this level of ATP decreases as it is converted to ADP. ApoGlow® measures ATP 
in cell lysates by the conversion of ATP and luciferin into oxyluciferin and AMP by the 
addition of luciferase. The light emitted as a by-product of this reaction is linearly related to 
the ATP concentration in the cells. ADP is quantified by first converting it into ATP. 
 
Glomerular endothelial cells were treated for durations of 2hours or 24hours with different 
concentrations of protease (PR3 and HLE) in a 96-well culture plate. The ApoGlow® 
reagents were made up following the manufacturer’s guidelines and allowed to warm to 
room temperature prior to use. Following treatment, the endothelial cells were removed from 
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the incubator and allowed to return to room temperature, after which 100µl of nucleotide 
releasing reagent (NRR) was added to each of the wells and left for a minimum of 5 minutes. 
Of the cell lysate, 180µl was transferred to a luminescent compatible 96-well plate and 20µl 
of nucleotide monitoring reagent (NMR) added. The plate was then read on the Mikrowin© 
program on a Centro LB 960 luminometer (Berthold Technologies, Harpenden, UK). The 
initial reading (A) gives the level of ATP in the cell lysate, and was followed by a 10minute 
incubation and a second reading (B). Following the addition of 20µl of ADP-converting 
reagent and a 5minute incubation protected from the light, a final reading is taken (C) from 
which the ADP:ATP ratio can be calculated using the following equation: 
ADP:ATP ratio = (C-B) 
                      A 
 
 
 
2.29 Crystal Violet Staining of Adherent Cells 
 
Crystal violet is a cellular dye that can allow for quantification of changes in cell number 
following treatment. Crystal violet staining was used to assess cell detachment following 
PR3 and HLE treatment. Endothelial cells were treated with PR3 and HLE for 2 hours in a 
96-well culture plate. After which, they were washed with PBS and fixed with 2% formalin 
(Fisher Scientific) for 15 minutes. 0.1% crystal violet (Sigma-Aldrich) was added to each of 
the wells for 10 minutes, then washed 5 times with PBS. 1% triton X100 (Sigma-Aldrich) 
was added 100µl per well for 10 minutes on a shaking plate. The plate was read at 550nm. 
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2.30 MTT assessment of Mitochondrial Activity 
 
To assess the changes in the mitochondrial activity of the endothelial cells, and hence 
endothelial injury, following treatment with PR3 and HLE we used an MTT (1-(4,5-
Dimethylthiazol-2-yl)-3,5-diphenylformazan, Sigma-Aldrich) assay. The MTT assay works 
via the conversion of solublised MTT into formazan crystals by mitochondrial succinate 
dehydrogenase. These formazan crystals can then be dissolved and quantified as a measure 
of cellular mitochondrial activity. Endothelial cells were treated in 24-well culture plates. 
Following treatment cells were washed in PBS, and 5µg/ml MTT in M199 + 0.1% BSA 
added to each well. Culture plates were incubated at 37°C on a shaking plate for 1 hour. The 
cells were washed in PBS and the plate dried on a clean tissue via inversion. DMSO 
(Dimethyl Sulfoxide, Sigma-Aldrich) was added to each of the well and the plate incubated 
on a shaking plate for a further 30 minutes at 37°C. The samples were transferred in 
triplicate to a 96-well plate and read at 540nm. 
 
 
 
2.31 Statistical Analyses 
Experiment data was assessed for significance using GraphPad Prism version 5 (Graphpad 
Software Inc., USA), and SPSS version 18 (IBM, USA) software. SPSS was used for 
analyses of experiments in which data sets were missing. Tests for normality were performed 
using the D’Agostino & Pearson omnibus normality test. Data sets contains greater than 3 
variables were assessed for significance using a 1-way ANOVA with pot-hoc test. 2-way 
ANOVAs were used to compare treatments between cell types. For experiments in which 
α1-antitrypsin and inhibitors were used, paired T-tests or wilcoxen signed rank tests 
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(depending on normality) were used to assess the significance of the inhibition compared to 
an uninhibited control. Significance was classed as p<0.05 and expressed and *<0.05, 
**<0.01 and ***<0.001. For experiment with inhibition + was used to denote significance 
compared to an uninhibited control. 
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3. Results 
 
 
3.1 Visualisation of Endothelial Cells at Different Time Points in Culture 
 
Two types of endothelial cell were used in this thesis, a conditionally immortalised 
glomerular endothelial cell line (GEnC) (gift from S. Satchell, Bristol UK [275]) and 
endothelial cells isolated from the human umbilical vein (HUVEC). The conditionally 
immortalised GEnC have been suggested to retain their morphological features until at least 
passage 41. GEnC were passaged at day 0 and split into three new culture flasks following 
the method described in section 2.1, whilst HUVEC were isolated from umbilical cords 
donated from the Birmingham Woman’s Hospital and added to culture flasks (see section 
2.2). The cells were visualised at day 3 and day 6 post passage or isolation (figure 7). 
Visualisation of cells at 3 days clearly demonstrates the endothelial cells in the log phase of 
development. During this stage of the cell cycle the endothelial cells are undergoing active cell 
division and proliferation. The cells, themselves, appear stretched and spindle-like as they 
attempt to form contacts with other endothelial cells. At 6 days, cultured endothelial cells 
take on the characteristic “cobblestone” appearance previously described by Striker et al., 
1984 [274]. The cells are subject to ‘contact inhibition’ and do not grow on top of each other. 
The cells become smaller and rounder in shape, forming connections with other cells to form 
a single endothelial cell monolayer. Endothelial cells were grown to form confluent monolayer 
before used in experiments. 
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Figure 7 - Visualisation of Endothelial Cells at Different Time-Point 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phase microscopy of glomerular endothelial cells and HUVEC 3 days post passage and isolation respectively. 
After 6 days of growth, phase microscopy depicts a typical confluent monolayer. 
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3.2 Crystal Violet Staining for Cell Adherence 
 
To investigate a role for the neutrophil serine proteases in endothelial cell injury, PR3 and 
HLE were first assessed for their ability to induce endothelial cell detachment after short 
incubations using a crystal violet cell stain. Changes in endothelial adherence could be 
assessed by changes in the intensity of crystal violet dye present after lysis of the endothelial 
cells. An increase in optimal density would suggest cellular proliferation, whilst decreases 
suggest loss of adherent cells. Glomerular endothelial cells were treated with 1µg/ml of PR3 
and HLE for between 15 minutes and 2 hours. Changes in the number of adherent 
endothelial cells following treatment were represented as percentages of untreated 
endothelial cells. The glomerular endothelial cells treated with 1µg/ml PR3 or HLE 
demonstrated no significant changes in cellular detachment when compared to the untreated 
control at all time points (figure 8). Further to this, confluent monolayers of glomerular 
endothelial cells were treated for 2 hours with concentrations of serine protease above and 
below our 1µg/ml standard treatment, to assess how a higher dose would affect cellular 
attachment in vitro. Here it was demonstrated that even at higher doses of PR3 and HLE 
(2µg/ml) there was no significant increase in endothelial cell detachment following a 2 hour 
treatment (figure 9). 
 
The crystal violet method assumes that the cells contain an equal intensity of dye, so that cell 
detachment accurately represents the changes in colour intensity. To confirm this we could 
have seeded known cell numbers and stained with crystal violet to determine if the dye 
intensity accurately represents the number of adherent cells. 
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Figure 8 – Timecourse of Crystal Violet Staining for Endothelial Detachment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glomerular endothelial cells were treated for up to 2 hours with 1µg/ml PR3 or HLE, fixed in 2% PFA and the 
number of adherent cells quantified by crystal violet staining. The results shown are the mean and standard 
error of 3 separate experiments displayed as a percentage of the unstimulated control (0min). Statistical 
significance was calculated using a 2-way ANOVA with Bonferroni post test (treatment p=0.1408, time 
p=0.9424). 
 
 
 
Figure 9 - Crystal Violet Staining for Endothelial Detachment following treatment with 
increasing concentrations of Serine Protease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glomerular endothelial cells were treated with increasing concentrations of PR3 and HLE (0.5µg/ml - 2µg/ml) 
for 2 hours, fixed in 2% PFA and adherent cells quantified by crystal violet staining. The data shown here are 
the mean and standard error from 3 separate experiments displayed as a percentage of the unstimulated control. 
Analysis by 1-way ANOVA with Bonferroni post-test demonstrated no significant difference between control 
and treated groups (PR3 p=0.8173, HLE p=0.1647). 
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3.3 Measure of Mitochondrial Activity in Serine Protease Treated 
Endothelial Cells 
 
The MTT assay was used in collaboration with the crystal violet to demonstrate changes in 
the viability of serine protease treated endothelial cells. The MTT assay uses the conversion 
of the MTT compound by mitochondrial succinate dehydrogenase as a measure of 
mitochondrial activity. Again, glomerular endothelial cells were treated with 1µg/ml PR3 or 
HLE for between 15 minutes and 2 hours. Mitochondrial activity of treated glomerular 
endothelial cells was displayed as a percentage of the unstimulated control. Even at 2 hours 
treatment there was no significant decrease in mitochondrial activity following treatment 
with 1µg/ml PR3 or HLE (figure 10). Moreover, GEnC treated with increasing 
concentrations of PR3 and HLE (0.5µg/ml - 2µg/ml) for 2 hours (figure 11) displayed no 
significant decrease in the level of mitochondrial activity following treatment of GEnC with 
higher concentrations of PR3 (p=0.2114). The analysis of HLE treatment by 1-way ANOVA 
demonstrated a significant difference between untreated and HLE treated GEnC (p=0.0337), 
although there was no significant difference between untreated GEnC and individual HLE 
concentrations (Bonferroni post-test p>0.05 for all concentrations). 
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Figure 10 - Mitochondrial Activity following a Timecourse of Protease Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glomerular endothelial cells were treated with 1µg/ml of PR3 and HLE for durations of up to 2 hours, after 
which, they were assessed for changes in mitochondrial activity by MTT assay. The data shown here are the 
mean and standard error from 3 separate experiments and displayed as a percentage of the unstimulated control. 
Statistical significance was assessed by 2-way ANOVA with Bonferroni post-test (treatment p=0.0561, time 
p=0.6347).  
 
 
 
Figure 11 - Mitochondrial Activity following treatment with increasing concentrations 
of Serine Protease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glomerular endothelial cells were treated with increasing concentrations of PR3 and HLE (0.5µg/ml - 2µg/ml) 
for 2 hours, before assessment of mitochondrial activity by MTT assay. The data shown here are the mean and 
standard error of 3 separate experiments, displayed as a percentage of the unstimulated control. Statistical 
significance was assessed by 1-way ANOVA with Bonferroni post-test (PR3 p=0.2114, HLE p=0.0337). 
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3.4 Measure of Apoptosis by Conversion of ATP into ADP 
 
The Apoglow® assay works on the principle that as cells prepare to undergo apoptosis, 
intracellular ATP stores are converted to ADP. GEnC treated for 2 hours with 0.5µg/ml - 
2µg/ml PR3 or HLE showed no significant decrease in the level of intracellular ATP. 
Alternatively, GEnC lysed in either water or 1x triton X100, used as positive controls of 
necrosis, demonstrated greatly reduced levels of ATP compared to untreated GEnC. The 
serine protease treated endothelial cells also showed no increase in the ADP:ATP ratio at 2 
hours, when compared to cells lysed with water or 1x Triton X100 (figures 12 and 13). 
Alternatively, GEnC treated for 24 hours with PR3 and HLE displayed significantly 
decreased levels of ATP, which were particularly evident with HLE treatment at 
concentrations of 1µg/ml and 2µg/ml. These cells also displayed an increased ADP:ATP 
ratio compared to untreated endothelial cells, however this did not reach significance (figures 
14 and 15). In particular, the ADP:ATP ratio from 2µg/ml HLE treated GEnC is more 
comparable to the levels seen in GEnC lysed in water than the untreated control (see table 
20). GEnC treated with 2µg/ml PR3 for 24 hours also demonstrated significantly decreased 
levels of ATP, as well as a 10-fold increased ADP:ATP ratio, although this also did not 
reach significance. Furthermore, comparison of endothelial cells at the two time points by 2-
way ANOVA indicates a significant difference between the ATP levels in 2 hour and 24 
hour treated GEnC (p=0.002), whilst untreated endothelial cells incubated for 24 hours only 
retain approximately 50% of the intracellular ATP present after a 2 hour incubation. 
Moreover, treatment with 2µg/ml HLE displayed a significantly increased ADP:ATP ratio at 
24 hours compared to 2 hours treatment (p<0.05, Bonferroni post-test). 
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It is of note, that whilst the ATP concentrations decreased significantly following a 24 hour 
incubation with PR3 and HLE, the ADP concentration did not increase by the same 
magnitude. One would expect that, as the cell converts internal stores of ATP into ADP, we 
would see an equal decrease and increase, respectively, in concentrations. It is possible that 
this may be due to technical issues with the ApoGlow® kit, specifically in not accurately 
converting all internal stores of ADP into ATP for measurement. As cells are not washed 
following treatment, the loss of ATP or ADP into supernatants would not exclude it from 
measurement. Because of this, the ADP:ATP ratio data should be regarded with caution, and 
apoptosis should be confirmed by alternative methods. 
 
Visualisation of the cells after PR3 or HLE treatment at both the 2 hour and 24 hour 
incubation times was used to help confirm the state of apoptosis and endothelial detachment. 
Following treatment with serine proteases the endothelial cells were captured using a phase 
microscope (Olympus). Although there appears to be some level of endothelial cell 
detachment, the GEnC that received a 2 hour treatment with 1µg/ml PR3 or 1µg/ml HLE still 
maintain a confluent monolayer. This cannot be seen in those samples that were treated with 
water. At 24 hours, the serine protease treated endothelial cells no longer uphold this 
observation, whilst untreated cells still display an intact endothelial monolayer (figure 16). 
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Table 18 - Numerical Data for ApoGlow® Assay at 2 hours 
 Mean ATP (RLU) Mean ADP:ATP Outcome 
 
Untreated Control 226731.1667 0.060610713 Healthy 
0.5µg/ml PR3 216713.1667 0.27892837 Healthy 
1µg/ml PR3 211072.3333 0.317791831 Healthy 
2µg/ml PR3 197621.6667 0.342578093 Healthy 
0.5µg/ml HLE 232723.3333 0.036910107 Healthy 
1µg/ml HLE 227018.5 0.095202433 Healthy 
2µg/ml HLE 204005.6667 0.206395723 Healthy 
Water 8651.5 1.1125037 Necrosis 
1x Triton X100 10012.5 7.707885 Necrosis 
For ApoGlow® assay guideline criteria please see appendix 
 
Table 19 - Numerical Data for ApoGlow® Assay at 24 hours 
 Mean ATP (RLU) Mean ADP:ATP Outcome 
 
Untreated Control 116003.0167 0.03266337 Healthy 
0.5µg/ml PR3 96808.16667 0.082283747 Healthy 
1µg/ml PR3 85784.5 0.111148703 Healthy 
2µg/ml PR3 64652.5 0.30285567 Early Apoptosis 
0.5µg/ml HLE 73216.66667 0.10441851 Arrested 
Proliferation 
1µg/ml HLE 27086.66667 0.3540396 Apoptosis 
2µg/ml HLE 11011.33333 0.840836333 Apoptosis 
Water 8651.5 1.1125037 Necrosis 
1x Triton X100 10012.5 3.2846265 Necrosis 
For ApoGlow® assay guideline criteria please see appendix 
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Figure 12 - Changes in Intracellular ATP levels at 2 hours 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glomerular endothelial cells were treated with increasing doses of PR3 and HLE (0.5µg/ml - 2µg/ml) for 2 
hours and measured for intracellular ATP concentration by the addition of a nuclear monitoring reagent. The 
level of luminescence produced in this reaction is directly proportional to the level of ATP. The data shown 
here are the mean and standard error for 3 separate experiments, displayed as a percentage of the unstimulated 
control. Statistical significance was calculated using a 1-way ANOVA with Bonferroni post-test (PR3 
p=0.1185, HLE p=0.1561). 
 
 
Figure 13 - Changes in the ADP:ATP Ratio at 2 hours 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ADP was measured in 2 hour treated glomerular endothelial cells by the conversion into ATP. The 
luminescence produced was linearly related to the level of ATP. Subtraction of the initial ATP reading from the 
total ATP reading after ADP conversion was equal to the ADP present within the cell. The data shown here are 
the mean and standard error from 3 separate experiments, represented as a percentage of the unstimulated 
control. Statistical significance was assessed by 1-way ANOVA with Bonferroni post-test (PR3 p=0.4585, HLE 
p=0.3400). 
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Figure 14 - Changes in Intracellular ATP Levels at 24 hours 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glomerular endothelial cells were treated with increasing doses of PR3 and HLE (0.5µg/ml - 2µg/ml) for 24 
hours and measured for intracellular ATP concentration by the addition of a nuclear monitoring reagent. The 
level of luminescence produced in this reaction is directly proportional to the level of ATP. The data shown 
here are the mean and standard error for 3 separate experiments, displayed as a percentage of the unstimulated 
control. Statistical significance was calculated using a 1-way ANOVA with Bonferroni post-test (PR3 
p=0.0198, HLE p<0.0001). *p<0.05, **p<0.01, ***p<0.001 
 
 
Figure 15 - Changes in the ADP:ATP Ratio at 24 hours 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ADP was measured in 24 hour treated glomerular endothelial cells by the conversion into ATP. The 
luminescence produced was linearly related to the level of ATP. Subtraction of the initial ATP reading from the 
total ATP reading after ADP conversion was equal to the ADP present within the cell. The data shown here are 
the mean and standard error from 3 separate experiments, represented as a percentage of the unstimulated 
control. Statistical significance was assessed by 1-way ANOVA with Bonferroni post-test (PR3 p=0.2513, HLE 
p=0.2835). 
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Figure 16 - Visualisation of GEnC after Serine Protease Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The images above are a representative of how unwashed glomerular endothelial cells appear under the 
microscope following a 2 hour (upper panel) or 24 hour (lower panel) treatment with 1µg/ml PR3 and HLE.  
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3.5 Von Willebrand Factor Release from Serine Protease Treated 
Endothelial Cells 
 
To further assess an injurious role for the neutrophil serine proteases in vasculitis, vWf 
release was measured from glomerular endothelial cells treated with 0.5µg/ml - 2µg/ml of PR3 
or HLE for 2 hours and 24 hours. The release of vWf from this conditionally immortalized 
microvascular glomerular endothelial cell line was compared to the level of release from 
HUVEC, a readily available primary macrovascular endothelial cell. vWf release was 
significantly increased from GEnC and HUVEC at 2 hours with all concentrations of HLE, 
with between a 7 and 9 fold increase (HUVEC and GEnC respectively) in vWf release from 
2µg/ml HLE treated endothelial cells above unstimulated control cells. The increased vWf 
release from PR3 treated endothelial cells was lower than that from HLE treated cells. Again, 
treatment of HUVEC with all concentrations of PR3 resulted in significantly increased vWf 
release above the untreated control (around 2-fold increase), whilst on GEnC, only 2µg/ml of 
PR3 resulted in a significant increase (4-fold), although vWf release does appear to increase at 
lower PR3 concentrations in a dose dependant fashion (figure 17). Endothelial cells were 
further treated with a higher concentration of serine protease (5µg/ml), however this resulted 
in endothelial cell detachment (see section 3.7) 
 
Following a 24 hour treatment with PR3 and HLE there was a greatly increased level of 
release vWf compared to 2 hour treatment, however, this is also true of untreated endothelial 
cells, and therefore the difference in release between treated and untreated is much less 
marked. HLE treatment at this timepoint appears to display a dose dependant decrease in 
vWf release, most evident with HUVEC (figure 18). Earlier timepoints for vWf release (15 
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minutes - 1 hour) were also investigated but no significant increase in vWf release was 
observed (figures 19 and 20). 
 
 
The vWf release from serine protease treated endothelial cells was calculated as a percentage 
of total endothelial vWf (released plus lysate). Treatment with 2µg/ml of HLE stimulated 
between 40% and 50% of total vWf to be released from HUVEC and GEnC respectively 
(figures 21 and 22). The percentage release from PR3 treated endothelial cells was not 
significantly increased and more comparable to the levels seen with untreated endothelial 
cells, although this is likely to be due to high variation between the individual experiments. 
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Figure 17 - vWf Release from PR3 and HLE Treated Endothelial Cells at 2 hours 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endothelial cells were treated with increasing concentrations of PR3 and HLE for 2 hours, after which vWf was 
measured in cell culture supernatants. HUVEC data shown are the mean and standard error of 9 separate 
experiments. GEnC data shown are the mean and standard error of 10 separate experiments. Statistical 
significance was calculated by 1-way ANOVA with Bonferroni post-test (HUVEC p=0.0001, GEnC 
p=0.0003). A 2-way ANOVA was used to test the significant difference between two cell types (p=0.0012). 
*p<0.05, **0<0.01, ***p<0.001 
 
 
 
Figure 18 - vWf Release from PR3 and HLE Treated Endothelial Cells at 24 hours 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endothelial cells were treated with increasing concentrations of PR3 and HLE for 24 hours, after which vWf 
was measured in cell culture supernatants. The data shown here are the mean and standard error of 4 separate 
experiments. Statistical significance was calculated by 1-way ANOVA with Bonferroni post-test (HUVEC 
p=0.0625, GEnC p=0.0048). A 2-way ANOVA was used to test the significant difference between two cell 
types (p=0.3097). *p<0.05, **p<0.01 
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Figure 19 - Timecourse of vWf Release from PR3 Treated Endothelial Cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endothelial cells were treated with 1µg/ml PR3 for up to 2 hours to see is vWf release could be detected from 
the cell at earlier timepoints. vWf was measured in cell culture supernatants by capture ELISA. The data shown 
here are the mean and standard error of 3 separate experiments. Statistical significance was assessed by 2-way 
ANOVA with Bonferroni post-test (P<0.0001 time, P=0.0930 cell type). ***p<0.001 
 
 
 
 
 
 
 
Figure 20 - Timecourse of vWf Release from HLE treated Endothelial Cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endothelial cells were treated with 1µg/ml HLE for up to 2 hours. vWf was measured in cell culture 
supernatants by capture ELISA. The data shown here are the mean and standard error of 3 separate 
experiments. Statistical significance was assessed by 2-way ANOVA with Bonferroni post-test (P=0.0384 time, 
P=0.1357 cell type). **p<0.01 
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Figure 21 - vWf Release from HUVEC as a Percentage of Total vWf 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vWf release from 2 hour PR3 and HLE treated HUVEC was calculated as a percentage of total vWf (released 
vWf + lysed cell vWf). vWf was measured in supernatants of cell lysates by capture ELISA. The data shown 
are the mean and standard error for 6 separate experiments. Statistical significance was calculated by 1-way 
ANOVA with Bonferroni post-test (PR3 p=0.6103, HLE p=0.0082). *p<0.05 
 
 
 
Figure 22 - vWf Release from GEnC as a percentage of Total vWf 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vWf release from 2 hour PR3 and HLE treated GEnC was calculated as a percentage of total vWf (released 
vWf + lysed cell vWf). vWf was measured in supernatants of cell lysates by capture ELISA. The data shown 
are the mean and standard error for 4 separate experiments. Statistical significance was calculated by 1-way 
ANOVA with Bonferroni post-test (PR3 p=0.6685, HLE p=0.0032). *p<0.05 
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3.6 Increased level of Intracellular vWf Protein and mRNA following 
Treatment 
 
Intracellular vWf was measured in PR3 and HLE treated endothelial cells by lysis in 1x 
triton X100 and the endothelial cell lysate quantified for remaining vWf. Surprisingly, there 
was an increased level of vWf protein remaining in the lysates of 2 hour treated endothelial 
cells following removal of the supernatants. The lysate vWf concentration was increased in 
both GEnC and HUVEC following PR3 and HLE treatment in a dose dependant manner, 
although this only reached significance in HUVEC treated with 2µg/ml HLE (figure 23 and 
24). There was also an unexpected significant increase in the cells’ total vWf (lysate + 
released) following 2µg/ml PR3 and HLE treatment on both GEnC and HUVEC (figures 25 
and 26). 
 
Further investigation demonstrated that treatment of recombinant vWf protein with 2µg/ml 
HLE in a cell-free system can increase the level of antibody binding by 30.7% on average 
(mean of the increased percentage from 7 dilutions of recombinant vWf), whilst PR3 does 
not have an effect on antibody binding (mean increase -1.67%) (figure 27). These results 
imply that HLE may be involved in processing of the vWf multimer to expose more antibody 
binding sites, although this only accounts for around 30% of the increased vWf we are 
detecting. Alternatively, PR3 does not appear to process the recombinant vWf, implying that 
the serine proteases are somehow acting to induce the production of vWf in endothelial cells. 
 
Interestingly, treatment of glomerular endothelial cells with 1µg/ml of PR3 or HLE for 2 
hours appeared to increase the vWf mRNA level (figure 28). The addition of serine protease 
inhibitor α1-antitrypsin (140nM) at the beginning of the 2 hour incubation did not appear to 
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reduce this increase in relative mRNA expression, probably due to early internalization of the 
protease. There was no difference in the expression of house-keeping gene, TATA-box 
binding protein, in untreated GEnC and those treated with 1µg/ml of PR3 or HLE for 2 
hours. The use of the traditional end-point PCR method for assessment of changes in mRNA 
has limitations in our ability to quantify these changes in vWf mRNA expression. Using this 
method, vWf mRNA expression could only be estimated by comparing the band intensity. 
This experiment (n=1) was performed as a preliminary ‘look-see’ experiment, and now needs 
to be repeated with more accurate methods. By using a quantitative real-time PCR method, 
we could use florescent labels to accurately quantify the changes in mRNA expression at 
each replication cycle. Another advantage of the qPCR method is the absence of a need to run 
the PCR products on a electrophoresis gel, thereby removing a second potential source of 
error. 
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Figure 23 - Level of Intracellular vWf Remaining in HUVEC after Serine Protease 
Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vWf was measure in the lysates of HUVEC that had undergone a 2 hour treatment with increasing 
concentrations of PR3 and HLE (0.5µg/ml - 2µg/ml) by capture ELISA. The data shown here are the mean and 
standard error of 6 separate experiments. Statistical significance was calculated by 1-way ANOVA with 
Bonferroni post-test (PR3 p=0.0504, HLE p=0.0058). **p<0.01 
 
 
 
 
Figure 24 - Level of Intracellular vWf Remaining in GEnC after Serine Protease 
Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vWf was measure in the lysates of GEnC that had undergone a 2 hour treatment with increasing concentrations 
of PR3 and HLE (0.5µg/ml - 2µg/ml) by capture ELISA. The data shown here are the mean and standard error 
of 4 separate experiments. Statistical significance was calculated by 1-way ANOVA with Bonferroni post-test 
(PR3 p=0.1352, HLE p=0.1798). 
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Figure 25 - Total vWf after Treatment of HUVEC with Serine Proteases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total vWf was calculated as the sum of vWf release into supernatants plus vWf measured in cell lysates. 
HUVEC were treated for 2 hours with increasing concentrations of PR3 and HLE. vWf was measured by 
capture ELISA. The data shown here are the mean and standard error of 6 separate experiments. Statistical 
significance was assessed by 1-way ANOVA with Bonferroni post-test (PR3 p=0.0216, HLE p=0.0206). 
*p<0.05 
 
 
 
Figure 26 - Total vWf after Treatment of GEnC with Serine Proteases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total vWf was calculated as the sum of vWf release into supernatants plus vWf measured in cell lysates. GEnC 
were treated for 2 hours with increasing concentrations of PR3 and HLE. vWf was measured by capture 
ELISA. The data shown here are the mean and standard error of 4 separate experiments. Statistical significance 
was assessed by 1-way ANOVA with Bonferroni post-test (PR3 p=0.0281, HLE p=0.0086). *p<0.05, **p<0.01 
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Figure 27 - Cleavage of vWf by PR3 and HLE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A serial dilution of recombinant vWf was incubated with 2µg/ml PR3 or HLE for 2 hours. Detectable vWf was 
then quantified by capture ELISA. The data shown here is the mean data from 1 experiment. 
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Figure 28 - vWf mRNA levels following Serine Protease Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The mRNA level of intracellular vWf (A) and a tubulin binding protein (B) loading control was measured in 
GEnC following a 2 hour treatment with 1µg/ml PR3 and HLE in the presence or absence of α1AT. mRNA 
was converted in cDNA via reverse transcription and amplified by PCR. mRNA and cDNA were quantified by 
Nano-Drop and equally loaded in all samples.  
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3.7 Inhibition of vWf Release by α1-Antitrypsin 
 
To confirm that the release of endothelial vWf was due to the enzymatic functions of the 
serine proteases, the irreversible serine protease inhibitor α1-antitrypsin was added to 
endothelial cells during PR3 and HLE treatment. α1AT was used in a molar excess (four 
times the concentration of PR3 and HLE) to inhibit the enzymatic functions of PR3 and 
HLE. vWf release from GEnC and HUVEC treated with 1µg/ml PR3 or HLE could be 
completely abolished by the addition of 140nM α1AT at both the 2 hour and 24 hour 
incubation periods (figures 29 and 30). Nevertheless, vWf release remained overall higher 
following a 24 hour treatment.  
 
vWf release could also be inhibited by α1AT following treatment with a higher 
concentration of PR3 and HLE (5µg/ml) following a 2 hour treatment. This concentration of 
PR3 and HLE induced significantly increased release of vWf into supernatants, which was 
inhibitable to untreated control levels of vWf release by α1AT (figures 31 and 32). 
Treatment with 5µg/ml HLE also induced significant levels of endothelial cell detachment, 
most evident with HUVEC, which could also be restored by α1AT (figures 33 and 34). 
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Figure 29 - Inhibition of vWf Release by α1AT at 2 hours 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endothelial cells were treated for 2 hours with 1µg/ml PR3 or HLE in the presence or absence of α1AT. vWf 
was measured in cell culture supernatants by capture ELISA. The data shown here are the mean and standard 
error for 4 separate experiments. Statistical significance was calculated using a Paired T-Test. * and + p<0.05, 
** and ++ p<0.01 
* compared to untreated cells 
+ compared to serine protease treatment 
 
 
 
Figure 30 - Inhibition of vWf Release by α1AT at 24 hours 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endothelial cells were treated for 24 hours with 1µg/ml PR3 or HLE in the presence or absence of α1AT. vWf 
was measured in cell culture supernatants by capture ELISA. The data shown here are the mean and standard 
error for 4 separate experiments. Statistical significance was calculated using a Paired T-Test. * and + p<0.05 
* compared to untreated cells 
+ compared to serine protease treatment 
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Figure 31 - α1AT Inhibition of vWf Release from HUVEC at Higher Concentrations of 
Serine Protease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HUVEC were treated for 2 hours with 5µg/ml PR3 or HLE in the presence or absence of α1AT. vWf was 
measured in cell culture supernatants by capture ELISA. The data shown here are the mean and standard error 
for 5 separate experiments. Statistical significance was calculated using a Paired T-Test. * and + p<0.05 
* compared to untreated cells 
+ compared to serine protease treatment 
 
 
Figure 32 - α1AT Inhibition of vWf Release from GEnC at Higher Concentrations of 
Serine Protease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GEnC were treated for 2 hours with 5µg/ml PR3 or HLE in the presence or absence of α1AT. vWf was 
measured in cell culture supernatants by capture ELISA. The data shown here are the mean and standard error 
for 4 separate experiments. Statistical significance was calculated using a Paired T-Test. * and + p<0.05 
* compared to untreated cells 
+ compared to serine protease treatment 
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Figure 33 - HUVEC Detachment Following Treatment with Higher Doses of PR3 and 
HLE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HUVEC were treated for 2 hours with 5µg/ml PR3 or HLE in the presence or absence of α1AT, fixed in 2% 
PFA and the level of cell adherence measured using a crystal violet cell stain. The data shown here are the 
mean and standard error for 3 separate experiments, displayed as a percentage of the unstimulated control. 
Statistical significance was assessed using a Paired T-Test. * p<0.05 
* compared to unstimulated control 
 
 
 
 
Figure 34 - GEnC Detachment Following Treatment with Higher Doses of PR3 and 
HLE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GEnC were treated for 2 hours with 5µg/ml PR3 or HLE in the presence or absence of α1AT, fixed in 2% PFA 
and the level of cell adherence measured using a crystal violet cell stain. The data shown here are the mean and 
standard error for 3 separate experiments, displayed as a percentage of the unstimulated control. Statistical 
significance was assessed using a Paired T-Test. 
* compared to unstimulated control 
0
50
100
**
 
0
50
100
 
 106 
3.8 Changes in vWf Surface Expression Following Serine Protease 
Treatment 
 
Given the ability of HLE to process the vWf protein, changes in the level of membrane 
bound vWf were investigated following PR3 and HLE treatment. The treatment of 
endothelial cells with increasing concentrations of PR3 and HLE (0.5µg/ml - 2µg/ml) 
significantly decreased the expression of membrane bound vWf (figures 35 and 36). This 
was most evident with HLE treatment on both GEnC and HUVEC. Interestingly, whilst 
reducing membrane bound vWf on HUVEC, PR3 treatment did not significantly decrease 
vWf surface expression on GEnC. 
 
As with vWf release into cell culture supernatants, α1AT could significantly restore this 
decreased membrane expression on GEnC (figure 38). α1AT also restored membrane vWf 
expression on HUVEC, although this did not reach significance when analysed by 2-tailed 
paired T-Test (PR3 p=0.4511, HLE p=0.1773) (figure 37). 
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Figure 35 - Surface Expression of vWf on HUVEC following Serine Protease 
Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HUVEC were treated for 2 hours with increasing doses of PR3 and HLE, after which they were fixed in 2% 
PFA and assessed for the level of vWf bound to the cell surface by ELISA. The data shown here are the mean 
and standard error for 3 separate experiments. Statistical significance was calculated using a 1-way ANOVA 
with Bonferroni post-test (PR3 p=0.0206, HLE p=0.0008). * p<0.05, *** p<0.001 
 
 
 
Figure 36 - Surface Expression of vWf on GEnC following Serine Protease Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HUVEC were treated for 2 hours with increasing doses of PR3 and HLE, after which they were fixed in 2% 
PFA and assessed for the level of vWf bound to the cell surface by ELISA. The data shown here are the mean 
and standard error for 4 separate experiments. Statistical significance was calculated using a 1-way ANOVA 
with Bonferroni post-test (PR3 p=0.2689, HLE p<0.0001). ** p<0.01, *** p<0.001 
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Figure 37 - Surface Expression of vWf on HUVEC can be restored by α1AT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HUVEC surface expression of vWf was measured after a 2 hour treatment with 1µg/ml PR3 or HLE in the 
presence or absence of α1AT by ELISA. The data shown here are the mean and standard error from 3 separate 
experiments, displayed as a percentage of the unstimulated control. Statistical significance was calculated using 
a Paired T-Test. * p<0.05 
* compared to unstimulated control 
 
 
 
Figure 38 - Surface Expression of vWf on GEnC can be restored by α1AT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GEnC surface expression of vWf was measured after a 2 hour treatment with 1µg/ml PR3 or HLE in the 
presence or absence of α1AT by ELISA. The data shown here are the mean and standard error from 3 separate 
experiments, displayed as a percentage of the unstimulated control. Statistical significance was calculated using 
a Paired T-Test. * and + p<0.05 
* compared to unstimulated control 
+ compared to serine protease treatment 
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3.9 vWf Release: Internal Stores versus Membrane Cleavage 
 
To investigate whether the increased detectable vWf in cell culture supernatants was due to 
increased release from internal stores or solely due to the increased cleavage of membrane 
bound vWf, fixed and permeablised endothelial cells were assessed for changes in vWf 
levels by flow cytometry in order to allow determination of total levels (internal and surface 
expression with permeabilised cells), versus surface expression alone (non-permeabilised 
cells). Figure 39 demonstrates that treatment of GEnC with 1µg/ml of PR3 or HLE 
significantly reduced both the surface and total levels of vWf when compared to untreated 
cells. Importantly, there is decreased detectable vWf in the total (fixed and permeablised 
cells) compared to the surface expressed vWf following treatment, suggesting that, whilst the 
majority of vWf detected in supernatants is due to cleavage and release of membrane bound 
vWf, PR3 and HLE also cause the release of vWf from Weibel-Palade bodies, although this 
did not reach significance (see figure 39C). Treatment of GEnC for 15 minutes with 1 unit 
thrombin caused a significant decrease in the level of total vWf, but had no effect on the 
level of surface bound vWf. This reinforces that thrombin acts a potent secretagogue in 
inducing Weibel-Palade body exocytosis.  
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Figure 39 - FACS Analysis of vWf Release from Surface and Internal Stores 
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Glomerular endothelial cells were treated 
for 2 hours with 1µg/ml of PR3 or HLE, 
or 15 minutes with 1Unit of Thrombin. 
All cells were fixed in 2% PFA, others 
were also permeablised using a fix and 
perm kit, before staining for vWf. Cells 
were immediately analysed after 
staining. (A) shows a typical FACS plot 
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3.10 Confocal Staining for vWf and the Plasma Membrane 
 
To further investigate the release of vWf from internal stores, glomerular endothelial cells 
were stained for vWf (FITC) and a membrane stain (Image iT™ Live, Alexa fluor®594) to 
identify areas of localisation, and thereby exocytosis. Treated glomerular endothelial cells 
were visualised using confocal microscopy with a 63x magnification and 2x zoom. Figure 40 
demonstrates a cross-sectional image across the untreated and 1µg/ml PR3 or HLE treated 
GEnC. The untreated endothelial cells appear to display less positive staining for vWf 
compared to PR3 and HLE treated cells. There also appears to be little or no co-localisation 
between the vWf and the plasma membrane in untreated GEnC. Increased magnification of 
PR3 and HLE treated GEnC displayed areas of dual staining (yellow) between the vWf and 
plasma membrane. 
 
To further investigate this observation, GEnC treated with PR3 and HLE were imaged using 
the Z-stack feature of the Zeiss confocal software. This allowed us to take cross-sectional 
images at varying depths through the cell to observe the localisation of vWf and direction of 
release. Images were captured in 1µm sections. Figure 41 shows five of the key sections 
through the GEnC from bottom to top. This cross-sectional analysis demonstrates the 
presence of vWf beneath the basal membrane of the monolayer, a well-documented 
phenomenon in resting endothelial cells [375]. vWf expression appears well distributed 
throughout both the treated and untreated endothelial cells, although present at a higher 
concentration close to the basolateral membrane.  
 
The Image-iT™ plasma membrane stain consists of a wheat germ agglutinin, which 
selectively binds to N-acetylglucosamine and N-acetylneuraminic acid residues. It is 
suggested to selectively stain the plasma membrane of unpermeablised cells, although can 
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interact with intracellular compartment membranes. Given the high background and 
pigmentation within the cell, it is likely that some intracellular compartments have been 
targeted by the wheat germ agglutinin. Other membrane stains exist, including CellMask™ 
and LavaCell™, but these too can target intracellular components if cells later become 
permeabilised. For assessment of interactions of WPB with the cell membranes other 
techniques will need to be investigated. 
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 Figure 40 - Localisation of vWf with the Plasma Membrane 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glomerular endothelial cells treated for 2 hours with 1µg/ml PR3 or HLE were dual stained for vWf (FITC ) 
and membrane stain (Alexa fluor®594 ), and visualised by confocal microscopy. Nuclei were stained with 
DAPI (UV ). 
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Figure 41 - Z-Stack Imaging of vWf Staining 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glomerular endothelial cells treated for 2 hours with 1µg/ml PR3 or HLE were dual stained for vWf (FITC ) 
and a membrane stain (Alexa Fluor 594 ), and visualised by confocal microscopy. Nuclei were stained with 
DAPI (UV ). Cells were imaged using a Z-stack to track changes in vWf localisation following treatment. 
The images shown above are 5 slices through the cells from bottom to top with a x63 magnification. 
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3.11 vWf Staining in Renal Biopsies 
 
Given the proposed role for the neutrophil serine proteases in inducing vWf release from 
GEnC following short incubations, we next wanted to investigate how the expression of vWf 
changes in the glomeruli from kidney biopsies of patients with ANCA associated vasculitis 
compared to ‘healthy control’ (ethics code 07/Q2602/42). ‘Healthy control’ biopsies were 
collected from non-transplanted donor kidneys. vWf staining in ASV patients were 
compared to patients with acute tubular necrosis (ATN), and anti-glomerular membrane 
antibody disease (anti-GBM). 
 
vWf has been demonstrated to be present in the GEnC and in tubular capillaries (figure 42). 
This pattern of endothelial vWf staining can be observed in ‘healthy’ non-transplanted 
kidneys. Biopsies from ASV patients display crescentic glomeruli with inflammatory cell 
infiltration. Here intraglomerular vWf staining is greatly reduced, with the majority of vWf 
positive cells present in the surrounding crescent formation. These biopsies still maintain 
‘normal’ vWf staining in medullary tubular capillaries. Anti-GBM biopsies have no vWf 
staining present in affected glomeruli, whilst glomerular vWf staining in ATN appears 
normal. 
 
This methods has many technical limitations. Firstly, staining of kidney sections with HRP-
conjugated antibodies routinely displayed high levels of background staining. Secondly, the 
precise location of the positive staining within the biopsy is questionable. Here, we are able 
to see vWf staining within the glomeruli but cannot pinpoint the cell type that may be 
expressing it, for example the endothelial cells or the platelets captured within the capillaries. 
To more accurately determine the localisation of the increased vWf expression, this staining 
should now be repeated using a fluorescent histochemistry technique using confocal 
 116 
microscopy. By using a fluorescent dual staining approach we can more accurately identify 
the cells that are expression vWf within the biopsy. This would be achieved by using 
different fluorescent dyes i.e. PE and FITC, which would appear yellow when both 
expressed at the same location. Examples of other targets could include CD31 (PECAM-1) 
for endothelial cells or GP1b for platelets. 
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Figure 42 - vWf Staining in Renal Biopsies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Paraffin sections from patient biopsies were used to assess changes in vWf distribution within the kidney. 
Renal biopsy samples collected from patients with ANCA-associated vasculitis, acute tubular necrosis and anti-
glomerular basement membrane disease were used. Patient biopsies were compared to vWf staining in a 
‘healthy’ non-transplanted kidney. A total of 2 (ATN and anti-GBM) to 4 (ANCA vasculitis) patients from 
each group were compared. Insert, top left, shows a representative isotype control staining for the non-
transplanted control. The sections were stained for vWf expression (HRP) and counterstained with Harris 
haematoxylin. Sections were imaged immediately using a x40 magnification, with representative images shown 
above of cortical glomeruli and medullary tubular staining of vWf.  
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3.11 Chemokine Ligand-8 Release Following Serine Protease Treatment 
 
Further to the identification of increased vWf release into cell culture supernatants, the 
release of other Weibel-Palade body constituents was investigated, in particular, CXCL8, 
angiopoietin-2, P-Selectin and CD63. Interleukin-8 release was measured in supernatants by 
capture ELISA following a 2hour treatment with increasing concentrations of PR3 and HLE 
(0.5µg/ml - 2µg/ml). Figures 43 and 44 demonstrate a significantly decreased level of 
detectable CXCL8 in supernatants following serine protease treatment in both HUVEC and 
GEnC. This decreased level of CXCL8 occurred in a dose-dependant manner and was most 
significant with HLE treatment. Further investigation demonstrated that PR3 and HLE could 
reduce the detectable level of CXCL8 in a cell-free system (figure 45). Again, this decreased 
level of CXCL8 occurred in a dose-dependant manner, with 2µg/ml HLE having the most 
evident effect. The addition of α1AT into this system was able to restore the reduced level of 
CXCL8 with 2µg/ml HLE treatment (figure 46). The ability for the serine proteases to 
decrease CXCL8 detection in a cell-free system suggests that the serine proteases are 
actively cleaving CXCL8, thereby rendering it undetectable in our assay. This observation 
has previously been demonstrated by Padrines et al, 1994 [113]. 
 
To overcome this, GEnC were treated with serine proteases for 2 hours, after which the cells 
were washed to remove any remaining PR3 or HLE and incubated for a further hour or 2 
hours in blank medium. Treatment of GEnC with increasing doses of serine protease 
following by a 1 hour incubation in blank medium resulted in an increased release of CXCL8 
into cell culture supernatants. However this only reached significance following treatment 
with 2µg/ml of HLE (figure 47). Incubation of 2µg/ml PR3 or HLE treated GEnC for 2 
hours demonstrated significantly increased levels of CXCL8 with both serine proteases 
(figure 48). This supports the idea that the serine proteases are acting to induce release of 
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Weibel-Palade body constituents, and implies that this can continue after removal of the 
enzyme. 
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Figure 43 - Chemokine Ligand-8 Release from Serine Protease Treated HUVEC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HUVEC were treated with increasing concentrations of PR3 and HLE for 2 hours. CXCL8 was measured in 
cell culture supernatants by capture ELISA. The data shown here are the mean and standard error from 4 
separate experiments, displayed as a percentage of the unstimulated control. Statistical significance was 
calculated using a 1-way ANOVA with Bonferroni post-test (p=0.0169). *p<0.05, **p<0.01 
 
 
 
 
Figure 44 – Chemokine Ligand-8 Release from Serine Protease Treated GEnC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HUVEC were treated with increasing concentrations of PR3 and HLE for 2 hours. CXCL8 was measured in 
cell culture supernatants by capture ELISA. The data shown here are the mean and standard error from 3 
separate experiments, displayed as a percentage of the unstimulated control. Statistical significance was 
calculated using a 1-way ANOVA with Bonferroni post-test (p<0.001). **p<0.01 
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Figure 45 - Cleavage of Chemokine Ligand-8 by PR3 and HLE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endothelial cells were treated with 100unit of TNFα for 4 hours, after which the supernatants were transferred 
to a separate 96-well culture plate and incubated with increasing doses of PR3 and HLE for a further 2 hours. 
CXCL8 was measured in these supernatants by CXCL8 capture ELISA. The data shown here is the mean and 
standard error from 1 experiment, displayed as a percentage of TNFα treated endothelial cells with no 
subsequent serine protease treatment. 
 
 
Figure 46 – Chemokine Ligand-8 Cleavage by HLE can be Inhibited by α1AT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endothelial cells were treated with TNFα for 4 hours, after which supernatants were transferred to a second 96-
well culture plate and incubated with 2µg/ml HLE in the presence or absence of α1AT, or α1AT alone, for a 
further 2 hours. CXCL8 was quantified by capture ELISA. The data shown here are the mean and standard 
error from 3 separate experiments, displayed as a percentage of TNFα treated cells that received no further 
treatment. Statistical significance was achieved used a paired T-Test. +p<0.05, **p<0.01 
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Figure 47 – Chemokine Ligand-8 Release Following Removal of Serine Proteases 1 
hour Incubation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GEnC were treated with increasing doses of PR3 and HLE for hours, after which the treated cells were washed 
to remove and residual enzyme and incubated for a further hour in blank medium 199. CXCL8 was quantified 
by capture ELISA. The data shown here are the mean and standard error for 3-9 separate experiments, 
displayed as a percentage of the unstimulated control. Statistical significance was calculated using a 1-way 
ANOVA with Bonferroni post-test (PR3 p=0.1268, HLE p=0.0303). *p<0.05 
 
 
 
Figure 48 – Chemokine Ligand-8 Release following Removal of Serine Proteases 1 and 
2 hour Incubations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GEnC were treated with 2µg/ml PR3 or HLE for 2 hours, after which the enzyme was removed by washing in 
PBS and the cells incubated in blank medium for 1 or 2 hours. CXCL8 release from these cells was quantified 
in supernatants by capture ELISA. The 1 hour data shown here are the mean and standard error from 9 separate 
experiments, displayed as a percentage of the unstimulated control. The 2 hour data here are the mean and 
standard error from 5 separate experiments, displayed as a percentage of the unstimulated control. Statistical 
significance was calculated using a paired T-Test. A 2-way ANOVA was used to determine significance 
between the two time-points (p=0.771). *p<0.05, **p<0.01 
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3.12 Angiopoietin-2 Release from Serine Protease Treated Endothelial 
Cells 
 
HUVEC and GEnC were treated with 2µg/ml of PR3/HLE or 1µg/ml PR3/HLE, 
respectively, for 2 hours, after which, supernatants were assessed for angiopoietin-2 release 
by capture ELISA. Both HUVEC and GEnC demonstrated a significantly decreased level of 
detectable Ang-2 following PR3 and HLE treatment, although this was most evident on 
GEnC (figures 49 and 50). HUVEC were originally treated with 1µg/ml PR3 or HLE but this 
did not show as marked a decrease in Ang-2 as with GEnC treatment (data not shown, N=1), 
so a higher concentration of PR3 and HLE were used in HUVEC treatment. It is also 
apparent that there are greatly increased levels of Ang-2 released from untreated GEnC 
compared to HUVEC. The addition of α1AT into the system significantly inhibited the 
effects of PR3 and HLE on decreasing detectable Ang-2. The incubation of recombinant 
Ang-2 with 1µg/ml PR3 or HLE for 1 hour reduced the level of detectable Ang-2 in our 
ELISA, demonstrating that both PR3 and HLE are cleaving Ang-2. Interestingly, PR3 
appeared to have a greater effect on the cleavage of Ang-2 (figure 51). This is also 
demonstrated in the treatment of HUVEC, in which PR3 greatly reduces detectable levels of 
Ang-2 whilst HLE treatment displays less of an effect (figure 49). The treatment of GEnC 
for 2 hours and consequent removal of the enzymes, with a further 1 or 2 hours incubation in 
blank medium, had no effect on increasing Ang-2 release in PR3 or HLE treated cells (figure 
52). However, the removal or PR3 and HLE did restore the Ang-2 levels back to those 
comparable to untreated control levels. 
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Figure 49 - Angiopoietin-2 Release from HUVEC following Serine Protease Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HUVEC were treated with 2µg/ml PR3 or HLE in the presence or absence of α1AT. Angiopoietin-2 was 
measured in cell culture supernatants by capture ELISA. The data shown here are the mean and standard error 
for 3 separate experiments. Statistical significance was calculated using a Paired T-Test. * and + p<0.05 
* compared to unstimulated control 
+ compared to serine protease treatment 
 
 
 
Figure 50 - Angiopoietin-2 Release from GEnC following Serine Protease Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GEnC were treated with 1µg/ml PR3 or HLE in the presence or absence of α1AT. Angiopoietin-2 was 
measured in cell culture supernatants by capture ELISA. The data shown here are the mean and standard error 
for 4 separate experiments. Statistical significance was calculated using a Paired T-Test. + p<0.05, **p<0.01 
* compared to unstimulated control 
+ compared to serine protease treatment 
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Figure 51 - PR3 and HLE Cleave Angiopoietin-2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recombinant Angiopoietin-2 was incubated for 1 hour with 1µg/ml PR3 or HLE before analysis of detectable 
Ang-2 by capture ELISA. The data shown here is the mean from 1 experiment, displayed as Angiopoietin-2 
concentration compared to optimal density. 
 
 
 
 
 
 
Figure 52 - Angiopoietin-2 Release after Removal of PR3 and HLE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GEnC were treated with 2µg/ml PR3 or HLE for 2 hours, following which the cells were washed to remove any 
residual enzyme and incubated for a further 1 or 2hours in blank medium. Supernatants were analysed for Ang-
2 by capture ELISA. The data shown here are the mean and standard error from 3 separate experiments. 
Statistical significance was calculated by 1-way ANOVA with Bonferroni  (1h p=0.669, 2hr p=0.697). A 2-way 
ANOVA was used to calculate significance between the two time points (p=0.7092). 
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3.13 CD63 Expression by Serine Protease Treated GEnC 
 
CD63 constitutes the second most dominant protein in the membrane structure of Weibel-
Palade bodies, although its exact roles in endothelial cells are questionable. The intracellular 
expression of CD63 (FITC) was assessed in GEnC following treatment with 1µg/ml PR3 or 
HLE by confocal microscopy. These GEnC were counterstained with Phalloidin Toxin 
(RPE) and Dapi (UV) to allow for determination of the localisation of CD63 expressing 
WPBs within the cell. Figure 53 shows a well-distributed localisation of CD63 within 
cytoplasm of the endothelial cell, with no distinct sites of WPB localisation. This distribution 
of expression does not appear to change upon treatment with PR3 or HLE for 2 hours, nor 
does there appear to be any change in the level of expression of CD63 following treatment. It 
is of note that CD63 does not appear to colocalise with the actin cytoskeleton (phalloidin 
toxin RPE).  
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Figure 53 - CD63 Staining following Protease Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glomerular endothelial cells treated for 2 hours with 1µg/ml PR3 or HLE were dual stained for CD63 (FITC 
) and phalloidin toxin (RPE ), which binds to F-Actin, and visualised by confocal microscopy. Nuclei were 
stained with DAPI (UV ). 
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3.14 Upregulation of Endothelial Membrane P-Selectin Expression by PR3 
and HLE 
 
Due to the rapid re-internalisation of P-Selectin following membrane expression, endothelial 
cells were fixed immediately following serine protease treatment. P-Selectin membrane 
expression was significantly increased on both GEnC and HUVEC following PR3 and HLE 
treatment when quantified by ELISA. The endothelial membrane expression of P-Selectin 
appeared to increase in a dose-dependant fashion, and was most markedly increased 
following PR3 treatment. Alternatively, only treatment with 2µg/ml of HLE reached 
significance (figure 54), although lower concentrations of HLE appear to increase in a dose 
dependant manner. The PR3 and HLE induced expression of endothelial P-Selectin could be 
significantly inhibited by the addition of α1AT into the system (figure 55). In these 
inhibition experiments, the treatment of GEnC with 1µg/ml of HLE also resulted in 
significantly increased membrane expression of P-Selectin compared to untreated endothelial 
cells (Paired T-Test p=0.0370). Again, treatment of HLE on HUVEC was not quite 
significant (p=0.0764). We believe that with further repeats HLE treatment of HUVEC 
would have resulted in significantly increased P-Selectin expression, however, due to 
problems accessing primary HUVEC, these experiments could not be repeated to reach 
significance. An attempt to reproduce these results using flow cytometry to quantify surface 
and total P-Selectin in PR3 and HLE treated endothelial cells was unsuccessful, whilst P-
Selectin expression could be easily measured on thrombin treated platelets (data not shown). 
Moreover, P-Selectin staining on GEnC by immunocytochemistry was also unsuccessful. 
The technical problems encountered when assessing P-Selectin expression by flow 
cytometry was likely due to the adherent nature of the endothelial cells, which was not an 
issue when using platelets. Removal of adherent cells from culture flasks after treatment 
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required washing with EDTA followed by scraping. Cells were then centrifuged and stained 
for P-Selectin. It is possible that the insult to the endothelial during the process of harvesting 
could have lost any membrane-expressed P-Selectin into supernatants, that could then not be 
measured by flow cytometry. To overcome this, other methods of cell detachment should be 
explored that do not require scraping. One such could be longer incubations of endothelial 
cells with EDTA (15minutes) and tapping the flasks to aid removal. Incubation with citric 
saline is also reported to aid cell detachment without the need for scraping. Interestingly, 
measuring P-Selectin expression by confocal was also a problem. P-Selectin was initially 
performed on HUVEC treated with thrombin and PAR-1 agonists using an anti-human P-
Selectin PE (eBioscience, Clone Psel.KO2.3) on fluorescent microscopy, staining was 
positive but had a high level of background and positive staining within the isotype control. 
This staining was later repeated on GEnC, due to problems accessing HUVEC, using dual 
staining with actin on confocal microscopy. For confocal staining P-Selectin antibodies were 
used at a 1:10 dilution. Once correcting for background no positive P-Selectin staining could 
not be observed. This may be due to problems with the antibodies suitability for confocal 
microscopy, or technical handling of the endothelial cells. Experiments should be repeated 
with a known immunocytochemistry antibody. 
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Figure 54 - P-Selectin Surface Expression following PR3 and HLE Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endothelial cells treated with increasing doses of PR3 and HLE were fixed in 2% PFA and surface P-Selectin 
expression assessed using a cell based ELISA. The HUVEC data shown here are the mean and standard error 
from 10 separate experiments. The GEnC data shown here are the mean and standard error from 8 separate 
experiments. Statistical significance was calculated used a 1-way ANOVA with Bonferroni post-test for each 
cell type. (HUVEC PR3 p=0.0018, HLE p=0.1401). (GEnC PR3 p<0.0001, HLE p<0.0001). A 2-way ANOVA 
was used to measure significance between the cell types (p=0.0629) * p<0.05, ** p<0.01, *** p<0.001. 
 
 
 
 
Figure 55 - Inhibition of P-Selectin Expression by α1AT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endothelial cells treated with 1µg/ml of PR3 and HLE in the presence or absence of α1AT were fixed in 2% 
PFA and surface P-Selectin expression assessed using a cell based ELISA. The data shown here are the mean 
and standard error from 6 separate experiments. Statistical significance was calculated using a Paired T-Test. A 
2-way ANOVA was used to measure significance between the two cell types (p=0.0095). * and + p<0.05 
* compared to untreated control 
+ compared to serine protease treatment 
 
HUVEC GEnC
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.5µg/ml PR3
1µg/ml PR3
2µg/ml PR3
0.5µg/ml HLE
1µg/ml HLE
2µg/ml HLE
Control
*
***
**
***
*
 
HUVEC GEnC
0.0
0.1
0.2
0.3
0.4
0.5
Control
PR3 1µg/ml
PR3 1µg/ml + α1AT
*
HLE 1µg/ml
HLE 1µg/ml + α1AT*
*+
+
+
 
 131 
3.15 vWf Release by PAR Agonist Peptides 
 
The release of vWf by PAR agonist peptides was investigated to determine optimal 
concentrations and times for use in future experiments (figure 56A). Both PAR-1 and PAR-2 
agonists had the greatest effects of stimulating vWf release from HUVEC at concentrations 
of 100µM and 2 hour incubations. The release of vWf from GEnC was much lower and 
didn’t appear to peak at any particular concentration or time point. For future experiments 
the optimal concentrations and times demonstrated on HUVEC were used on both cell types. 
Figure 56B demonstrates that the addition of increasing concentrations of these peptides had 
no effect endothelial mitochondrial activity. Furthermore, the treatment of endothelial cells 
with 100µM of PAR agonist for 2 hours also had no significant effect on cellular detachment 
(figure 58). 
 
The ability of PAR-1 and PAR-2 agonists to stimulate vWf release from HUVEC and GEnC 
was compared to the levels previously demonstrated following treatment with 1µg/ml PR3 or 
HLE. Figure 57 shows that treatment of endothelial cells with PAR agonist peptides did not 
result in a significant increase in vWf release, although levels were increased above the 
unstimulated control. The PAR induced levels of vWf release are more comparable to the 
levels observed following 1µg/ml PR3 treatment.  
 
To further assess a role for the PARs in vWf release, original experiments attempted to 
inhibit vWf release using pharmacological inhibitors directed at PAR-1 and PAR-2. These 
experiments were discontinued, as the PAR antagonists were unable to inhibit PAR agonist 
induced vWf release from HUVEC (N=1-3, data not shown). 
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Figure 56 - Optimisation of PAR Agonist Peptide induced vWf Release 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) Preliminary experiments were performed to investigate optimal concentrations (at 2 hour incubations) and 
times (with a 100µM agonist concentration) of PAR agonist peptides (PAR-1 and PAR-2) for release of vWf. 
vWf was measured in supernatants from treated HUVEC and GEnC by capture ELISA. This data is the mean 
of 2 replicates from 1 experiment. (B) Mitochondrial activity was measured in HUVEC and GEnC treated with 
increasing concentrations of PAR agonist peptides by MTT assay. This data is from 1 experiment, displayed as 
a percentage of untreated control. 
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Figure 57 - Effect of PAR Agonists on vWf Release 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endothelial cells were treated with 1µg/ml PR3, 1µg/ml HLE, 100µM PAR-1 agonist peptide, 100µM PAR-2 
agonist peptide, or a PAR-2 negative control for 2 hours. vWf was measured in cell culture supernatants by 
capture ELISA. The HUVEC data shown here are the mean and standard error of 3 separate experiments. The 
GEnC data shown here are the mean and standard error of 5 separate experiments. Statistical significance was 
calculated using a 1-way ANOVA with Bonferroni post-test (HUVEC p=0.0602, GEnC p=0.0137). A 2-way 
ANOVA was used to measure significance between the two cell types (p=0.5342). 
 
 
 
Figure 58 - Effect of PAR Agonists on Endothelial Cell Detachment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endothelial cell adherence was measured by crystal violet staining following treatment with PR3, HLE and 
PAR agonists. The data shown here are the mean and standard error of 3 separate experiments, displayed as a 
percentage of the unstimulated control. Statistical significance was assessed using a 1-way ANOVA with 
Bonferroni post-test (HUVEC p=0.0342, GEnC p=0.0671). 
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Figure 59 - Confirmation of Knockdown of PAR-1 and PAR-2 by mRNA Levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HUVEC were knocked down for the expression of PAR-1 and PAR-2 by small interference RNA (siRNA). 
Knockdown was confirmed by the reduction of PAR mRNA. PAR-1 and PAR-2 relative mRNA expression 
was compared to a lipofectamine (LF) and scrambled siRNA control. The PAR-1 siRNA data shown here are 
the mean and standard error from 5 separate experiments. The PAR-2 siRNA data shown here are the mean and 
standard error from 4 separate experiments. Statistical significance was calculated using a 1-way ANOVA with 
Bonferroni post-test (PAR-1 p=0.0003, PAR-2 p<0.0001). This data was produced by S. Tull. + p<0.05, *** 
and +++ p<0.001 
* compared to Lipofectamine RNAiMax 
+ compared to Control SiRNA 
 
 
Figure 60 - Confirmation of PAR-1 Knockdown by Flow Cytometry 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Successful knockdown of the PAR-1 protein in HUVEC was also confirmed by FACS. The data shown here 
are the mean and standard error from 3 separate experiments. Statistical significance was calculated using a 1-
way ANOVA (p=0.0004). A 2-way ANOVA was used to compare any significance between PAR-1 expression 
and the isotype control (PAR1 versus Isotype p<0.0001, treatment p=0.0090). This data was produced by S. 
Tull. ** p<0.01, ***p<0.001 
*  PAR-1 siRNA compared to all other treatments 
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3.16 siRNA Knockdown of PAR-1 and PAR-2 does not reduce vWf Release 
 
HUVEC knocked down for the expression of PAR-1 and PAR-2 by small interference RNA 
(siRNA) were generated in our laboratory by Samantha Tull. Successful knockdown was 
confirmed by mRNA and protein expression (figure 59 and 60). PAR-1 and PAR-2 mRNA 
was significantly reduced compared to lipofectamine and control siRNA treated HUVEC. 
PAR-1 protein expression was not significantly different to the isotype control when 
assessed by flow cytometry. (All of the data discussed above was produced by Samantha 
Tull). 
 
We next wanted to investigate a role for the protease-activated receptors in PR3 and HLE 
mediated vWf release. Using HUVEC knocked down for the expression of PAR-1 and PAR-
2 by siRNA, endothelial cells were stimulated with 1µg/ml PR3 and HLE to see if the levels 
of vWf release would be reduced compared to HUVEC that received no siRNA treatment. 
Figure 61 demonstrates that the knockdown of PAR-1 and PAR-2 in HUVEC has no effect 
on the release of vWf following treatment with PR3 or HLE. There was no significant 
difference in vWf release between HUVEC knocked down for the expression of PAR-1, 
PAR-2 or both, compared to those cells that received no treatment or were knocked down for 
a scrambled code of siRNA, indicating that PR3 and HLE do not require signalling through 
the protease activated receptors for Weibel-Palade body exocytosis.  
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Figure 61 - Knockdown of PAR-1 and PAR-2 does not reduce vWf Release 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HUVEC knocked down for the expression of PAR-1 and PAR-2 were compared untreated HUVEC for their 
ability to release vWf in response to PR3 and HLE stimulation. HUVEC were treated with 1µg/ml PR3 or HLE 
for 2 hours and vWf measured in cell culture supernatants by capture ELISA. The data shown here are the 
mean and standard error from 3 separate experiments. Statistical analysis was performed using 2-way ANOVA 
comparing the siRNA treatment of HUVEC (p=0.9961). 
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3.17 Signalling Pathways involved in vWf Release 
 
A mechanism by which PR3 and HLE were acting to induce vWf release was investigated 
using pharmacological inhibitors directed at components of known signalling pathways 
involved in ligand induced Weibel-Palade body exocytosis. These inhibitors were cultured in 
increasing concentrations (a log above and below their optimal IC50 concentration) with PR3 
or HLE on GEnC for 2 hours. 
 
Incubation with PKC inhibitor, Gö6983, had no effect on reducing the level of PR3 or HLE 
mediated vWf release into cell culture supernatants (figures 62 and 63). Importantly, this 
inhibitor did not induce vWf release when cultured in the absence of any serine protease 
(data not shown), and did not affect mitochondrial activity (figure 64). The activity of 
Gö6983 was confirmed by its ability to inhibit ANCA and fMLP induced superoxide 
production from healthy donor neutrophils (figure 65). Interestingly, neither the PKA 
inhibitor, myristoylated PKI (14-22) amide, nor the calmodulin inhibitor, Calmadizolium, 
had an inhibitory effect on vWf release when incubated with 2µg/ml PR3 or HLE (figures 
66, 67, and 69, 70 respectively). As with Gö6983, these inhibitors were also unable to induce 
vWf when cultured alone, and had no effect on mitochondrial activity (figures 68 and 71). 
The PI3-kinase inhibitor, wortmannin, has been routinely used in our lab to inhibit the 
effects of ANCA on inducing neutrophil degranulation (figure 75, data produced by Neil 
Holden). However, it had no effect on the inhibition of vWf release from glomerular 
endothelial cells in our system (figures 72 and 73). Again, wortmannin, itself, was unable to 
induce vWf release (data not shown) and had no effect on mitochondrial activity (figure 74). 
Statistical analyses for the inhibition of vWf release by these pharmacological inhibitors 
were performed by 1-way ANOVA, in which all inhibited cells were compared to an 
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uninhibited serine protease control. The level of vWf from untreated endothelial cells is also 
displayed on these data sets as an indication of the level of desired inhibition.  
 
The use of these pharmacological inhibitors was also investigated in vWf release from 
HUVEC treated with 2µg/ml of HLE (N=3, data not shown). As with the GEnC, there was 
no effect on inhibition of vWf release (PKC p=0.2847, PKA p=0.5449, Calmodulin 
p=0.6701, PI3K p=0.1588).  
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Figure 62 – PR3 Mediated vWf Release following Inhibition of PKC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glomerular endothelial cells were treated with PR3 with increasing doses of PKC inhibitor, Gö6983, for 2 
hours. vWf was measured in cell culture supernatants by capture ELISA. The data shown here are the mean and 
standard error from 4 separate experiments. Statistical significance was assessed by 1-way ANOVA with 
Bonferroni post-test (p=0.9529). 
 
 
 
 
Figure 63 - HLE Mediated vWf Release following Inhibition of PKC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glomerular endothelial cells were treated with HLE with increasing doses of PKC inhibitor, Gö6983, for 2 
hours. vWf was measured in cell culture supernatants by capture ELISA. The data shown here are the mean and 
standard error from 4 separate experiments. Statistical significance was assessed by 1-way ANOVA with 
Bonferroni post-test (p=0.4390). 
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Figure 64 - Effect of PKC Inhibitor on Mitochondrial Activity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glomerular endothelial cells were treated with 2µg/ml PR3 or HLE with increasing doses of PKC inhibitor, 
Gö6983, for 2 hours, fixed in 2% PFA and mitochondrial activity measured by MTT assay. The data shown 
here are the mean and standard error from 3 separate experiments. Statistical significance was assessed by 2-
way ANOVA with Bonferroni post-test (inhibitor concentration p=0.1764). ** p<0.01 
 
 
Figure 65 - Confirmation of the PKC Inhibitor by measuring Superoxide Production 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The activity of Gö6983 (1µM) was assessed by its ability to inhibit the production of superoxide from ANCA 
IgG (200µg/ml) stimulated neutrophils. The data shown here is the mean and standard error from 1 experiment. 
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Figure 66 - PR3 Mediated vWf Release following Inhibition of PKA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glomerular endothelial cells were treated with PR3 with increasing doses of PKA inhibitor, myristoylated PKI 
(14-22) amide, for 2 hours. vWf was measured in cell culture supernatants by capture ELISA. The data shown 
here are the mean and standard error from 4 separate experiments. Statistical significance was assessed by 1-
way ANOVA with Bonferroni post-test (p=0.3276). 
 
 
Figure 67- HLE Mediated vWf Release following Inhibition of PKA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glomerular endothelial cells were treated with HLE with increasing doses of PKA inhibitor, myristoylated PKI 
(14-22) amide, for 2 hours. vWf was measured in cell culture supernatants by capture ELISA. The data shown 
here are the mean and standard error from 4 separate experiments. Statistical significance was assessed by 1-
way ANOVA with Bonferroni post-test (p=0.3674). 
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Figure 68 - Effect of PKA Inhibitor on Mitochondrial Activity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glomerular endothelial cells were treated with 2µg/ml PR3 or HLE with increasing doses of PKA inhibitor, 
myristoylated PKI (14-22) amide, for 2 hours, fixed in 2% PFA and mitochondrial activity measured by MTT 
assay. The data shown here are the mean and standard error from 3 separate experiments. Statistical 
significance was assessed by 2-way ANOVA with Bonferroni post-test (inhibitor concentration p=0.3766). 
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Figure 69 - PR3 Mediated vWf Release following Inhibition of Calmodulin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glomerular endothelial cells were treated with PR3 with increasing doses of Calmodulin inhibitor, 
calmadizolium, for 2 hours. vWf was measured in cell culture supernatants by capture ELISA. The data shown 
here are the mean and standard error from 3 separate experiments. Statistical significance was assessed by 1-
way ANOVA with Bonferroni post-test (p=0.6589). 
 
 
Figure 70 - HLE Mediated vWf Release following Inhibition of Calmodulin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glomerular endothelial cells were treated with HLE with increasing doses of Calmodulin inhibitor, 
calmadizolium, for 2 hours. vWf was measured in cell culture supernatants by capture ELISA. The data shown 
here are the mean and standard error from 3 separate experiments. Statistical significance was assessed by 1-
way ANOVA with Bonferroni post-test (p=0.5615). 
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Figure 71 - Effect of Calmodulin Inhibitor on Mitochondrial Activity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glomerular endothelial cells were treated with 2µg/ml PR3 or HLE with increasing doses of Calmodulin 
inhibitor, calmadizolium, for 2 hours, fixed in 2% PFA and mitochondrial activity measured by MTT assay. 
The data shown here are the mean and standard error from 3 separate experiments. Statistical significance was 
assessed by 2-way ANOVA with Bonferroni post-test (inhibitor concentration p=0.5507). 
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Figure 72 - PR3 Mediated vWf Release following Inhibition of PI3k 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glomerular endothelial cells were treated with PR3 with increasing doses of PI3-kinase inhibitor, wortmannin, 
for 2 hours. vWf was measured in cell culture supernatants by capture ELISA. The data shown here are the 
mean and standard error from 4 separate experiments. Statistical significance was assessed by 1-way ANOVA 
with Bonferroni post-test (p=0.0734). 
 
 
 
Figure 73 - HLE Mediated vWf Release following Inhibition of PI3k 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glomerular endothelial cells were treated with HLE with increasing doses of PI3-kinase inhibitor, wortmannin, 
for 2 hours. vWf was measured in cell culture supernatants by capture ELISA. The data shown here are the 
mean and standard error from 4 separate experiments. Statistical significance was assessed by 1-way ANOVA 
with Bonferroni post-test (p=0.1796). 
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Figure 74 - Effect of PI3k Inhibitor on Mitochondrial Activity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glomerular endothelial cells were treated with 2µg/ml PR3 or HLE with increasing doses of PI3-kinase 
inhibitor, wortmannin, for 2 hours, fixed in 2% PFA and mitochondrial activity measured by MTT assay. The 
data shown here are the mean and standard error from 3 separate experiments. Statistical significance was 
assessed by 2-way ANOVA with Bonferroni post-test (inhibitor concentration p=0.4897). 
 
 
 
Figure 75 - Confirmation of the PI3k Inhibitor by measuring Neutrophil Degranulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The activity of wortmannin was assessed by its ability to inhibit ANCA IgG (200µg/ml) stimulated neutrophil 
degranulation (measured by MPO release). The data shown here is the mean and standard error from 10 
experiments. Data produced by N Holden. 
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Figure 76 - Inhibition of Actin Polymerisation by Cytochalasin B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) vWf was measured in cell culture supernatants from HLE treated HUVEC with increasing doses of 
cytochalasin B. Cytochalasin B was pre-incubated for 5 minutes, before the addition of HLE for a further 2 
hours. The data shown here are the mean and standard error from 2-3 separate experiments. Statistical 
significance was assessed by 1 way ANOVA with Bonferroni post test (p=0.2456). (B) Treated HUVEC were 
assessed for mitochondrial activity by MTT assay. The data shown here is from 1 experiment, displayed as a 
percentage of the unstimulated control. (C) Treated HUVEC were visualised by phase microscopy. 
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3.18 Inhibition of vWf Release by Inhibition of Actin Polymerisation 
 
Cytochalasin B, a fungal metabolite that inhibits F-actin polymerisation, was used to 
investigate a role for the actin cytoskeleton in vWf release from serine protease treated 
endothelial cells. It was observed that treatment with increasing concentrations of 
cytochalasin B reduced the level of vWf release into cell culture supernatants, albeit not 
significantly (figure 76A). This reduction in the level of detectable vWf from HUVEC 
treated with 2µg/ml HLE occurred at the expense of endothelial cell viability. The disruption 
of the actin cytoskeleton by cytochalasin B, resulted in the endothelial cells becoming 
rounded and detached from the culture plates as well as displaying a decreased level of 
mitochondrial activity (figures 76B and C). 
 
Furthermore, confocal staining for vWf and F-actin stain, Phalloidin, demonstrated that there 
was no evident interactions between the Weibel-Palade bodies and the actin cytoskeleton 
following treatment of GEnC with 1µg/ml of PR3 or HLE (figure 77), as previously 
demonstrated by CD63 staining. Interestingly, these confocal images further support a role 
for PR3 and HLE in increasing the level of detectable internal vWf, compared to levels 
observed in untreated endothelial cells. 
 
 149 
Figure 77 - Confocal Staining for vWf and F-Actin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glomerular endothelial cells treated for 2 hours with 1µg/ml PR3 or HLE were dual stained for vWf (FITC ) 
and phalloidin toxin (RPE ), which binds to F-Actin, and visualised by confocal microscopy. Nuclei were 
stained with DAPI (UV ). 
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3.19 Inhibition of vWf Release by Inhibition of Phosphatase Activity 
 
Okadaic acid, a phosphatase 2B inhibitor, was used to investigate a role for signalling 
molecule dephosphorylation in PR3 and HLE induction of Weibel-Palade body exocytosis. 
Preliminary experiments were performed to further assess the proposed role for okadaic acid 
to induce vWf in its own right. Here the level of vWf release from GEnC and HUVEC 
treated with increasing concentrations of okadaic acid was compared to the level of release 
observed following serine protease treatment. Figure 78 demonstrates that whilst higher 
concentrations of okadaic acid had the ability to induce vWf release from GEnC, the 
phosphatase 2B inhibitor had no effect on inducing vWf from HUVEC at any concentration. 
Furthermore, treatment with 500nM of okadaic acid appeared to induce endothelial 
detachment in HUVEC (figure 79). For future experiments into the effects of okadaic acid on 
vWf release we used a concentrations of 100nM, as this did not appear to induce endothelial 
detachment, whilst still displayed an increased level of vWf release from GEnC. 
 
GEnC and HUVEC were treated with 100nM okadaic acid in the presence or absence of 
1µg/ml PR3 or HLE to investigate a possible additive effect for okadaic acid on vWf release 
from endothelial cells. These endothelial cells were also treated with PR3, HLE and 100nM 
okadaic acid alone. Interestingly, okadaic acid treatment had different effects on the two 
types of endothelial cell. Again, okadaic acid treatment alone resulted in an increased level 
of vWf release into cell culture supernatants of GEnC (not significant), however it had no 
additive effect with PR3 or HLE treatment. Interestingly, okadaic acid not only had no effect 
on vWf release from HUVEC, but also appeared to abrogate the effects of PR3 and HLE on 
inducing vWf release (figure 80). It appears that whilst okadaic acid does not increase PR3 
and HLE induced vWf release from GEnC, inhibition of the activity of phosphatase 2B also 
has no effect on reducing serine protease induced Weibel-Palade body exocytosis. 
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Alternatively, HUVEC inhibited for phosphatase 2B displayed complete abrogation of vWf 
release following PR3 or HLE treatment, suggesting a role for phosphatase 2B activity in 
PR3 and HLE induced vWf release in HUVEC.  
 
The assessment of mitochondrial activity following okadaic acid treatment demonstrated a 
significant decrease compared to the unstimulated control. Additionally, endothelial cells 
treated with PR3 or HLE with 100nM okadaic acid displayed a decreased mitochondrial 
activity to endothelial cells treated with serine protease alone (figure 81). 
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Figure 78 - vWf Release by Okadaic Acid  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Preliminary experiments were performed to find an optimal concentration of okadaic acid for vWf release. 
Supernatants from treated endothelial cells were assessed for vWf by capture ELISA. The data shown here is 
the mean of 2 replicates from 1 experiment. 
 
 
 
 
 
Figure 79 - Crystal Violet of Okadaic Acid Dose Curve 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endothelial cells treated with increasing concentrations of okadaic acid were stained with crystal violet to 
quantify the effects of the treatment of endothelial detachment. The GEnC data shown here are the man and 
standard error from 2 experiments, displayed as a percentage of the untreated control. The HUVEC data is the 
mean from 1 experiment.  
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Figure 80 - Effects of Okadaic Acid on PR3 and HLE Mediated vWf Release 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endothelial cells were treated with 1µg/ml PR3 or HLE, 100nm okadaic acid, or a mixture of PR3/HLE and 
okadaic acid for 2 hours. vWf was measured in cell culture supernatants by capture ELISA. The data shown 
here are the mean and standard error from 3 separate experiments. Statistical significance was calculated using 
a 1-way ANOVA with Bonferroni post test (GEC p=0.0001, HUVEC p=0.0092). *p<0.05, **p<0.01, 
***p<0.001 
 
 
 
 
Figure 81 - Mitochondrial Activity after Okadaic Acid Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mitochondrial activity was analysed in endothelial cells after 2 hour treatment with 1µg/ml PR3, 1µg/ml HLE, 
100nm okadaic acid or a mixture of okadaic acid with PR3 or HLE, using a MTT assay. The data shown here 
are the mean and standard error from 3 separate experiments, displayed as a percentage of the unstimulated 
control. The data here is paired to the vWf release data in figure 80. Statistical significance was calculated 
using a 1-way ANOVA with Bonferroni post test (GEnC p=0.0002, HUVEC p<0.0001). **p<0.01, ***p<0.001 
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3.20 Changes in Phosphopeptides following Serine Protease Treatment 
 
In the absence of any involvement of PKC, PKA, calmodulin or PI3k activity, we wanted to 
investigate whether the serine proteases were acting via an intracellular signalling pathway 
or whether they were inducing WPB exocytosis by cleavage mechanisms once internalised. 
To investigate a global role of PR3 and HLE in endothelial signalling we assessed changes in 
tyrosine and serine/threonine phosphorylation by western blotting (figures 82 and 83). 
Importantly, endothelial lysates were treated with a protease and phosphatase inhibitor 
cocktails to prevent any further changes in phosphopeptide expression. Interestingly, 
treatment of GEnC with HLE resulted in the loss of multiple phosphorylated tyrosine 
peptides compared to untreated endothelial cells. Furthermore, the identification of newly 
phosphorylated tyrosine peptides could be observed between the molecular weights of 52 
and 31kDa. Again, the treatment with α1AT inhibited the effects of HLE on protein 
phosphorylation/dephosphorylation. Endothelial treatment with PR3 did not display any 
changes in the pattern of phosphopeptides. Although, this may be due to changes in the 
phosphorylation of minor peptides that are masked by more dominant peptides on the 
western blot. Western blotting for serine/threonine phosphorylation was less successful. 
However, there does appear to be minor changes in the pattern of phosphopeptides between 
the molecular weights of 38 and 24kDa following HLE treatment. Interestingly, PR3 treated 
GEnC demonstrated the loss of a phosphorylated peptides with a molecule weight of around 
225kDa. 
 
These preliminary results can now be further explored by identifying the changes in peptide 
phosphorylation using a novel mass spectrometry method developed at the University of 
Birmingham by Dr Ashley Martin. To achieve this endothelial cells treated with PR3 and 
HLE will be lysed and the phosphopeptides extracted for mass spectrometry. This method 
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will allow us to assess changes in phosphorylated peptides that are less abundant within the 
endothelial cell and may be masked by more abundant peptides in our western blots.  
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Figure 82 - Western Blot for Tyrosine Phosphorylation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lysates from serine protease treated glomerular endothelial cells were assessed for tyrosine phosphorylation by 
western blotting. Lysates were nano-dropped prior to loading and 250µg of protein was added to each lane. (A) 
2 representative western blots of tyrosine phosphorylation from 1µg/ml PR3 or 1µg/ml HLE treated endothelial 
cells in the presence or absence of α1AT (with one blot showing more clearly the presence of additional bands 
(top) and the other, missing phosphorylated proteins (bottom). The blot was developed using ECL+ with a 
15minute development exposure. This blot is an example from 5 separate experiments. Yellow boxes highlight 
changes in pattern of phosphorylated proteins. (B) The gel was simultaneously stained for protein by coomassie 
staining to demonstrate equal protein loading. 
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Figure 83 - Western Blot for Serine/Threonine Phosphorylation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lysates from serine protease treated glomerular endothelial cells were assessed for serine/threonine 
phosphorylation by western blotting. Lysates were nano-dropped prior to loading and 250µg of protein was 
added to each lane. (A) Western blot of serine/threonine phosphorylation from 1µg/ml PR3 or 1µg/ml HLE 
treated endothelial cells in the presence or absence of α1AT. The blot was developed using ECL+ with a 
15minute development exposure. This blot is an example from 3 separate experiments. Yellow boxes highlight 
changes in pattern of phosphorylated proteins. (B) The gel was simultaneously stained for protein by coomassie 
staining to demonstrate equal protein loading. 
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 3.21 Neutrophil Adhesion to TNFα  Treated Endothelial Cells 
 
Neutrophil adhesion to TNFα treated endothelial cells was measured using a static model of 
adhesion, in which 2.5x105 unprimed neutrophils were co-cultured with endothelial cells 
treated with increasing concentrations of TNFα for 4 hours. The level of neutrophil adhesion 
to both GEnC and HUVEC increased in a dose-dependant fashion with increasing 
concentration of TNFα (figure 84). At the higher TNF〈 concentrations there is a statistically 
significant difference between the level of neutrophil adhesion when compared to the 
unstimulated control, which received 0 units of TNF〈. This statistical difference became 
more apparent at the highest concentrations of TNF〈 i.e. 100 units. The dose-dependant 
increase in neutrophil adhesion was not statistically different between the two cell types, as 
determined by 2 way ANOVA, thereby implying that the conditionally immortalised 
glomerular cell line respond to activation by TNF〈 in the same manner as primary cells. This 
observation reinforces the idea that priming of endothelial cells with TNF〈 can result in 
endothelial activation and consequently increased adhesion of neutrophils, thereby 
supporting Gamble et al., 1985, who proposed that neutrophil adhesion to TNF〈 treated 
HUVEC was maximal following 4 hours incubation, whilst also describing a dose-dependant 
appearance to the increased adhesion [208].  
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Figure 84 - Neutrophil Adhesion to TNFα Treated Endothelial Cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Neutrophil adhesion to endothelial cells was measured in a static model of adhesion. Endothelial cells were 
treated with increasing concentrations of TNFα for 4 hours, followed by 250,000 neutrophils for 1 hour. The 
level of adherence was measurement by conversion of OPD substrate by neutrophil myeloperoxidase. Cell 
numbers were calculated from a standard curve. The data shown here are the mean and standard error from 6 
separate experiments. Statistical significance was assessed using a 1-way ANOVA with Bonferroni post test 
(GEnC p=0.0039, HUVEC p=0.0005). *p<0.05, **p<0.01, ***p<0.001 
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3.22 Neutrophil Adhesion to PR3 and HLE treated Endothelial Cells 
 
To investigate an effect of the neutrophil serine proteases in neutrophil adhesion, endothelial 
cells were treated with increasing concentrations of PR3 and HLE for 2 hours, and then 
further incubated for 1 hour with 250,000 unprimed neutrophils in a static model of 
adhesion. The incubation time for serine protease treatment was previously determined by 
Samantha Tull (unpublished data), who demonstrated that neutrophil adhesion was optimal 
in these conditions. The level of neutrophil adhesion induced by PR3 or HLE treatment was 
compared to a 4 hour TNFα positive control. Figure 85 demonstrates a significantly 
increased level of neutrophils adhered to HUVEC treated with 1µg/ml PR3 or HLE. The 
level of neutrophil adhesion achieved was not statistically different from that achieved with 
TNFα treatment (PR3 p=0.3121, HLE p=0.8446). GEnC treated with PR3 and HLE also 
displayed significantly increased neutrophil adhesion, although this was lower than that 
observed on HUVEC (figure 86). 
 
The addition of α1-antitrypsin into this model of serine protease induced adhesion, 
significantly inhibited the number of neutrophils adhered to PR3 and HLE treated 
endothelial cells. This observation can be seen in both GEnC and HUVEC, following 2 hour 
treatment with 1µg/ml PR3 and HLE in the presence of α1AT in molar excess (figures 87 
and 88). Although, it is of note that the addition of α1AT did not completely abolish 
neutrophil adhesion. Although significantly decreased compared to protease treatment alone, 
the inhibition of neutrophil adhesion to GEnC by α1AT remained significantly increased 
above untreated levels (PR3 p=0.0282, HLE p=0.0236). HUVEC α1AT treatment however, 
was not significantly different from neutrophil adhesion to untreated endothelial cells when 
analysed by paired T-Test (PR3 p=0.1665, HLE p=0.1623). 
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Figure 85 - Neutrophil Adhesion to PR3/HLE Treated HUVEC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HUVEC treated for 2 hours with 1µg/ml PR3 or HLE, or 4 hours with 100 units TNFα as a positive control 
(yellow), were assessed for increased neutrophil adhesion using a static model of adhesion. The level of 
adherence was measurement by conversion of OPD substrate by neutrophil myeloperoxidase. The data shown 
here are the mean and standard error from 8 separate experiments. Statistical significance was calculated using 
a paired T-Test. *p<0.05, **p<0.01 
* compared to the untreated control 
 
 
Figure 86 - Neutrophil Adhesion to PR3/HLE Treated GEnC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GEnC treated for 2 hours with 1µg/ml PR3 or HLE, or 4 hours with 100 units TNFα as a positive control 
(yellow), were assessed for increased neutrophil adhesion using a static model of adhesion. The level of 
adherence was measurement by conversion of OPD substrate by neutrophil myeloperoxidase. The data shown 
here are the mean and standard error from 9 separate experiments. Statistical significance was calculated using 
a paired T-Test. **p<0.01, ***p<0.001 
* compared to the untreated control 
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Figure 87 - Inhibition of Neutrophil Adhesion to HUVEC by α1AT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HUVEC treated for 2 hours with 1µg/ml PR3 or HLE in the presence or absence of α1-antitrypsin, were 
assessed for increased neutrophil adhesion using a static model of adhesion. The data shown here are the mean 
and standard error from 7 separate experiments. Statistical significance was calculated using a paired T-Test. 
*p<0.05 
* compared to serine protease treatment alone 
 
 
Figure 88 - Inhibition of Neutrophil Adhesion of GEnC by α1AT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GEnC treated for 2 hours with 1µg/ml PR3 or HLE in the presence or absence of α1-antitrypsin, were assessed 
for increased neutrophil adhesion using a static model of adhesion. The data shown here are the mean and 
standard error from 8 separate experiments. Statistical significance was calculated using a paired T-Test. 
*p<0.05, **p<0.01 
* compared to serine protease treatment alone 
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3.23 Membrane Expression of E-Selectin Following Serine Protease 
Expression 
 
We next wanted to investigate a mechanism by which serine proteases treated endothelial 
cells could increase neutrophil adhesion. We began by assessing the changes in endothelial 
membrane expression of classical adhesion molecules, E-Selectin, ICAM-1 and VCAM-1, 
following 2 hour treatments with PR3 and HLE. Interestingly, we had already observed 
increased expression of endothelial P-Selectin. Optimal concentrations of the E-Selectin 
primary and secondary antibodies were determined by titration on HUVEC treated with 100 
units TNFα for 4 hours (data not shown). 
 
Next, HUVEC were treated with increasing concentrations of TNFα for 4 hours to assess the 
optimal concentration for increased E-Selectin expression (figure 89A). The membrane 
expression of E-Selectin on HUVEC increases in a dose-dependant manner with optimal 
surface expression observed with 100 units TNFα, although, even at lower concentrations, 
E-Selectin expression is increased above the untreated control. This concentration was 
further evaluated in a timecourse of TNFα treatment to assess at what time point increased 
E-Selectin expression could be observed (figure 89B). The earliest time point by which 
increased E-Selectin expression could be distinguished from the isotype control was at 4 
hours, with expression increasing further at 6 hours following 100 units TNFα treatment. 
From this preliminary data, all future E-Selectin expression experiments were compared to a 
4 hour 100 unit TNFα positive control. 
Figures 90 and 91 demonstrate the level of membrane expression on PR3 and HLE treated 
HUVEC and GEnC, respectively. There was no apparent increase in the surface expression 
of E-Selectin on either cell type following 2 hour treatment with increasing concentrations of 
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PR3 or HLE. E-Selectin expression was neither observed on untreated endothelial cells, with 
expression equal to that of the isotype control. 
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Figure 89 - Optimisation of E-Selectin ELISA 
 
 
 
 
HUVEC were treated with increasing concentrations of TNFα for 4 hours (A), with 100 Units of TNFα over a 
timecourse of 0-6hours (B). Treated HUVEC were fixed in 2% PFA and assessed for membrane E-Selectin 
expression by ELISA. The data shown here is from 1 experiment.  
 
 
 
 
 
 
A 
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Figure 90 - E-Selectin Expression on HUVEC following Serine Protease Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HUVEC treated for 2 hours with increasing concentrations of PR3 and HLE, or 4 hours 100U TNFα as a 
positive control (yellow), were assessed for surface expression of E-Selectin by ELISA. The data shown here 
are the mean and standard error from 3 separate experiments minus the isotype control. Statistical significance 
was assessed by 1-way ANOVA with Bonferroni post-test (PR3 p<0.0001, HLE p=0.0004). ***p<0.001 
 
 
 
 
Figure 91 - E-Selectin Expression on GEnC following Serine Protease Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GEnC treated for 2 hours with increasing concentrations of PR3 and HLE, or 4 hours 100U TNFα as a positive 
control (yellow), were assessed for surface expression of E-Selectin by ELISA. The data shown here are the 
mean and standard error from 3 separate experiments minus the isotype control. Statistical significance was 
assessed by 1-way ANOVA with Bonferroni post test (PR3 p=0.0116, HLE p0.0057). *p<0.05, **p<0.01 
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3.24 Expression of Surface ICAM-1 following Serine Protease Treatment 
 
Preliminary experiments were carried out to investigate the optimal time by which TNFα 
increased ICAM-1 expression on the surface of GEnC and HUVEC (figure 92). ICAM-1 is 
constitutively expressed on the surface of endothelial cells, and this is confirmed in these 
experiments. However, the expression of ICAM-1 on HUVEC was greatly increased over 
the untreated control in a time dependant manner with 100 units TNFα. Increased expression 
can first be observed at 4 hours, although this continues with maximal expression observed 
following 8 hours treatment. TNFα treated GEnC also displayed an increased expression of 
ICAM-1, although to a much lesser extent than seen on HUVEC. GEnC also appear to 
express a higher constitutive level of ICAM-1 than HUVEC. For future ICAM-1 expression 
experiments, an 8 hour treatment with 100 units TNFα was used as a positive control. 
 
Next, HUVEC and GEnC were treated for 2 hours with increasing concentrations of PR3 and 
HLE (0.5µg/ml - 2µg/ml). Figures 93 and 94 show that following serine protease treatment, 
ICAM-1 expression was not significantly increased above constitutive expression on either 
HUVEC or GEnC, respectively. Again, endothelial cells treated with 100 units TNFα for 8 
hours displayed significantly increased ICAM-1 expression. 
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Figure 92 - Optimisation of ICAM-1 ELISA 
 
Confluent endothelial monolayers were treated for a timecourse with 100 units TNFα. Treated endothelial cells 
were fixed in 2% PFA and assessed for ICAM-1 expression by ELISA. The data shown here is from 1 
experiment. 
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Figure 93 - ICAM-1 Expression on HUVEC following Serine Protease Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HUVEC treated for 2 hours with increasing concentrations of PR3 and HLE, or 8 hours 100U TNFα as a 
positive control (yellow), were assessed for surface expression of ICAM-1 by ELISA. The data shown here are 
the mean and standard error from 3 separate experiments minus the isotype control. Statistical significance was 
assessed by 1-way ANOVA with Bonferroni post test (PR3 p=0.0011, HLE p<0.0001). **p<0.01, ***p<0.001 
 
 
 
Figure 94 - ICAM-1 Expression on GEnC following Serine Protease Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GEnC treated for 2 hours with increasing concentrations of PR3 and HLE, or 8 hours 100U TNFα as a positive 
control (yellow), were assessed for surface expression of ICAM-1 by ELISA. The data shown here are the 
mean and standard error from 3 separate experiments minus the isotype control. Statistical significance was 
assessed by 1-way ANOVA with Bonferroni post test (PR3 p<0.0001, HLE p<0.0001). ***p<0.001 
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3.25 Expression of VCAM-1 on Serine Protease treated Endothelial Cells 
 
As with previous adhesion molecule ELISAs, preliminary experiments were performed to 
determine the optimal time point for increased VCAM-1 expression on 100 units TNFα 
treated endothelial cells. The expression of VCAM-1 on TNFα treated HUVEC increases 
steadily in a time dependant manner and was optimal following a 24 hour incubation. 
Interestingly, the expression of VCAM-1 on GEnC could not be stimulated with TNFα 
treatment, and remained at basal levels even after 24 hours treatment (figure 95). This 
observation has previously been reported in our laboratory by Tanya Pankhurst, who 
confirmed the absence of VCAM-1 in our GEnC line and also in primary GEnC 
(unpublished data). 
 
As expected, treatment with increasing concentrations of PR3 and HLE also had no effect on 
increasing VCAM-1 expression on GEnC (figure 97). The treatment of HUVEC, however, 
with 100 unit TNFα for 8 hours significantly increased the expression of surface VCAM-1, 
although no significantly increased expression could be observed following treatment with 
0.5µg/ml - 2µg/ml of PR3 or HLE (figure 96).  
 
 171 
Figure 95 - Optimisation of VCAM-1 ELISA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endothelial cells were treated at 2 hour intervals in a timecourse with 100 units TNFα to determine optimal 
time points for VCAM-1 expression. A later time point of 24 hours was included due to absence of VCAM-1 
expression on GEnC. Treated endothelial cells were fixed in 2% PFA and assessed for membrane VCAM-1 
expression by ELISA. The data shown here is from 1 experiment. 
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Figure 96 - VCAM-1 Expression on HUVEC following Serine Protease Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HUVEC treated for 2 hours with increasing concentrations of PR3 and HLE, or 8 hours 100U TNFα as a 
positive control (yellow), were assessed for surface expression of VCAM-1 by ELISA. The data shown here are 
the mean and standard error from 3 separate experiments minus the isotype control. Statistical significance was 
assessed by 1-way ANOVA with Bonferroni post test  (PR3 p<0.0001, HLE p=0.0002). ***p<0.001 
 
 
Figure 97 - VCAM-1 Expression on GEnC following Serine Protease Treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GEnC treated for 2 hours with increasing concentrations of PR3 and HLE, or 8 hours 100U TNFα (yellow), 
were assessed for surface expression of VCAM-1 by ELISA. The data shown here are the mean and standard 
error from 3 separate experiments minus the isotype control. Statistical significance was assessed by 1-way 
ANOVA with Bonferroni post test  (PR3 p=0.6013, HLE p=0.2480). 
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3.26 Blocking PSGL-1 on Neutrophils Inhibits Adhesion 
 
Previous data demonstrating an increased level of adhesion following serine protease 
treatment and an increased expression of adhesion molecule P-Selectin, posed the hypothesis 
that by blocking the P-Selectin ligand, PSGL-1, on the neutrophil we could potentially 
inhibit neutrophil adhesion to PR3 and HLE treated endothelial cells. Endothelial cells were 
routinely treated with 1µg/ml PR3 and HLE for 2 hours, and then further incubated with 
250,000 neutrophils for a further hour. The neutrophils that were incubated with the serine 
protease treated endothelial cells were either untreated or else were incubated for 15 minutes 
with blocking antibodies directed at PSGL-1 or a relevant isotype control. Untreated 
endothelial cells were incubated with untreated neutrophils to indicate the basal level of 
neutrophil adhesion. Figures 98 and 99 demonstrate that the incubation of neutrophils with 
blocking antibodies directed at PSGL-1, we can significantly inhibit neutrophil adhesion to 
1µg/ml PR3 and HLE treated HUVEC and GEnC. The level of neutrophil adhesion 
following blocking PSGL-1 could be completely abolished to basal levels of adhesion 
achieved on unstimulated endothelial cells. Incubation of neutrophils with a non-specific 
isotype control was unable to inhibit neutrophil adhesion. 
 
 174 
Figure 98 - Blocking PSGL-1 on Neutrophils Inhibits Adhesion to HUVEC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HUVEC were treated with either 1µg/ml PR3 or HLE for 2 hours, and then further incubated with 250,000 
neutrophils in a static adhesion assay. Neutrophils were either untreated or incubated with blocking antibodies 
directed at PSGL-1, or the relevant isotype control for 15 minutes. The data shown here are the mean and 
standard error from 6 separate experiments. Samples were statistically tested for normality by D’Agostino & 
Pearson omnibus normality test with Wilcoxen signed rank test (p=0.0312). *p<0.05 
 
 
 
Figure 99 - Blocking PSGL-1 on Neutrophils Inhibits Adhesion to GEnC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GEnC were treated with either 1µg/ml PR3 or HLE for 2 hours, and then further incubated with 250,000 
neutrophils in a static adhesion assay. Neutrophils were either untreated or incubated with blocking antibodies 
directed at PSGL-1, or the relevant isotype control for 15 minutes. The data shown here are the mean and 
standard error from 6 separate experiments. Samples were statistically tested for normality by D’Agostino & 
Pearson omnibus normality test with Wilcoxen signed rank test (p=0.0312). *p<0.05 
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3.27 Inhibition of CXCR1 and CXCR2 on Neutrophils Inhibits Adhesion 
 
Previous data has suggested that blocking the CXCL8 receptors on neutrophils has the ability 
to inhibit ANCA induced neutrophil transmigration in a flow model of neutrophil adhesion 
[168]. We wanted to further investigate a role for interleukin-8 in our model of neutrophil 
adhesion. Previous experiments have demonstrated that the neutrophil serine proteases have 
the ability to cleave interleukin-8, potentially amplifying its inflammatory actions. 
Interestingly, blocking the CXCL8 receptors, CXCR1 and CXCR2, on neutrophils in a static 
model of adhesion significantly inhibits neutrophil adhesion to PR3 and HLE treated 
endothelial cells. Significant inhibition of neutrophil adhesion to both PR3 and HLE treated 
GEnC was achieved by both the CXCR1 and CXCR2 blocking antibodies (figure 101). 
There appeared to be no preferential action of one receptor over the other, with both 
abolishing adhesion to levels observed to untreated GEnC. Blocking CXCR1 and CXCR2 
also significantly inhibited neutrophil adhesion to PR3 treated HUVEC, but had less of an 
effect on HLE treated cells. Moreover, only treatment of neutrophils with anti-CXCR2 had a 
significant effect on adhesion (figure 100). Interestingly, neutrophils incubated with blocking 
antibodies against both CXCR1 and CXCR2 did not have a significant effect on inhibiting 
adhesion to HLE treated HUVEC (p=0.1200). 
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Figure 100 - Blocking CXCR1 and CXCR2 on Neutrophils Inhibits Adhesion to 
HUVEC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HUVEC were treated with either 1µg/ml PR3 or HLE for 2 hours, and then further incubated with 250,000 
neutrophils in a static adhesion assay. Neutrophils were either untreated or incubated with blocking antibodies 
directed at CXCR1 or CXCR2 for 15 minutes. The data shown here are the mean and standard error from 5 
separate experiments. Samples were statistically tested for significance by paired T-Test. *p<0.05 
* compared to serine protease treatment 
 
 
 
Figure 101 - Blocking CXCR1 and CXCR2 on Neutrophils Inhibits Adhesion to GEnC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GEnC were treated with either 1µg/ml PR3 or HLE for 2 hours, and then further incubated with 250,000 
neutrophils in a static adhesion assay. Neutrophils were either untreated or incubated with blocking antibodies 
directed at CXCR1 or CXCR2 for 15 minutes. The data shown here are the mean and standard error from 7 
separate experiments. Samples were statistically tested for significance by paired T-Test. *p<0.05, **p<0.01 
* compared to serine protease treatment 
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4. Discussion 
 
4.1 Neutrophil Serine Proteases do not induce Endothelial Cell Injury 
following Short Incubations 
 
In has previously been suggested that the neutrophil serine proteases may be responsible for 
the endothelial cell injury observed during ANCA-associated vasculitis, rather than the 
previously identified release of toxic oxygen radicals [309]. In this study, the level of 
endothelial injury following the release of serine proteases from ANCA activated neutrophils 
was demonstrated through the release of von Willebrand factor [309]. Indeed, HLE has been 
repeatedly linked to endothelial cell injury [376-378]. Furthermore, deposits of HLE have 
been identified in the glomerular endothelium in renal biopsies from patients with crescentic 
glomerulonephritis [379]. To further investigate this mechanism of endothelial injury, we 
incubated GEnC with two of these neutrophil serine proteases, PR3 and HLE, and monitored 
changes in endothelial injury. Here we have demonstrated that there is no significant 
difference in the level endothelial cell detachment or mitochondrial activity, following short 
durations of treatment of GEnC with physiological concentrations of PR3 and HLE. This 
observation was also noted when incubating the endothelial cells on a time course with 
1µg/ml. Interestingly, the 2 hour treatment with a higher concentration (5µg/ml) of HLE did 
result in significant detachment from the endothelial monolayer in vitro, thereby confirming 
the ability of this neutrophil serine protease to cause vascular injury. The treatment of 
endothelial cells with HLE and more importantly, PR3, has been well documented to induce 
DNA fragmentation and apoptosis. It has been demonstrated that this PR3 induced apoptosis 
can occur following treatment with concentrations as low as 1µg/ml [106]. Using changes in 
the intracellular ATP and ADP ratios as markers of cellular apoptosis, we could observe no 
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significant changes in the ability of PR3 or HLE to induce apoptosis following short 2 hour 
treatments of glomerular endothelial cells with concentrations of up to 2µg/ml. Furthermore, 
recent data produced by Samantha Tull supports this observation, as the treatment of 
endothelial cells for 2 hours with 1µg/ml PR3 or HLE was not able to induce the expression 
of the active form of caspase 3 in western blots, whilst the enzymatic cleavage of P21waf1 at 
this time suggests that PR3 and HLE can prevent continuation of the cell cycle, and hence 
endothelial proliferation (unpublished data). The ability of PR3 to cleave P21waf1 has 
previously been identified, resulting in the loss of functional P21waf1 from the cytoplasm 
[138]. Interestingly, purified PR3 can cleave purified procaspase 3 following a 30 minute 
incubation in a cell-free model. Further to this, caspase 3 activity is increased in a PR3 
transfected RBL mast cell line, whilst HLE transfection had no effect on caspase 3 
expression [380]. The absence of caspase 3 in our PR3 treated endothelial cells may be due 
to the time taken for internalisation and translocation to the nuclei. It was therefore important 
to assess the injurious effects of PR3 at a later time point. 
 
Investigation of a role for PR3 and HLE in endothelial cell injury at later time-points 
suggested that the neutrophil serine proteases are likely to have a later injurious effect. Using 
a 24 hour incubation, we demonstrated that PR3 and HLE induce a significant decrease in 
the level of intracellular ATP. This observation was more evident with HLE treatment, 
whilst only treatment with 2µg/ml PR3 demonstrated a significant change. Moreover, GEnC 
treated for 24 hours with PR3 and HLE displayed significantly decreased levels of 
intracellular ATP compared to cells treated for 2 hours. As a cell prepares to undergo 
apoptosis, it converts internal stores of ATP into ADP. The hugely increased rate of this 
conversion would be suggestive of a necrotic pathway of cell death, as seen following 
treatment of endothelial cells with 1x Triton X100 or water. Endothelial treatment with PR3 
and HLE for 24 hours, resulted in increased ADP:ATP ratios, which together with a reduced 
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ATP concentration, suggests that at later time points PR3 and HLE have to ability to induce 
apoptosis. It is of note that the increased ADP was not comparable to the decrease in ATP, 
which suggests that there may be technical issues within this assay in which, not all 
intracellular ADP was converted to ATP for quantification. The technical limitations of this 
assay mean that the increased ADP:ATP ratio has to be taken with caution and supported by 
other evidence confirming apoptosis. 
 
The 24 hour treated glomerular endothelial cells appear rounded and detached from the 
culture plates, with no confluent monolayer remaining. These observations may account for 
the increased number of circulating endothelial cells in the peripheral blood of ASV patients 
[381]. Furthermore, research in our laboratory has demonstrated the presence of active 
caspase 3 in endothelial cells treated for 24 hours with PR3 and HLE, although the absence 
of serum for a 24 hour duration also caused the upregulation of caspase 3 in untreated 
endothelial cells (Sahithi Panchagnula, unpublished data). 
 
 
 
4.2 Release of vWf occurs due to Activation not Injury 
 
Historically, vWf has been described as a marker for endothelial cell dysfunction, however 
this has many limitations. Whilst vWf release has been demonstrated to occur as a result of 
direct injury to the endothelial cell monolayer, itself playing key functions in coagulation and 
thrombus formation, vWf release has also been shown to occur following endothelial 
activation. In this situation, vWf is released from neighboring endothelial cells in response to 
activating stimuli, such as thrombin and histamine. Therefore, vWf cannot be used as a 
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marker of endothelial cell dysfunction in the absence of complimentary experiments that 
confirm the presence of cellular injury and death. 
 
Previously Lu et al., demonstrated the ability of ANCA-activated neutrophils to induce vWf 
release from endothelial cells in culture, and that this vWf release could be abolished by the 
addition of serine protease inhibitors [309]. This proposes a role for the neutrophil serine 
proteases in the induction of vWf release from endothelial cells. Our data supports this idea 
by demonstrating that endothelial incubation with PR3 and HLE for 2 hours results in 
significantly increased vWf in cell culture supernatants. However, the absence of any other 
markers of injury at this time implies that this release is occurring due to an activatory role of 
the serine proteases on the vascular endothelium. The treatment of GEnC with increasing 
concentrations or PR3 and HLE resulted in a dose-dependant increase in vWf release, with 
2µg/ml of PR3 and HLE inducing significantly increased levels. Interestingly, HUVEC 
treatment with increasing concentrations did not display such a dose-dependant increase in 
vWf, rather an all or nothing response, with 0.5µg/ml causing a similar level of vWf release 
as treatment with 2µg/ml protease. In both cell types, HLE appeared to be the more potent 
stimuli, inducing increased levels of vWf release compared to PR3 treatment. The inhibition 
of the enzymatic activity of PR3 and HLE by the addition of the irreversible inhibitor α1-
antitrypsin, significantly abolished the release of vWf. α1AT could also inhibit vWf release 
from endothelial cells treated with a higher concentration of PR3 and HLE (5µg/ml) and 
prevent endothelial detachment at this serine protease concentration. 
 
Longer incubations (24 hours) of serine proteases with GEnC also caused increased release 
of vWf into cell culture supernatants, although vWf release from HUVEC treated with PR3 
and HLE was not significantly increased compared to untreated control levels. As expected, 
 181 
the level of detectable vWf after 24 hours was hugely increased compared to the levels 
present after 2 hours treatment. However, there appeared to be less of a distinction between 
endothelial cells that had received treatment with PR3 or HLE, and those cells that remained 
untreated. Moreover, vWf release appeared to decline with increasing concentrations of 
HLE. Given that we have previously demonstrated that at this 24 hour time point HLE and 
the higher concentrations of PR3 have the ability to induce endothelial apoptosis, it is likely 
that, as these cells undergo programmed cell death they stop producing and releasing vWf, 
hence the decreased levels in supernatants. It is therefore likely that these endothelial cells 
are undergoing apoptosis at an earlier time point, and at 24 hours they have been dead for 
some time. 
 
It previously been described that patients with active Wegeners’ granulomatosis or 
microscopic polyangiitis have an increased level of circulatory vWf [307, 308, 382]. The 
data discussed here suggests that this may be due to the early activation and consequent vWf 
release from serine protease stimulated endothelial cells. Although with longer exposures of 
endothelial cells to serine proteases vWf is further increased, here HLE also induces 
endothelial detachment and apoptosis, which limits the release of further vWf into cell 
culture supernatants, thereby displaying a decreasing level of vWf in supernatants of 
endothelial cells treated with increasing concentrations of HLE. 
 
Apart from its haemostatic roles, vWf release has been implicated in the development of 
inflammation. vWf deficient mice display a decreased level of neutrophil recruitment in 
response to cytokine-induced meningitis, most likely because of a decreased ability to 
increase endothelial P-Selectin expression [383]. Furthermore, mice deficient for vWf and 
low-density lipoprotein receptor (LDLR) display a decreased level of monocytes recruitment 
to aortic fatty streaks than LDLR–/–vWf+/+ mice [384]. This ability of vWf to increase 
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neutrophil and monocytes recruitment may be in part due its ability to bind selectin ligands 
(PSGL-1) [385] and integrins (VLA-4) [386]. Indeed, further investigation is required to 
outline the functional effects of this early vWf release. 
 
 
 
4.3 Confocal Staining of vWf and the Endothelial Membrane produces 
Inconclusive Results 
 
Confocal staining for vWf and a membrane marker confirmed that, with these early 2-hour 
serine protease treatments, there is indeed some co-localisation of vWf with the plasma 
membrane. Given that this method of microscopy captures vWf co-localisation at one 
window in time, it is impossible to decipher whether this is membrane bound vWf or else 
WPB budding with the plasma membrane. To get a more accurate account of vWf release 
from endothelial cells following PR3 and HLE treatment, one would need to capture the 
movement of WPBs over time. Furthermore, the staining of non-permeabilised cells would 
allow quantification of membrane bound vWf which could be subtracted from the amount of 
vWf in contact with the plasma membrane of permeabilised endothelial cells. A further 
complication of this method was the staining of intracellular compartment membranes with 
the wheat germ agglutinin stain. As mentioned previously, alternative stains for the plasma 
membrane should be investigated to overcome this undesired staining.  
 
Furthermore, analysis of different depths of microscopy through the endothelial cell using 
the Z-stack feature, revealed the deposition of released vWf beneath the endothelial 
monolayer. The release of vWf through the endothelial basolateral membrane is a well-
documented phenomenon. It has previously been demonstrated that unstimulated endothelial 
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cells constitutively release vWf through their basolateral membrane, whilst release through 
the apical membrane is increased following endothelial stimulation [375]. It is therefore 
likely that this build up of vWf release beneath the basolateral membrane of PR3 and HLE 
treated endothelial cells has accumulated during the culturing and growing of the cells prior 
to any treatment. The release of any vWf through the apical membrane cannot be detected 
through these methods, as it will have dispersed into cell culture supernatants. 
 
 
 
4.4 PR3 and HLE cause exocytosis of Weibel-Palade Body Constituents 
 
Whilst vWf comprises the main Weibel-Palade body constituent, these endothelial organelles 
are also known to contain P-Selectin, CXCL8, angiopoietin-2 and CD63. Following our 
observation that PR3 and HLE have the ability to cause release of vWf, it was important to 
investigate the effects of the neutrophil serine proteases on the release of other endothelial 
WPB constituents. 
 
A role for CXCL8 in ANCA systemic vasculitis has previously been identified. Increased 
CXCL8 expression has been demonstrated in the crescentic glomeruli of ASV patients, 
whilst incubation of patient ANCA-IgG with healthy donor neutrophils increases CXCL8 
release, and consequently, enhances neutrophil recruitment [387, 388]. Furthermore, 
chimeric IgG1 and IgG3 PR3-ANCA can increase CXCL8 release from healthy neutrophils, 
as well as inducing neutrophil degranulation and serine protease release [389]. During the 
investigation into the effects of PR3 and HLE on the release of CXCL8 from endothelial 
cells, early experiments indicated that these serine proteases could actively cleave CXCL8 
thereby rendering it undetectable in our assays. Moreover, the decreased level of detectable 
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CXCL8 in cell culture supernatants occurred in a dose-dependant fashion with increasing 
concentrations of serine protease. This potential ability for PR3 and HLE to cleave CXCL8 
has previously been demonstrated [113], in which it was proposed that this cleavage can act 
to amplify the functions of CXCL8, such as its chemotactic role in the recruitment of 
neutrophils to inflammatory sites. As with vWf release, HLE appeared to have a greater 
effect on the cleavage of CXCL8 than PR3, whilst the addition of α1AT could significantly 
prevent this HLE mediated cleavage. To overcome this interference in the detection of 
CXCL8 caused by its cleavage by PR3 and HLE, we investigated the ability of serine 
protease treated endothelial cells to maintain the release of CXCL8 following the removal of 
PR3 and HLE from the system. Through this mechanism, we could demonstrate that GEnC 
treated with 2µg/ml PR3 and HLE, and further incubated with blank medium displayed 
increased CXCL8 in cell culture supernatants compared to cells that received no previous 
serine protease treatment. This allows us to conclude a role for PR3 and HLE in the 
induction of CXCL8 release from the endothelial monolayer. ANCA has been demonstrated 
to induce CXCL8 release from neutrophils, which is suggested to be increased in glomerular 
crescentic lesions [387]. Here we identify a second source of increased CXCL8 release that 
may contribute to intraglomerular expression. It is possible that ANCA induced neutrophil 
serine protease release can actively induce CXCL8 release from the glomerular endothelium, 
as well as the previously reported neutrophil release, which the serine proteases can then 
cleave to amplify the immune response and, potentially, disease propagation through the 
continued recruitment of neutrophils. 
 
This same phenomenon of enzymatic cleavage was observed in angiopoietin-2 release from 
PR3 and HLE treated endothelial cells. Endothelial cells treated for 2 hours with 
physiological concentrations of PR3 or HLE displayed significantly decreased levels of 
angiopoietin-2 in cell culture supernatants compared to untreated endothelial cells. 
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Interestingly, PR3 had the greatest effect on cleavage of Ang-2. Again, the addition of α1AT 
could significantly prevent the cleavage of Ang-2 by PR3 and HLE. It is of note that 
untreated glomerular endothelial cells constitutively release a much higher level of Ang-2 
than HUVEC (1700pg/ml and 300pg/ml respectively), with PR3 and HLE having a greater 
role in cleavage of glomerular released Ang-2. This may be due to the required maintenance 
of the glomerular capillary structure. Ang-2 is expressed at sites of vascular remodelling, 
where it can act with VEGF to induce new vessel formation. The injection of VEGF into rats 
with glomerulonephritis has been demonstrated to have a beneficial role based on its 
angiogenic properties [390]. Alternatively, endothelial cells from the human umbilical vein 
require much less vascular remodelling, and hence Ang-2 release is lower. 
 
Unlike CXCL8 release, the removal of PR3 and HLE from the system did not increase the 
detection of Ang-2 release from serine protease treated glomerular endothelial cells. It 
appears that the neutrophil serine proteases may not be inducing the release of Ang-2 from 
endothelial cells, and are further cleaving the angiopoietin-2 constitutively released. 
Alternatively, it is also possible that the removal of the enzyme and along with it the Ang-2 
releasing stimulus, may mean that these cells cannot continue to release Ang-2 in the 
absence of PR3 and HLE, and not that these serine proteases have no effect on release. It is 
well-known that angiopoietin-2 is a natural antagonist for its sister ligand angiopoietin-1, 
thereby acting to promote vessel leakage, along with VEGF, by destabilization of the 
endothelial cell-cell junctions [286, 321]. Interestingly, 10µg/ml concentrations of HLE can 
partially degrade VEGF to produce a large VEGF fragment (VEGFf), which can potentiate 
the activity of VEGF through ERK1/2 signalling whilst itself able to signal through Akt 
activation in endothelial cells and monocytes [391]. Taken with the observation of increased 
circulating Ang-2 in ASV patients [324], I would suggest that the neutrophil serine proteases 
are unlikely to be inactivating Ang-2 but rather enhancing its actions on endothelial leakage 
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and cell detachment and hence, disease propagation. Indeed further research is required to 
investigate the effects of the neutrophil serine proteases on the activity and release of Ang-2, 
and its involvement in ANCA vasculitis. 
 
It is proposed that there are different subclasses of Weibel-Palade bodies within endothelial 
cells, and in particular, Ang-2 and P-Selectin are never co-expressed in the same ones [286]. 
The absence of release of Ang-2 from endothelial cells in the presence of vWf and CXCL8 
suggests that it may be a P-Selectin containing WPB that the serine proteases are selectively 
releasing. Indeed, the treatment of both GEnC and HUVEC resulted in a dose-dependant 
increase in membrane P-Selectin expression, thereby confirming the release of this subset of 
WPB. Again, the addition of α1AT into this system significantly inhibited the effects of PR3 
and HLE on P-Selectin expression. 
 
 
 
4.5 vWf is Cleaved and Released 
 
As previously discussed, the treatment of endothelial cells with PR3 and HLE resulted in an 
increased level of vWf into cell culture supernatants. We further demonstrated that treatment 
with 2µg/ml resulted in the release of between 40-50% of the total cell vWf. Interestingly, 
analysis of endothelial surface expression of vWf by ELISA identified a role for the 
neutrophil serine proteases in reducing the membrane bound vWf. The treatment of GEnC 
and HUVEC with increasing concentrations of PR3 and HLE resulted in a dose-dependant 
decrease in surface vWf expression. As with vWf release, HLE treatment had the greatest 
effect on surface expression causing around a 30% decrease in membrane bound vWf. As 
with all previous experiments the presence of α1AT could significantly inhibit the effects of 
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PR3 and HLE. The ability of the serine proteases to cleave membrane bound vWf has 
recently been demonstrated by another group. Here they suggested that PR3 and HLE cleave 
multimeric membrane vWf between the V1607-T1608 peptide bond. Interestingly, cathepsin G, 
another neutrophil serine protease, has a separate point of cleavage from PR3 and HLE 
Y1605-M1606 [392]. 
 
To confirm that this loss of surface vWf expression was caused by enzymatic cleavage rather 
than re-internalisation of the protein, endothelial cells were permeabilised to allow detection 
of both internal and external vWf, and total levels compared to levels of membrane vWf 
only, following 2 hour treatment with 1µg/ml PR3 and HLE (figure 39). Glomerular 
endothelial cells treated with PR3 and HLE displayed a significantly decreased level of 
membrane bound and total (membrane and internal) vWf. More importantly, the reduction of 
total vWf following serine protease treatment was greater than the loss from the endothelial 
membrane. This observation confirms the previously proposed hypothesis that, along with 
cleavage of surface bound vWf, the neutrophil serine proteases can induce the release of 
further vWf from internal stores. The active cleavage of membrane bound vWf will also 
contribute to the increased circulating vWf in ASV patients [307, 308]. 
 
This data was not reproduced in HUVEC due to problems in their availability, however, 
given that HUVEC show the greatest increase in vWF release into supernatants and decrease 
in surface expression, we hypothesis that HUVEC data would have been similar to that 
observed in GEnC but more marked. 
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4.6 vWf protein and mRNA is Increased by Serine Proteases 
 
Further to the effects of the neutrophil serine proteases on vWf release and cleavage, analysis 
of endothelial lysates after a 2 hour treatment with PR3 and HLE identified a possible role 
for the serine proteases in increasing early de novo synthesis of vWf. Lysates from GEnC 
and HUVEC displayed increased levels of internal vWf occurring in a dose-dependant 
fashion with increasing concentrations of PR3 and HLE, although this increase was only 
significant following treatment with 2µg/ml of enzyme. Furthermore, both endothelial cell 
types displayed an increased total level of vWf (the sum of the released and lysate 
concentration) compared to untreated cells. Following assessment of mRNA levels in 
glomerular endothelial lysates, it became apparent that PR3 and HLE could increase the 
relative expression of vWf mRNA. Endothelial cells have previously been shown to 
internalise PR3, which is rapidly distributed through the endothelial cytoplasm [136]. This 
ability to internalise PR3, and therefore potentially HLE, may account for the inability of 
α1AT to inhibit the increased production of vWf mRNA, as once internalised, α1AT is 
unable to inhibit their enzymatic activity. Endothelial cells have also been demonstrated to 
internalise MPO, which is suggested to increase the production of oxygen radicals associated 
with tissue injury [136, 393].  
 
Knowing the ability of the serine proteases to cleave a host of cytokines and proteins, it was 
important to assess whether PR3 or HLE were having any effect on the detectable level of 
vWf. The incubation of 2µg/ml HLE with recombinant vWf in a cell-free system increased 
the level of detection by around 30%. As new vWf could not have been generated in such a 
system, it became apparent that HLE is having an effect on the structure of the vWf protein, 
potentially unfolding it to expose further antibody binding sites. This HLE modification of 
antibody binding, however, does not account for the entirety of the increased intracellular 
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vWf, as this increased by much more than 30%. Additionally, PR3 did not cause an increase 
in antibody binding, and detection remained the same as with untreated recombinant vWf. 
The inability of PR3 to cause protein modifications that increase antibody binding, and the 
unaccounted protein following HLE treatment, begs the questions of increased de novo 
synthesis of the vWf protein. It is of note that the ability of HLE and inability of PR3 to 
increase antibody binding, suggests that there may be less of a difference between the 
capability of these enzymes to induce vWf release as previously suggested from the ELISA 
measurements on supernatant levels of vWf (see figure 17). 
 
The production of the multimeric form of vWf released from endothelial cells is very closely 
related to the formation of mature Weibel-Palade bodies. Moreover, the absence of WPB 
biogenesis can be restored by the expression of vWf [282]. Early PrePro-vWf, derived from 
the trans-golgi network, undergoes modification by the formation of disulfide bonds during it 
translocation to the endoplasmic reticulum. From here the protein undergoes further 
modifications and disulfide bond formation in the golgi-apparatus, after which, the resulting 
vWf multimers can ‘bud off’ the golgi in what we know as the Weibel-Palade bodies [279, 
280]. Due to our early incubation point, it is likely that, should we be observing increased 
protein synthesis, we are detecting an early PrePro- or Pro-vWf rather than the complete 
multimeric vWf protein. It is likely that the complete lysis of our endothelial cells is 
releasing this early vWf protein from the trans-golgi network and thereby increasing our 
level of intracellular vWf detection. Comparatively, with E-Selectin de novo synthesis, an 
incubation of 4 hours is required to see significantly unregulated membrane expression, 
whilst increased mRNA can be first seen after a 1 hour stimulation [394]. 
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4.7 vWf Expression in Renal Biopsies 
 
After highlighting an activatory role for the neutrophil serine proteases in increasing 
circulating levels of vWf. We wanted to investigate changes in the distribution of renal vWf 
associated with ANCA systemic vasculitis. Using biopsies taken from patients with active 
ASV, changes in the staining pattern for vWf was compared to non-transplanted ‘healthy’ 
kidney. Acute tubular necrosis and anti-glomerular membrane disease were used as disease 
controls. The renal distribution of vWf in ASV appeared normal in unaffected glomeruli, 
with evenly dispersed vWf staining throughout the glomerular capillary structure, however, 
upon development of crescentic glomerulonephritis, vWf became localised to the areas 
surrounding the crescent formation. The glomerular crescents develop as huge infiltrates of 
immune cells and mediators enter the bowman’s space and surround glomeruli. This causes 
compression of the glomeruli due to the limited space available. These early reversible 
cellular crescents are later replaced by fibrin and collagen deposits, during the development 
of irreversible glomerular fibrosis and scarring [395]. It is suggested that infiltrating 
macrophages are primarily responsible for the induction of glomerular fibrosis [213]. 
Interestingly, activation of the coagulation cascade appears to be important in the 
development of fibrous crescents, with macrophages themselves involved in the increased 
fibrin deposition [395]. 
 
The vWf staining within these crescentic glomeruli supports a role for the coagulation 
cascade as increased vWf was observed within the surrounding crescents. Intraglomerular 
vWf staining within crescentic glomeruli appears reduced, perhaps due to the glomerular 
compression caused by substantial cellular infiltration. A further explanation for the 
decreased intraglomular vWf expression may be due to a loss of endothelial cells. It is also 
possible that there could be endothelial cells within the crescents as a result of angiogenesis 
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to maintain the required recruitment of inflammatory cells, although such an occurrence has 
not been reported. Furthermore, the vWf staining in the peritubular capillaries appears 
unchanged in ASV. Comparatively, anti-GBM disease biopsies, a type I rapidly progressive 
glomerulonephritis (RPGN), did not display this crescentic formation in the biopsies used in 
this study, rather, the affected glomeruli appeared collapsed and were not positive for vWf. 
This observation may be due to the severity of disease at the point that the biopsies were 
collected, as the literature suggests that crescent formation is prominent in anti-GBM disease 
[395]. Furthermore, glomerular vWf staining in acute tubular necrosis appeared normal. To 
further assess the cell specific expression of vWf in renal biopsies, one could utilise a 
fluorescence staining method to dual stain sections for vWf and endothelial cell markers 
such as CD31. 
 
The severity of the crescentic development in ANCA-associated glomerulonephritis is 
proposed to be a good indicator of the renal outcome for the patient; in particular the 
percentage of fibrous crescents decreases the long-term renal outcome [396]. Until recently 
there has been no classification system for defining the severity of disease based on renal 
biopsies. Berden et al., has proposed a four-point classification system for the severity of 
vasculitic disease in renal biopsies, namely focal, crescentic, mixed and sclerotic, based on 
the level of glomerular cellular infiltrate and fibrosis [396]. 
 
 
 
4.8 PR3 and HLE Signal through a Unique Pathway to induce vWf Release 
 
We hypothesized a role for the protease-activated receptors in mediating the effects of the 
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serine proteases in endothelial cells, in particular the exocytosis of Weibel-Palade bodies. 
Endothelial surface expression of P-Selectin can be induced by stimulation with PAR-1 
agonist peptide, TRAP-6 (SFLLRN) [397]. Similarly, Lindner et al., showed that mice 
deficient for endothelial PAR-2 displayed a delayed onset of leukocyte recruitment, possibly 
due to a delayed upregulation of P-Selectin [366]. It has also been demonstrated that the 
knockdown of PAR-1 and PAR-2 results in a reduced rate of neutrophil transmigration 
[398]. Furthermore, PAR-2 agonists have been used to induce release of vWf [287]. Taken 
with the observation of an interaction between PAR-2 and PR3 [367], we investigated a role 
for the PAR-1 and PAR-2 receptors in PR3 and HLE mediated endothelial vWf release. As 
previously described by Cleator et al., agonist peptides directed at PAR-1 and PAR-2 could 
induce the release of vWf from HUVEC, and to less of an extent, GEnC [287]. However, in 
endothelial cells treated with siRNA targeting PAR-1, PAR-2 or both, the serine protease 
induced release of vWf could not be inhibited. The observation that PR3 and HLE do not 
require signalling through the protease activated receptors for Weibel-Palade body exocytosis 
invited further investigation into the signalling pathways that may be involved. 
 
Investigation into the mechanism of communication and initiation of endothelial signalling 
pathways has highlighted other groups of receptors of particular interest. Firstly, a role for 
the toll-like receptors in vWf release has been outlined, as mice deficient for TLR-2 and TLR-
4 are unable to release vWf in response to uric acid [281]. More recently, the formation of 
PR3-kinin, by incubation of PR3 with high molecular weight kininogen, has been shown to 
interact with the B2 receptors on endothelial cells [370]. Further to this, the endothelial 
expression of the B1 receptors has been shown to be upregulated in glomeruli and renal 
interstitium of ANCA-vasculitis patients, whilst blocking these receptors reduces renal 
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macrophage recruitment and chemokine production [399]. Although, there is currently little 
evidence to support a role for the receptors discussed here in ASV, further investigation of 
these pathways may highlight potential therapeutic targets. 
 
A recent review article by Goligorsky et al. highlighted the known signalling pathways for 
ligand induced vWf release (see figure 5 [281]). Moreover, thrombin and PAR-1 are suggested 
to signal through increased intracellular calcium and calmodulin activation, whilst VEGF 
utilizes PKA and PKC signalling [371, 372, 400]. Using these proposed signalling pathways 
we investigated whether inhibition of key signalling components would decrease PR3 and 
HLE mediated vWf release. In particular, the use of pharmacological inhibitors directed at 
PKC, PKA, calmodulin or PI3K had no effect on inhibiting vWf release from serine protease 
treated glomerular cells. Furthermore, these inhibitors could not reduce HLE mediated vWf 
release from HUVEC. 
 
The use of pharmacological inhibitors within experiments is often viewed with caution, as we 
have previously discovered when PAR antagonists were unable to inhibit PAR agonist 
induced vWf release. A more accurate method for investigating cell signalling pathways 
would be to use siRNA to knockdown the key signalling molecules, either individually or 
combined, to more accurately investigate their roles in PR3 and HLE mediated vWf release. 
 
The release of vWf from thrombin and histamine stimulated endothelial cells requires the 
reorganization of the actin cytoskeleton structure and the formation of stress fibers. 
Moreover, the preincubation of HUVEC with cytochalasin B and cytochalasin E, an inhibitor 
of actin polymerization, potentiated the release of vWf in response to thrombin [401]. The 
disruption of the actin cytoskeleton by cytochalasin D is also reported to increase vWf 
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release in response to PAR-1 and PAR-2 [361]. Here we further investigated a role for the 
actin cytoskeleton in the release of vWf from PR3 and HLE treated endothelial cell. 
Preliminary experiments aimed to investigate the potential ability of cytochalasin B to 
further release vWf from HLE treated endothelial cells. Interestingly, treatment of HUVEC 
with increasing concentrations cytochalasin B (0.1 - 100µM) resulted in a reduction of vWf 
release, with 100µM reducing vWf release by almost 50%. Moreover, cytochalasin B treated 
endothelial cells displayed a hugely decreased mitochondrial activity, became rounded and 
detached and no longer displayed a confluent monolayer. Clearly, maintenance of the actin 
cytoskeleton is essential for endothelial viability, whilst it is likely that the decreased release 
of vWf is not due to the requirement of actin disruption for WPB exocytosis, but more to 
endothelial apoptosis. To overcome this toxic effect of cytochalasin B on endothelial 
monolayers, we treated endothelial cells with PR3 and HLE and stained for F-actin using a 
RPE labeled phalloidin toxin. Interestingly, PR3 and HLE did not appear to change the actin 
cytoskeleton, nor did they appear to localize to the cytoskeleton to facilitate WPB 
exocytosis. 
 
Phosphatase 2B (PP2B) is a serine/threonine phosphatase linked to the calcium dependant 
intracellular signalling. Incubation of endothelial cells with the phosphatase 2B inhibitor, 
okadaic acid, is reported to induce vWf release [402, 403].  Furthermore, treatment with 
other PP2B inhibitors cyclosporine A and FK506 also increased vWf release from HUVEC 
[402]. In preliminary experiments, we investigated the ability of okadaic acid to induce vWf 
release from HUVEC and GEnC without a second stimulus. Interestingly, whilst treatment 
with concentrations of 100nm and 500nm of okadaic acid increased vWf from GEnC, okadaic 
acid appeared to have an inhibitory effect on release from HUVEC. Moreover, whilst okadaic 
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acid had no additive effects on PR3 and HLE mediated vWf release from GEnC, treatment 
appeared to completely inhibit vWf release from HUVEC in response to PR3 and HLE 
treatment. The differing effects of okadaic acid on GEnC and HUVEC was an interesting 
observation. Whilst phosphatase 2B appears to have no role in PR3 and HLE signalling in 
GEnC, inhibition in HUVEC completely abrogates serine protease stimulated vWf release, 
potentially highlighting a role for PP2B in PR3 and HLE signalling. Further investigation 
demonstrated that okadaic acid caused decreased mitochondrial activity following treated 
with concentrations of 100nM. This effect appeared more potent on HUVEC, with 
mitochondrial activity reduced to only 50%. However, treatment with 100nM okadaic acid 
did not appear to cause endothelial detachment. Moreover, recent reports have confirmed the 
ability of okadaic acid induce cellular apoptosis [404, 405]. 
 
To further investigate a role for PR3 and HLE in endothelial cell signalling, serine protease 
treated endothelial cells were assessed for changes in their pattern of peptide 
phosphorylation. Interestingly, HLE treatment appeared to have a potent effect on 
endothelial cell phosphorylation. HLE treated GEnC displayed the loss of phosphorylated 
tyrosine and serine/threonine peptides, as well as the presence of newly phosphorylated 
tyrosine peptides with molecular masses of between 31 and 52kDa. PR3 treatment did not 
produce the same pattern of phosphorylation and remained much unchanged from 
unstimulated endothelial cells, although a missing serine/threonine phosphopeptide with a 
molecule weight of around 225kDa can be seen. It is possible, however, that PR3 may be 
inducing minor changes in protein phosphorylation, which is being masked by more abundant 
unaffected peptides. A role for PR3 and HLE in altering endothelial cell signal transduction 
has been outlined in the induction of apoptosis. Preston et al., identified that PR3 and HLE 
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altered endothelial expression of members of the JNK and ERK signalling pathways. In 
particular, PR3 appeared to increase the expression of phosphorylated JNK-2, whilst HLE 
treatment decreased phospho-JNK-1 expression. Moreover, both serine proteases actively 
downregulate ERK-1 and -2 phosphorylation [137]. More recently, another neutrophil serine 
protease, cathepsin G, has been demonstrated to increase ERK-1/-2, p38 mitogen activated 
protein kinase (MAP-kinase) and Akt phosphorylation [406]. We are actively investigating 
the precise signalling targets of PR3 and HLE by mass spectrometry of phosphorylated 
peptides, following which it will be interesting to further assess the changes in 
phosphorylation of JNK and ERK, as well as other members of MAP-kinase pathway. It is 
of interest that PR3 and HLE do not appear to require signalling through PKC, PKA, 
calmodulin or PI3k, to mediate the exocytosis of vWf. We hope that identification of a novel 
signalling components targeted by the neutrophil serine proteases may highlight potential 
therapeutic targets. 
 
Using a novel mass spectrometry method to assess changes in peptide phosphorylation will 
allow us to globally assess signalling pathways that are utilised by PR3 and HLE. Mass 
spectrometry will allow identification of proteins with known molecular masses. It will allow 
us to assess changes in phosphorylation that may be occurring in less abundant proteins that 
are currently masked by more abundant proteins when assessed by western blotting. The 
identification of these signalling pathways will not be specific to WPB, in particular vWf, 
release, however, we can take these observations and use inhibitors or siRNA in vitro to 
assess their actions in WPB exocytosis. 
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4.9 The Serine Proteases Increase Neutrophil Adhesion through 
Interactions between P-Selectin and PSGL-1 
 
Two independent animal models of MPO-vasculitis have reported an increased level of 
leukocyte transmigration in vivo [165, 166]. Here we investigated the hypothesis by which 
this increased neutrophil adhesion may be the result of serine protease release from ANCA-
activated neutrophils. The incubation of endothelial cells with 1µg/ml PR3 or HLE resulted in 
significantly increased neutrophil adhesion in a static in vitro model. The level of adhesion to 
serine protease treated HUVEC was not significantly different from those levels observed 
following treatment with 100 units TNFα (PR3 p=0.3121, HLE p=0.8446), a well-known 
stimulus for neutrophil activation. Furthermore, this increased neutrophil adhesion to serine 
protease treated endothelial cells appeared to be occurring in the absence of the upregulation 
of the classical endothelial adhesion molecules; namely, E-Selectin, ICAM-1 and VCAM-1. 
 
The expression of E-Selectin on PR3 and HLE treated endothelial cells could not be increased 
at 2 hours with concentrations of protease up to 2µg/ml, whilst a 4 hour incubation with 
TNFα significantly increased surface expression. Similarly, ICAM-1 could not be 
upregulated with PR3 or HLE treatment, and was again significantly increased following 8 
hour TNFα treatment on both cell types. Interestingly, whilst PR3 and HLE could not 
increase VCAM-1 expression of either cell type, treatment with TNFα for up to 24 hours 
also resulted in no expression on GEnC. Furthermore, Tanya Pankhurst demonstrated no 
VCAM-1 expression on primary endothelial cells (unpublished data). This absence of 
glomerular VCAM-1 may act as a safety mechanism to prevent inappropriate recruitment of 
T-cells and monocytes into the glomeruli. VCAM-1 expression is increased on renal tubules 
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and glomeruli in biopsies from patients with ANCA associated glomerulonephritis, whilst 
histological staining also demonstrates the presence of T-cells and macrophages in and around 
the glomeruli [184, 407]. The expression of VCAM-1 and ICAM-1 within the cellular 
crescents is also increased, whilst epithelial cells within fibrious crescents can maintain 
VCAM-1 expression [408]. Furthermore, treatment of nephrotoxic nephritic rats with 
blocking antibodies directed at VCAM-1 ligand VLA-4 significantly improved renal function 
[409]. The inability of TNFα or the neutrophil serine proteases to upregulate glomerular 
VCAM-1 expression suggests that VCAM-1 expression in ASV patients is the result of an 
unidentified stimulation. Alternatively, the glomerular epithelial cells may account for the 
increased expression of VCAM-1 in ASV, rather than the endothelial cells. 
 
The increased surface expression of these ‘classical’ endothelial adhesion molecules that 
occurs during inflammation first requires de novo synthesis of these proteins before 
translocation to the membrane can occur. As previously mentioned, E-Selectin expression is 
not increased until 4 hours post stimulation, with increased protein synthesis becoming 
apparent after 1 hour [394]. It is therefore, not surprising that we observe no upregulation of 
these adhesion molecules following a short 2 hour incubation. 
 
Unlike E-Selectin, P-Selectin, one of the key adhesion molecules involved in neutrophil 
rolling, is stored as a preformed molecule in endothelial Weibel-Palade bodies and can 
therefore be rapidly upregulated to the endothelial membrane upon stimulation. Treatment of 
GEnC or HUVEC with 1 unit of thrombin for 15 minutes significantly increased P-Selectin 
membrane expression, thereby reemphasizing the rapid ability of endothelial cells to increase 
expression upon stimulation. It was also observed that 2 hour treatment of endothelial cells 
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with increasing concentrations of PR3 and HLE could significantly increase surface P-Selectin 
expression in a dose-dependant manner, when measured by ELISA. We initially wanted to 
confirm this expression by flow cytometry, however, the removal of the enzyme following 
by 10 minutes of washing and spinning before fixation was sufficient for re-internalisation of 
the adhesion molecule (data not shown). It has previously been demonstrated that the half-
time for the re-internalisation of membrane expressed P-Selectin and translocation to the 
trans-golgi network is only 20-25 minutes [330]. This data suggests that PR3 and HLE do 
not have prolonged effects on P-Selectin expression, as the removal of the serine proteases 
following endothelial treatment is sufficient to induce re-internalisation. Interestingly, this 
may suggest that the prolonged release of CXCL8 caused by PR3 and HLE, even after their 
removal, is not due to the release of Weibel-Palade bodies. Although this does not rule out 
their release completely, as it has been demonstrated that there is differential methods of 
release for the different sub-classes of WPB [287]. Furthermore, the localization of CXCL8 
within the endothelial cells is a highly controversial topic, although there is evidence for a co-
localisation with vWf [283, 284]. CXCL8 is suggested to be increased in the endothelial 
WPBs following the initiation of inflammation [283], and release may therefore be occurring 
from other sources within the endothelial cell. 
 
One of the key ligands for P-Selectin during neutrophil rolling is PSGL-1. PSGL-1 is 
expressed on the surface of leukocytes and has been demonstrated to bind the endothelial 
selectins via its sialyl lewisX domain. Although the primary ligand for P-Selectin, PSGL-1 is 
suggested to also weakly interact with E-Selectin and L-Selectin [175]. In the absence of E-
Selectin expression on our serine protease treated endothelial cells, we aimed to further 
investigate the role of P-Selectin in increased neutrophil adhesion by blocking the PSGL-1 
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ligand on neutrophils, since antibodies that reliably block P-Selectin adhesion functions are 
lacking. The use of monoclonal blocking antibodies directed at PSGL-1 significantly inhibited 
the level of neutrophil adhesion to PR3 and HLE treated endothelial cells. Furthermore, this 
reduced level of neutrophil adhesion was similar to the number of neutrophils adhered to 
untreated endothelial cells. It is apparent, therefore, that the serine protease mediated 
upregulation of P-Selectin may be interacting with neutrophil PSGL-1 to increase adhesion. 
In the complex system of leukocyte transmigration, P-Selectin is involved in the initial 
sequestration of flowing neutrophils by forming weak bonds between the endothelium and 
PSGL-1. The repeated formation of these weak bonds, termed ‘rolling’, is not sufficient to 
support the required firm adhesion for transmigration. Alternatively, in our static model of 
neutrophil adhesion this increased expression of P-Selectin and its interactions with PSGL-1 
may be able to support adhesion due to the constitutive expression of ICAM-1. Although 
ICAM-1 is not increased on serine protease treated endothelial cells, it is possible that the 
activation of constitutively expressed ICAM-1 may be sufficient for firm adhesion. Indeed, 
neutrophil derived HLE can cleave endothelial ICAM-1 after a 2 hour incubation [410, 411], 
whilst a role for HLE and cathepsin G in VCAM-1 cleavage has also been described [412]. 
Moreover, HLE–/– neutrophils demonstrate decreased ability to transmigrate compared to 
wild-type neutrophils [410]. Interestingly, vWf may be involved in this increased PSGL-1 
mediated neutrophil adhesion, firstly due to the requirement of vWf for increasing P-Selectin 
membrane expression [383] and secondly as a ligand for PSGL-1 in its own right [385]. 
Furthermore, vWf can induce firm neutrophil adhesion via interactions with the β2 integrins 
[385], and therefore could support neutrophil adhesion in the absence of increased ICAM-1 
expression. 
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4.10 A Role for CXCL8 in Neutrophil Adhesion 
 
CXCL8 is also proposed to be involved in neutrophil adhesion during inflammation. CXCL8 
is a potent neutrophil chemotactic agent that has been demonstrated to increase the binding 
activity of β2 integrins Mac-1 and LFA-1 to induce integrin mediated firm adhesion of 
neutrophils [191]. Furthermore, perfusion of CXCL8 over neutrophils rolling on P-Selectin 
can induce arrest and firm adhesion through ICAM-1/β2 integrin interactions [190]. Here we 
have demonstrated that the neutrophil serine proteases can increase release of CXCL8 from 
endothelial cells, after which CXCL8 is cleaved by PR3 and HLE in supernatants. The 
amplification of CXCL8 activity induced by this serine protease cleavage previously 
proposed by Padrines et al. [113] may account for the induction of firm adhesion of P-
Selectin bound neutrophils through interactions between constitutively expressed endothelial 
ICAM-1 and its integrin ligands on neutrophils. Furthermore, CXCL8 could exert its effector 
functions before it is cleaved by PR3 and HLE. 
 
To further evaluate this possibility, blocking antibodies directed at the CXCL8 receptors, 
CXCR1 and CXCR2, on neutrophils were used in our static model of adhesion. Neutrophils 
incubated with anti-CXCR1, anti-CXCR2 or both displayed a significantly reduced level of 
neutrophil adhesion to PR3 or HLE treated endothelial cells. The inhibition of this CXCL8 
mediated firm adhesion decreased the number of adherent neutrophils to serine protease 
GEnC to levels observed in untreated endothelial cells. This observation confirms a role for 
CXCL8 in inducing a confirmation change within the neutrophil to increase its binding 
activity, possibly through Mac-1 or LFA-1 interactions with endothelial ICAM-1. P-Selectin 
mediated weak interactions are insufficient to maintain increased neutrophil adhesion after 
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washing in the absence of firm neutrophil adhesion induced through CXCL8 activity. 
Furthermore, the inhibition of adhesion by blocking PSGL-1 demonstrates that CXCL8 alone 
cannot induce adhesion without an early capture phase by P-Selectin binding. Figure 102 
highlights how signalling through the PSGL-1 and CXCR1/2 receptors may support disease 
propagation in ANCA-associated vasculitis. 
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Figure 102 - Serine Proteases cause Disease Propagation by Supporting Inflammatory 
Processes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An enhanced inflammatory environment causes the upregulation of PR3 on the surface of neutrophils, and the 
increased expression of endothelial adhesion molecules. ANCA can bind to its antigen on the surface of the 
neutrophil, inducing neutrophil activation and adhesion to the vascular endothelium. From here the ANCA 
activated neutrophil can degranulate and release the neutrophil serine proteases directly onto the endothelial 
surface. PR3 and HLE cause endothelial activation and release of the Weibel-Palade body constituents: vWf, 
CXCL8 and P-Selectin. The further amplification of CXCL8 by PR3 and HLE increase neutrophil recruitment 
to the site, which can interact with increased endothelial P-Selectin via their PSGL-1 ligand. CXCL8 further 
causes a conformational change in the neutrophil β2 integrins to induce firm adhesion to endothelium via 
ICAM-1 or vWf interactions. Hence, the neutrophil serine proteases support the induction of inflammation by 
increased neutrophil recruitment. 
 
 
A role for the serine proteases in the recruitment of inflammatory cells has previously been 
described in an dipeptidyl pepptase I (DPPI) knock-out mouse, which lacks the ability to 
produce active serine proteases. Adkison et al., 2002 demonstrated that these mice display 
reduced recruitment of inflammatory cells into synovial tissues in a model of murine 
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arthritis. Furthermore, the injection of CXCL8 restored neutrophil recruitment, suggesting 
that the serine proteases contribute to the cytokine production required for normal neutrophil 
recruitment, in particular, the release and processing of CXCL8 [413]. 
 
 
 
4.11 α1-Antitrypsin – A Potential Therapy in ANCA Vasculitis? 
 
Throughout this project, a therapeutic preparation of α1-antitrypsin, Prolastin® (a 
preparation of α1AT prepared from human plasma), has routinely been used to inhibit the 
actions of the neutrophil serine proteases. We have demonstrated that α1AT can inhibit the 
release of vWf from Weibel-Palade bodies, inhibit membrane cleavage of vWf, as well as the 
cleavage of CXCL8 and Ang-2, can inhibit the effects of PR3 and HLE on increasing 
neutrophil adhesion, and the expression of membrane P-Selectin. It is proposed that it is the 
neutrophil serine proteases that are most important in the induction of endothelial activation, 
injury and therefore the propagation of inflammation, whilst inhibition of their effects would 
be beneficial. It is therefore worth exploring whether that Prolastin® would make a good 
addition to the current treatment regime. 
 
Prolastin® is already being used as a therapeutic drug in restoring α1AT in patients with 
alpha1-antitrypsin deficiency. Although currently, α1AT has not been investigated in the 
treatment of ASV or any other immune mediated diseases. In vasculitis, there is no reason 
why Prolastin® could not be used alongside the current regime, but is there any need for it? 
At present there is no scientific grounds by which Prolastin® would make a beneficial 
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therapy, as α1AT is naturally increased in the circulation during inflammation [152, 153]. 
α1AT is a key inflammatory mediator released from hepatocytes, monocytes and 
macrophages during the acute phase response. This is a protective response induced by 
trauma, injury or infection, in which humoral mediators are released to prevent tissue damage 
and initiate repair mechanisms [154]. It is due to this increased presence of α1AT during 
inflammation that there is unlikely to be a requirement for Prolastin® as a therapeutic 
treatment in immune mediated diseases. Furthermore, its presence in ASV may already be 
having an effect on dampening the injurious activities of the serine proteases. However, the 
effect of an over-saturation of α1AT in these patients has not been investigated and so we 
cannot conclude that Prolastin® would have no beneficial effects. 
 
Recently, a defective α1AT allele (piZ) has been identified to occur at an increased frequency 
in patients with ANCA-associated vasculitis. Patients homozygous for this piZ allele 
display a significantly reduced level of functional α1AT. It has been suggested that a 
deficiency in α1AT may account for the high ANCA titres observed in some patients [160], 
furthermore, a cohort of 8 ASV patients with α1AT deficiency typically manifested multiple 
organ involvement [414]. There have been multiple studies that suggest that patients with a 
heterozygous piZ phenotype more commonly present with PR3-ANCA associated 
vasculitis [162, 415, 416], moreover, in a study of 88 patients with microscopic vasculitis, 
23% of the 66 Wegener’s granulomatosis patients displayed the piZ phenotype [417]. This 
study further hypothesized that the piZ allele may predispose patients to WG. 
Interestingly, these piZ patients may not present a decrease in serum concentrations of 
α1AT [415]. Alternatively, Audrain et al. demonstrated an increased incidence of ANCA 
directed at HLE or αGR in a cohort of 191 piZZ patients. These patients did not develop 
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systemic disease, and so α1AT deficiency may not be sufficient for the development of 
ANCA-systemic vasculitis [161]. It would be of benefit to monitor serum levels and 
phenotypes of α1AT in ASV patients, as Prolastin® may prove an effective supplement to 
these patients treatment regime. 
 
 
 
4.12 Differential Roles for PR3 and HLE? 
 
Both PR3 and HLE are stored in the primary granules of the neutrophils and released upon 
degranulation. Although both chymotrypsin-like serine proteases, they have been described 
to have both similarities and differences in their effector functions (see table 3). During this 
project we have used HLE as a comparative enzyme for the functional studies on PR3 as a 
target and mediator of disease in ASV. Interestingly, we have demonstrated that treatment 
with HLE appears to have a greater role than PR3 in the induction of endothelial cell injury. 
We have demonstrated that a 24 hours treatment with HLE has a greater effect on endothelial 
apoptosis compared to treatment with equivalent concentrations of PR3. In particular HLE 
treatment resulted in the most significant decrease in intracellular ATP, although treatment 
with 2µg/ml PR3 also resulted in a reduction. Although both serine proteases have 
previously been demonstrated to induce cellular apoptosis, there has been more interest into 
the mechanisms by which PR3 can enter endothelial cells and initiate apoptosis. Here we 
suggest that, if released in equal concentrations, HLE may be having a more detrimental 
effect of the endothelial cells than PR3. Furthermore, treatment with 5µg/ml HLE resulted in 
significant endothelial detachment. This phenomenon has also been reported by other 
members of our group, who demonstrated that HLE is more potent that PR3 at inducing 
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endothelial detachment and decreasing mitochondrial activity (Sahithi Panchagnula, 
unpublished data). 
 
In regards to Weibel-Palade body exocytosis, HLE had a much greater effect on the release 
of vWf from both GEnC and HUVEC than PR3 treatment, whilst PR3 treated endothelial 
cells displayed a higher membrane expression of P-Selectin than those treated with HLE. 
Furthermore, endothelial cells treated with HLE demonstrated a decreased level of 
membrane bound vWf than PR3 treated endothelial cells. Interestingly, there was little 
difference between the ability of either serine protease to induce CXCL8 release, following 
removal of the enzyme and incubation for 2 hours in blank medium. Both serine proteases 
have previously been demonstrated to process a host of cytokines, however the result of this 
processing appears to differ. Specifically, whilst cleavage of TNFα by HLE results in its 
inactivation, PR3 appears to further activate the functions of TNFα. This difference in 
effector functions has also been suggested for CXCL8 cleavage, with HLE resulting in 
inactivation and PR3 in amplification. Interestingly, however, both serine proteases 
inactivate IL-6 and IL-2 (see table 3). In this research we have demonstrated that HLE has a 
greater affinity for the cleavage of CXCL8 than PR3, although the resulting functions of this 
cleavage were not investigated. HLE was also demonstrated to process recombinant vWf to 
enable increased antibody binding activity, whilst PR3 had no effect on the level of antibody 
binding. Alternatively, PR3 demonstrated an increased affinity for the cleavage of 
recombinant and released angiopoietin-2 than was demonstrated by HLE. These differences 
in protein cleavage by HLE and PR3 may be due to their different abilities to cleave certain 
peptide bonds. Interestingly, neither serine protease demonstrated a difference in their ability 
to induce neutrophil adhesion to either GEnC or HUVEC. Again, neither serine protease 
could increase the expression of ICAM-1, VCAM-1 or E-Selectin. 
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This work demonstrates that, whilst both serine proteases have similar effects on the 
endothelium in the induction of injury and Weibel-Palade body exocytosis, HLE in the main, 
has a more dominant effect than PR3 when used at the same concentration. There are few 
exceptions in which PR3 appeared the most potent stimulus, in particular, the expression of 
P-Selectin and cleavage of Ang-2. One factor that we were unable to account for when 
performing this research was to match the serine proteases not by concentration but by their 
enzymatic activity. Due to an absence in the market of a PR3 specific substrate we could not 
accurately account for any differences in the activity of the two enzymes, and this may 
account for some of the differences observed in their potency to perform effector functions. 
 
 
 
4.13 Can a GEnC line Accurately Represent a Primary Glomerular 
Endothelial Cell?  
 
Throughout this research we have used an immortalised microvascular glomerular 
endothelial cell line, in part, to overcome the difficulties and costs associated with using 
primary glomerular endothelial cells. To confirm that experimental results were due to their 
endothelial lineage, data was routinely collected on a primary macrovascular umbilical 
endothelial cell. HUVEC were used due their low cost and accessibility, but do not represent 
the microvascular endothelial cell targeted in ASV. The GEnC line appeared to be more 
hardy than the primary HUVEC, with less markers of endothelial injury observed following 
serine protease treatment, an observation also noted by Sahithi Panchagnula (unpublished 
data). HUVEC also displayed a greater response to serine protease treatment in vWf release 
and cleavage as well as neutrophil adhesion and expression of adhesion molecules. Although 
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both GEnC and HUVEC responded in the same manner, serine protease treatment of 
HUVEC consistently demonstrated a greater effect. 
 
It is of note that, whilst in the main, these cells behaved in a similar manner, albeit to 
different capacities, we did note some distinct differences in the responses of the two cell 
types throughout this research. Firstly, GEnC do not express VCAM-1, unlike HUVEC, 
which is likely a characteristic of their glomerular microenvironment. Another difference 
between these micro- and macrovascular endothelial cells attributable to their specific 
environments is the level of constitutive release of Ang-2. Given the ability of endothelial 
cell to adapt to the requirements of their microenvironment, we believe that the high 
constitutive release of Ang-2 by glomerular cells is due to the required maintenance of the 
glomerular capillary structure, a function not required by HUVEC. 
 
Whilst HUVEC confirmed the responses of the GEnC line to neutrophil serine proteases to 
be due to an endothelial lineage, with observed responses just more marked with HUVEC 
than GEnC, the use of a combination of these cells can not truly represent the responses of a 
primary glomerular endothelial cell. We can therefore not discount a possibility that this data 
may be skewed due to the use of an endothelial cell line. 
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5. Concluding Remarks 
 
The data presented in this thesis supports the hypothesis that the neutrophil serine proteases 
have an early activatory role on the vascular endothelial that supports the development of an 
inflammatory response. At this early time point, PR3 and HLE do not appear to have effects 
on reducing endothelial viability, whilst we also support the idea of a later more injurious 
effect of the serine proteases in inducing endothelial detachment and apoptosis. This later 
injurious effect may account for the increased circulating and necrotic endothelial cells 
described in ASV patients [381].  
 
We further describe an activated endothelial phenotype, induced by a 2 hour serine protease 
stimulation, that demonstrates increased WPB exocytosis and increased neutrophil adhesion, 
in the support of the development of an inflammatory response. We have demonstrated that 
PR3 and HLE can increase circulating vWf by the cleavage of membrane bound endothelial 
vWf as well as release from internal stores. This increased release of vWf may support a pro-
coagulant state and the thrombus formation seen in the glomeruli of ASV patients. 
Furthermore, PR3 and HLE can increase the expression of vWf mRNA and increase 
intracellular protein concentrations, most probably by early de novo synthesis following the 
internalisation of the serine protease by endothelial cells. 
 
The release of intracellular vWf occurs with an increased membrane expression of P-Selectin 
and release of CXCL8. Furthermore, we support the proposal that PR3 and HLE can actively 
cleave CXCL8, which is suggested to result in an amplified form of CXCL8 with enhanced 
functions. We propose that the formation of weak bonds between the upregulated endothelial 
P-Selectin and its PSGL-1 ligand on neutrophils results in increased neutrophil adhesion. 
This adhesion is further supported by an interplay between CXCL8 and its neutrophil 
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receptors CXCR1 and CXCR2. The stimulation of neutrophils by CXCL8 is reported to 
result in a conformational change of its β2 integrins to enhance their binding activity. We 
believe that cleavage of the constitutively expressed ICAM-1 by the serine proteases could 
support the firm adhesion of weakly bound neutrophils via interactions with the activated β2 
integrins. Furthermore, vWf may also be involved in the increased neutrophil adhesion to 
serine protease stimulated endothelial cells, either by assisting in increasing P-Selectin 
expression during WPB exocytosis, or acting as a adhesion molecule for PSGL-1 and the β2 
integrins in its own right. Moreover, as a potent neutrophil chemoattractant, the enhanced 
CXCL8 activity induced by serine protease cleavage would increase neutrophil recruitment 
and hence, inflammation and disease propagation.  
 
This project originally sought to investigate the transmigration of neutrophils across the 
glomerular capillary endothelium using a 2-compartmental co-culture system using 
glomerular endothelial and epithelial cells. Due to time restraints, only neutrophil adhesion 
to serine protease endothelial cells was investigated. The role of glomerular cross-talk and 
neutrophil migration using this co-culture system is currently being investigated by Sahithi 
Panchagnula. 
 
We have demonstrated the ability of the serine proteases to cleave angiopoietin-2, although 
the functional consequences of this cleavage are unknown. We hypothesize that this cleavage 
would result in the amplification of Ang-2 activity to, along with VEGF, increase vascular 
leakiness and cause destabilisation of the cell-cell junctions to facilitate leukocyte 
recruitment. The high constitutive release of glomerular angiopoietin-2 is probably required 
for the maintenance of the complex capillary structure. 
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We have attempted to shed light on a mechanism by which the neutrophil serine proteases 
can induce endothelial cell activation. We have demonstrated that PR3 and HLE do not 
required signalling through the protease activated receptors, or through PKC, PKA, 
calmodulin or PI3k for vWf release, nor do they appear to co-localise with the actin 
cytoskeleton. Investigation into a role for PP2B has identified a possible link between the 
serine proteases and vWf release from HUVEC, but the decreased endothelial cell viability 
prevents us from drawing any conclusions from this work. We have, however, demonstrated 
a role for HLE, and to a lesser extent, PR3, in altering the pattern of tyrosine and 
serine/threonine phosphorylation. We are currently awaiting results as to identify a host of 
peptides with altered phosphorylation phenotypes, which will require further investigation to 
identify the signalling components associated with WPB exocytosis.  
 
Investigation into the mechanisms underlying disease pathogenesis in ASV allows for the 
identification of novel targets for the development of therapies with an improved profile of 
adverse effects, rather than the current regime of wide-spread immunosuppression. Whilst 
the presence of Prolastin® proved beneficial in preventing the serine protease induced 
inflammatory responses, there appears to be no reason why it would be a beneficial addition 
to the current treatment regime. An exception to this would be the use of Prolastin® in 
patients with a piZ α1AT phenotype.  
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6. Future Work 
 
Research generated for this thesis has identified some interesting results that require further 
investigation. Firstly, we have demonstrated the ability of HLE to process the vWf protein 
and increase antibody binding by approximately 30%. We hypothesise that this is due to 
structural changes within the protein to unveil further antibody binding sites. It would be of 
interest to further evaluate the effects of HLE on the structure of endothelial vWf by using 
methods such as x-ray crystallography and 2-dimensional gel electrophoresis to determine 
atomic structure and protein unfolding respectively. Given that HLE cleavage can alter the 
functions of a number of cytokines, it would be of benefit to assess whether this cleavage of 
vWf results in any changes in is pro-coagulant or inflammatory functions. Furthermore, we 
have described a role for PR3 and HLE in the cleavage of angiopoietin-2. Again, 
identification of functional changes that result from this enzymatic cleavage could highlight 
a further role for Ang-2 in the pathogenesis of ASV, potentially acting in an amplified form 
to increase vascular leakage and facilitate the immune response. Indeed, circulating Ang-2 
appears increased in serum of ASV patients [324]. 
 
We have identified a role for the serine proteases in increased neutrophil adhesion to the 
vascular endothelium via an interplay between P-Selectin/PSGL-1 and 
CXCL8/CXCR1/CXCR2. Not surprisingly, the expression of E-Selectin and ICAM-1 are not 
increased following a 2 hour incubation. It has been demonstrated that PR3 can be rapidly 
internalised by endothelial cells [136], and so may have a later role in inducing adhesion 
molecule expression. Given the time, it would have been interesting to see if PR3 and HLE 
can induce increased surface expression of E-Selectin and ICAM-1 following a 4 or 6 hour 
incubation, and whether, at 2 hours, relative mRNA expression for these adhesion molecules 
is increased. Furthermore, HLE has been demonstrated to cleave membrane bound ICAM-1. 
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Further investigation into the functional implications of this cleavage may provide evidence 
as to a mechanism by which the serine proteases can activate constitutively expressed 
ICAM-1 to facilitate firm adhesion at early time points. It would also be interesting to assess 
what role, if any, vWf is playing in the induction of neutrophil adhesion. 
 
Recently, there has been much interest into an animal model of ANCA-vasculitis. The use of 
an animal model would be of benefit to this research to confirm the observation of neutrophil 
adhesion through PSGL-1 and CXCR signalling. Currently there are few successful animal 
models of PR3-ANCA vasculitis. The immunisation of mice and rats with human or murine 
PR3 has resulted in the generation of PR3-ANCA but these animals did not develop 
pathological disease [418, 419]. Only one PR3-vasculitis animal model has been successful 
in generating clinical disease. In this model the transfer of splenocytes from PR3 immunised 
non-obese diabetic (NOD) mice into NOD-severe combined immunodeficiency (SCID) mice 
resulted in crescent formation in 19% of glomeruli [419]. Further research involving this 
PR3 model of vasculitis is eagerly awaited. 
 
Two successful mouse models of experimental MPO-ANCA vasculitis have been defined. 
Firstly, the transfer of splenocytes from MPO-/- mice immunised with MPO, into Rag2-/- 
mice, which lack B-cell function, induced production of MPO-ANCA, and severe crescentic 
glomerulonephritis in approximately 84% of glomeruli and pulmonary haemorrhage. This 
was also reproduced in Rag2-/- mice that received MPO-ANCA alone with about 10% of 
glomeruli developing crescents [420]. A second model induced experimental MPO-vasculitis 
by the intraperitoneal injection of C57BL6 mice with anti-MPO IgG, which resulted in 
approximately 15% crescentic glomeruli. Interestingly, these mice displayed increased 
expression of CXCR2 within renal tissue during the development of disease; however 
blocking CXCR2 had no effect on renal disease [421]. The intraperitoneal injection of 
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C57BL6J mice with anti-MPO IgG has also been used to demonstrate the accumulation of 
neutrophils and macrophages within the glomerulus [422], and so this model could 
potentially be utilised to further investigate our in vitro observations. To achieve this we 
could treat experimental MPO-vasculitic mice with blocking antibodies for PSGL-1, or 
CXCR1 and CXCR2 together to see if neutrophil recruitment could be attenuated. We could 
also use these mice models to investigate a role for α1AT in reducing clinical disease. A 
further rat model of experimental autoimmune vasculitis as also been described, with a mean 
of 10.5% crescentic glomeruli [423]. 
 
We have identified a role for the serine proteases in increasing vWf mRNA and intracellular 
protein levels. Due to the early time point by which we note this observation we believe this 
is a pro- form of the vWf protein. It would be of interest to further investigate a role for the 
serine proteases on de novo synthesis at later time points, and whether inhibition of protein 
synthesis, would prevent the increased intracellular vWf protein levels associated with serine 
protease treatment. It would be of interest to assess whether other Weibel-Palade body 
constituents are also increased.  
 
Following the identification of phosphopeptides targeted by PR3 and HLE by mass 
spectrometry, further investigation will be required to identify which signalling components 
are involved in the endothelial activation, in particular during the exocytosis of WPBs. 
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7. Appendices 
1. PCR Mastermixes 
Table 20 – TaqMan® Reverse Transcription Mastermix 
  Reagent 1x Mastermix Volume 
10x RT Buffer 5µl 
MgCl2 Solution 11µl 
dNTP Mixture 10µl 
Random Hexamers 2.5µl 
RNase Inhibitor 1µl 
MultiScribe™ Reverse Transcriptase 3.1µl 
RNA 16.9µl (1. 5µg) 
 
Table 21 - PCR Mastermix 
  Reagent 1x Mastermix Volume 
10x DreamTaq™ Buffer 5µl 
dNTP Mixture 5µl (0.2mM) 
Forward Primer 1µl 
Reverse Primer 1µl 
DreamTaq™ DNA polymerase 0.25µl 
Water 36.75µl 
cDNA 1µl (1µg) 
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2. Real-Time PCR Mix 
Table 22 - Real-Time PCR Mastermix 
 PAR-1 PAR-2 Source 
QuantiTech™ Probe Mastermix 12.5µl 12.5µl Qiagen 
QuantiTech™ RT Mastermix 0.25µl 0.25µl Qiagen 
β-Actin-VIC labelled Primer 1µl 1µl Applied Biosystems 
PAR-1/PAR-2-FAM labelled Primer 1µl 1µl Applied Biosystems 
RNAse Free Water 8.25µl 8.25µl Qiagen 
RNA (5ng/µl) 2µl 2µl N/A 
 
3. Western Blot Recipes 
Table 23 - Gel Recipes 
10% Resolving Gel Volume Source 
Protogel (National Diagnostics) 3.3ml Geneflow 
Tris 1.5M pH8.8 (181.71g in 1L) 2.5ml Sigma-Aldrich 
Distilled Water 4.07ml N/A 
10% SDS (0.1g in 1ml) 100µl Sigma-Aldrich 
10% APS (0.1g in 1ml) 100µl Sigma-Aldrich 
TEMED 10µl Sigma-Aldrich 
 
 
 
4% Stacking Gel Volume Source 
Protogel (National Diagnostics) 1.3ml Geneflow 
Tris 0.5M pH6.8 (60.57g in 1L) 2.5ml Sigma-Aldrich 
Distilled Water 6.1ml N/A 
10% SDS 100µl Sigma-Aldrich 
10% APS 100µl Sigma-Aldrich 
TEMED 10µl Sigma-Aldrich 
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Table 24 - Constituents of Western Blot Running Buffer 
Medium and Additives Volume Source 
Tris Base 12.11g Sigma 
Glycine 57.65g Calbiochem 
SDS 2g Sigma 
Distilled Water 2L N/A 
 
 
Table 25 - Constituents of Western Blot TBS-T 
Medium and Additives Volume Source 
Tris Base 2.42g Sigma 
Sodium Chloride 8g Sigma 
Distilled Water 1L N/A 
Tween 20 1ml Sigma 
 
 
Table 26 - Constituents of Western Blot Transfer Buffer 
Medium and Additives Volume Source 
Tris Base 5.81g Sigma 
Glycine 2.93g Calbiochem 
SDS 0.375g Sigma 
Methanol 200ml BDH 
Distilled Water 800ml N/A 
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Table 27 - Constituents of SDS-PAGE Loading Buffer 
Medium and 
Additives 
Stock Volume Source 
Tris Base 1M (121.14g in 1L) 1.2ml Sigma-Aldrich 
Glycerol 75% 4.8ml Fisher Scientific 
SDS N/A 1.28g Sigma-Aldrich 
β-Mercaptoethanol 100% 0.5ml Sigma-Aldrich 
Distilled Water N/A 1.2ml N/A 
Bromophenol Blue 100% To Colour Sigma-Aldrich 
 
 
Table 28 - Constituents of Coomassie Stain/Destain 
Medium and Additives Volume Source 
Methanol 400ml BDH 
Distilled Water 500ml N/A 
Acetic Acid 100ml Fisher Scientific 
Brilliant Blue Dye 1g Sigma-Aldrich 
NB Destain does not contain Brilliant Blue Dye 
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4. ApoGlow® Assay Guideline Criteria 
Apoptosis. Test gives lower levels of ATP compared to controls but shows an increase in 
ADP = Increase in ADP:ATP ratios over control ratios. These ratios vary according to the 
degree of apoptosis in the cell population. 
 
Necrosis. Test gives considerably lower ATP levels than control but greatly increased ADP 
= Markedly increased ADP:ATP ratios over control ratios. 
 
Arrested Proliferation. Test gives lower ATP values than control, with little or no change 
in ADP:ATP ratio; the treatment arrests proliferation but does not kill the cells. 
 
Proliferation. Test gives markedly elevated ATP values compared to control wells with no 
significant increase in ADP levels. Stimulation with growth/mitogenic factors will induce 
proliferation and thus lead to an increase in ATP readings. 
 
No effect. Test gives similar or slightly higher levels of ATP and with little or no change in 
ADP compared to control. 
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